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ABSTRACT 
High quality population based data are essential to evaluate breast cancer. This study has 
improved data quality at the West Midlands Cancer Intelligence Unit through the development 
of a staging algorithm which significantly increased the proportion of cases with stage 
recorded. It has also demonstrated the benefits of combining cancer registry data with those 
from the NHS Breast Screening Programme (NHSBSP). This study identified stage as the 
most significant prognostic factor for breast cancer patients, and the favourable staging 
characteristics of screen detected cancers thus suggest that improved survival should result. 
The study also found that only 3 1.6% of cancers in eligible women were screen detected in the 
prevalent round. As 3 1% of breast cancers arose in women in the screening age range, only an 
estimated 10% of breast cancer patients benefit directly from screening. High interval cancer 
rates were identified, along with the need for clarification of the definitions used to identify 
interval cancers. This investigation identified changes in treatment over time across the region 
towards the King's Fund guidelines. However, treatment varied across the region and clear 
divergences from the guidelines were apparent. Furthermore, no association was identified 
between surgical caseload and survival, suggesting that the use of caseload as a proxy for 
specialist care may be questionable. 
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CHAPTER ONE 
INTRODUCTION 
1.1 FOREWORD 
Breast cancer is the most common female neoplasm in the developed world (IARC, 
1992). In 1988 over 26,700 cases were reported in England and Wales (Office of 
Population, Censuses and Surveys (OPCS), 1994), and in 1989 over 14,000 women died 
from the disease (OPCS, 1991). This thesis examines female breast cancer in the West 
Midlands and the impact of the NHS Breast Screening Programme (NHSBSP) in this 
region. 
The burden created by breast cancer can be depicted by the processes shown in Figure 
1.1. Incidence is determined by a number of risk factors, and reflected in mortality which 
in turn reflects curabilty, which is influenced by factors such as stage at diagnosis. 
1 
With breast cancer, deaths attributable to the disease can continue over a long period 
and the definition of cure is not simple. The impact of treatment is often determined by 
the stage of disease, and the earlier breast cancer is diagnosed, the more likely a patient 
is to enjoy prolonged remission. However, some "early" cancers are aggressive, and 
respond poorly to treatment, and occasionally patients with advanced cancers respond 
well to treatment and enjoy prolonged remission. 
This chapter provides an overview of the incidence of breast cancer, prognostic factors, 
and a brief description of the introduction and organisation of NHSBSP. 
1.2 
The highest incidence rates of breast cancer are found in more economically developed 
countries including North America and Northern Europe, and lowest rates in less 
developed areas such as Asia. Japan has exceptionally low rates, although these have 
been increasing (Coleman et al., 1993). These international differences could reflect 
genetic predisposition to breast cancer, or differences in exposure to risk factors 
associated with lifestyle or environmental exposures in different countries. Migration 
studies have provided evidence that risk is, in part, influenced by external factors. 
Japanese women living in the US experience higher rates than those in Japan, and rates 
in second-generation immigrants are higher still (Buell 1973). Furthermore, as lifestyle in 
Japan has become more Westernised, so breast cancer risk has risen. Thus the incidence 
in Miyagi, Japan for 35-74 year olds in 1970 was 27.8/100,000 rising to 61.2/100,000 in 
1985 (Coleman et al., 1993). The risk of breast cancer rises as women approach middle 
age, approximately doubling with each decade of life until the menopause after which 
the rise slows down (McPherson et al., 1994). The highest risk approximately co-incides 
with the menopause, an observation suggestive of a hormonal influence in pathogenesis. 
A full review of the evidence for putative aetiological factors is inappropriate here but 
the data presented in recent reviews (McPherson et al., 1994, Torenson, 1994) are 
summarised in Table 1.1. 
THE INCIDENCE OF BREAST CANCER 
2 
1.3 PROGNOSTIC FACTORS FOR BREAST CANCER 
Some characteristics of breast tumours have been identified as having prognostic 
significance. Such prognostic factors provide a means of estimating likely overall 
survival, aid selection of appropriate treatment, allow comparison between groups of 
patients and improve understanding of the biology of breast cancer. In recent years many 
putative prognostic factors have been identified and these have been recently reviewed in 
a UICC publication (Hermaneck et al., 1995). As the authors of this review point out, 
the proliferation of prognostic factors, although providing the potential to increase 
predictive accuracy, suffers from both poor reproducibility of results, and the inability of 
a large number of factors to be incorporated into a predictive system. For this reason, 
only those factors that are reasonably well established are presented here. 
Prognosis can be described in terms of two time intervals - the time to relapse (the 
disease-free interval), and the overall survival. Although local control is advantageous to 
the patient, there is no firm evidence that it always translates into improved overall 
survival (Dixon 1995). Tumour factors are sometimes classified into two groups, those 
that are "chronological", and those that are "biological". Chronological factors indicate 
the length of time that the tumour has been growing. Biological factors relate to innate 
3 
histological, biochemical or genetic properties of tumours which influence malignant 
behaviour and are assumed by some to remain constant throughout the lifetime of the 
tumour and are thus phenotypic properties of the tumour. The use of such classifications 
may be misleading as some factors may reflect both biology and chronology. Opinion is 
divided over whether biological factors change with time in a process termed phenotypic 
progression. A Finnish study concluded that such progression did not occur (Hakama et 
al., 1995), but doubts over the validity of these conclusions have been raised due to 
small sample size and low sensitivity of the study (Day et al., 1995). It seems likely that 
factors such as nodal status are both chronological and biological (Pater et al., 1981). 
The term "anatomical" is used in this thesis to describe factors which can be observed 
clinically at diagnosis (although pathological confirmation is always desirable). The term 
"biological" is used to describe factors for which laboratory investigation is required. 
Breast cancers arise from epithelial cells lining the terminal lactiferous duct units in the 
breast. Cancer cells are initially confined to the duct or lobule, and are termed in situ. 
Dissemination though the basement membrane of the duct indicates invasive cancer. 
Tumours usually grow initially as a single mass within the breast, although some 
tumours are diffuse, or multi-focal, and a few primary breast tumours are sited in the 
axilla. The incidence of tumour recurrence post-operatively suggests that, although the 
majority of the tumour bulk is sited in a single mass, in many cases micro-metastatic 
disease is present even with apparently localised disease (Sacks et al., 1993). 
The breast is well supplied by lymphatic vessels which drain into nodes in the axilla and 
the internal nodes. The regional nodes include the ipsilateral axillary nodes, the 
interpectoral (Rotter's) mammary nodes and ipsilateral mammary lymph nodes. The 
axillary lymph nodes are divided into three levels according to their position in relation 
to the pectorals minor muscle, shown in Figure 1.2. 
On average there are 20 nodes in each axilla, most being at level I (Bundred et al., 
1994). As tumour size increases risk of metastasis to the axilla rises, with spread to level 
I followed by level II and III. Occasionally "skip" metastasis occurs to level II or III via 
the internal mammary nodes without level I involvement (Sacks et al., 1993). Involved 
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nodes are initially mobile, but become fixed to surrounding tissue if the cancer breaches 
the capsule. Fixed nodes are associated with poorer prognosis than mobile nodes. 
The degree of progression in relation to the site of origin is termed the disease extent. 
As disease progresses, the tumour extends beyond the breast, leading to ulceration of 
the skin, or fixation to the chest wall. If lymphatic vessels in the skin are blocked, 
oedematous swelling can give the appearance of orange peel ("peau d'orange"). The final 
stages of disease are reached when distant lymph nodes including the cervical, 
supra-clavicular, contralateral axillary or contralateral internal mammary nodes become 
involved or metastases appear in sites including bone, brain, liver and lungs. 
1.3.1 Anatomical prognostic factors 
Tumour size correlates directly with overall survival, increased tumour size being 
associated with decreased survival (Carter et al., 1989). The pathological size of 
tumours is more valuable in prognosis than the clinical size (Hermaneck et al., 1995), 
but cannot be used where the tumour was removed in several pieces, if the excision 
margins are not free of tumour, or where pre-operative tumour-shrinking therapy has 
been given. The status of the local nodes indicates the tendency of tumours to 
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metastasise, and again, pathological data are more prognostically valuable than clinical 
data (Hermaneck et al., 1995). Patients with positive nodes show poorer survival than 
those with negative nodes, and prognosis worsens as the number of involved nodes rises. 
The influence of the status of the local nodes is additive with, and independent from, that 
of tumour size (Carter et al., 1989). Metastases in distant sites are indicative of poor 
survival, although patients with metastasis to the supra-clavicular nodes have slightly 
better prognosis than those with metastases elsewhere (Miller et al., 1994). The 
chronological nature of these factors means that status of a patient with respect to 
tumour size, nodal status and distant metastases is partly a reflection of the degree of 
delay prior to diagnosis, or the lead time. Patients presenting with small tumours, for 
example, will often have sought medical help earlier than those with larger tumours. 
1.3.2 Biological factors 
1. Tumour histology 
Most breast cancers are invasive ductal adenocarcinomas. Non-invasive tumours make 
up a small proportion of symptomatic cancers and are subdivided into ductal carcinoma 
in situ (DCIS), and the rarer lobular variant (LCIS), depending on microscopic 
appearance. The risk of invasive cancer following in situ disease has been estimated at 
25-50% at 20 years (Page et al., 1995). In situ tumours are often associated with 
excellent prognosis. Concerns have been raised over inconsistency in the classification of 
in situ cancers, lack of consensus on the risk of subsequent invasive disease, and lack of 
knowledge of the underlying incidence of in situ cancer (Foucar, 1996; Fricker, 1996). 
The majority (>70%) of ductal adenocarcinomas are of no special type (NST), having no 
distinguishing features on microscopic examination. A further 10- 15% are lobular 
adenocarcinomas (Gallager, 1984). The remainder are "special types". These include 
tubular, cribriform, mucinous, papillary, medullary and adenoid cystic carcinoma. Some 
special types have favourable prognostic characteristics, for exampIe mucinous tumours 
tend to be well differentiated (Gallagher, 1984; Ellis et al., 1992). The favourable 
survival rates for some "special type" tumours can be seen in Figure 1.3, with ten year 
survival rates varying from 47% for ductal carcinomas of no special type to 91% for 
cribriform carcinoma (Ellis et al., 1992). 
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ii. Tumour grade 
Tumour grading is the classification of tumours based on morphological appearance, and 
is predictive of tumour behaviour. A number of histological features have been assessed 
in different grading systems including the degree of glandular formation, epithelial 
secretion, the size of cells, the size of nuclei, variation in the size of cells and nuclei, 
nuclear hyperchromatism and mitotic activity. The system currently recommended by the 
NHS Breast Screening Programme (NHSBSP, 1995a), and by the British Association of 
Surgical Oncologists (BASO, 1995) is that devised by Bloom and Richardson (Bloom et 
al., 1957) and modified by Elston and his colleagues (Elston et al., 1991). This system 
combines three features (tubule formation, nuclear pleomorphism, mitotic activity) for 
each of which a score of 1 to 3 is allocated based on the whether the feature is apparent 
to a slight (score i), moderate (score 2) or marked degree (score 3). Higher scores 
indicate a higher degree of malignancy. Tubule formation is lost in aggressive tumours 
and replaced by solid tumour growth. Assessment of the second feature, nuclear 
pleomorphism, quantifies the degree of variability of both size and shape of tumour 
nuclei. Normal tissue has cells with generally small nuclei, and little variation in nuclear 
size and shape. Classification of the third feature, mitotic activity, has been modified by 
Elston and his colleagues so that scoring is based on the number of mitoses per 10 high 
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power fields assessed at the tumour periphery, with a high mitotic count indicating a 
high score. The three scores are added, and banded into three grades. Grade I tumours 
display the best survival and grade III the poorest. Although in the past it was thought 
unnecessary to grade "special type" tumours, the NHSBSP currently recommends that 
grading is carried out for all histological subtypes. An obstacle to the widespread use of 
grade for prognostic purposes is lack of inter-observer reproducibility (Gilchrist et al., 
1985; Sloane et al., 1994), although provision of clear guidelines has been found to 
improve consistency (Robbins et al., 1995). Although grading has been shown to be 
prognostically useful, it is not always performed, and if recorded, it is difficult to be sure 
whether the recommended criteria (Elston et al., 1991) were used. 
Grading is also applied to in situ carcinomas in order to identify cancers that are likely to 
progress to invasive disease. Grading is based on nuclear appearance (Page et al., 1995), 
and may be combined with the degree of comedo-type necrosis to form a prognostic 
classification (Silverstein et al., 1995). In situ cancers most likely to progress are high 
grade. Extensive in situ tumour necrosis is also a sign of progressive potential. 
iii. Lymphatic and vascular invasion 
Lymphatic or vascular invasion is found in up to 25% of breast cancer patients, and is 
associated with increased risk of local recurrence after surgery (Miller et al., 1994; 
Hermanek et al., 1995). 
iv. Other factors 
A high proliferation rate increases the risk of poor survival and the ploidy of malignant 
cells is often abnormally high, with aneuploid tumours of worse prognosis than diploid 
tumours (Miller et al., 1994). 
The presence of oestrogen receptors in breast cancers has been used to predict likely 
response to hormonal manipulation, with receptor positive tumours producing a better 
response and a lower recurrence rate than receptor-negative tumours (Donegan, 1992). 
Receptors for epidermal growth factor oncogene erbB2 are associated with poorer 
survival (Miller et al., 1994). Alterations in the p53 tumour suppresser gene are the most 
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frequent genetic changes found in breast cancer, especially in familial breast cancer, and 
are associated with poor prognosis (Elledge et al., 1993). Aggressive tumour behaviour 
has also been linked to reduced expression of the Nm23 gene (Steeg et al., 1993). 
Combining factors to produce prognostic indices 1.3.3 
To improve prognostic accuracy systems have been produced which combine prognostic 
factors. The first system to be used in the UK was the clinical Manchester staging 
system (Paterson, 1948), which used tumour size, extent, and nodal status to assign 
stage. A number of different systems have been developed since then, based on the 
Manchester system. The commonest staging system used currently is the TNM system. 
i. The TNM staging system 
The TNM (Tumour, Nodes, Metastases) staging system was recommended in 1959 by 
the International Union Against Cancer (UICC) and the American Joint Committee on 
Cancer and has undergone revisions in 1974,1987, and 1992 (UICC, 1992). The criteria 
on which the TNM system is based are 
the size of the primary tumour (the T stage) 
the extent of invasion beyond the breast (also T stage) 
the malignant status and malignancy of axillary (local) lymph nodes (the N stage) 
the presence or absence of distant metastases (the M stage) 
Appendix One provides a description of the classification of T, N, and M stages for 
breast cancer. Clinical or pathological data may be used, although clinical assessment of 
the lymph nodes may be unreliable and detracts from the usefulness of the staging 
system (Barr et al., 1992), and exclusion of biological factors has also provoked 
criticism (Barr et al., 1992, Sacks et al., 1993). An important drawback of the system is 
that it takes no account of some factors which are critical in clinical decision-making, 
such as tumour grade, multi-focality, the presence of in situ in combination with invasive 
cancer, and the position of the tumour in relation to the nipple or chest wall. Despite 
these limitations TNM staging is useful for predicting survival (Hermanek et al., 1995), 
and is in common use. Five year relative survival for breast cancers diagnosed in the UK 
from 1975-80 were reported as 84% for stage ‘1’, 71% for stage '2', 48% for stage '3', 
and 18% for stage '4' cancers (Cancer Research Campaign, 1988). The 1992 TNM 
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revision is used at the WMCIU for the purposes of the national Minimum Data Set for 
Cancer Registration (MDSCR). However, lack of recorded stage at cancer registries is a 
recognised problem. For example, stage was available for only 0.89% of breast cancers 
diagnosed in 1982-86 in the South West region (Bristol Cancer Epidemiology Unit, 
1995). That this lack of staging data is, at least in part, a reflection of the absence of 
staging at diagnosis is supported by a study in the South East in which, even in 1990, 
only 24% of the 334 breast cancers had stage recorded in the hospital case notes 
(Chouillet et al., 1994). The problem of absence of routinely recorded stage at cancer 
registries, and indeed the absence of staging at diagnosis, is a potential limitation to 
population-based assessments of prognosis, treatment and survival for breast cancer. 
ii. The Nottingham Prognostic Index 
The Nottingham Prognostic Index (NPI) (Haybittle et al., 1982) combines grade, lymph 
node stage, and tumour size to produce three prognostic groups - good, moderate, and 
poor using the following formula 
' 
NPI = (0.2 x size in cm) + lymph node stage + grade 
Lymph node stage is based on pathological examination of three nodes. If all three nodes 
are disease-free the tumour is classified as stage A. If only the lowest (level I) node is 
involved, the tumour is stage B, and if the apical or internal mammary node is involved, 
stage C. Grading follows the modified Bloom and Richardson regimen (Elston et al., 
1991). The utility of this index in predicting outcome and for stratifying groups of 
patients has been confirmed (Todd et al., 1987, Brown et al., 1993). 
1.3.4 Treatment factors 
The aims of treatment are eradication of disease, achievement of local control, 
prevention of recurrence, and minimisation of side-effects. Treatment falls into three 
types - surgery, locoregional radiotherapy, and systemic cytotoxic or endocrine therapy. 
i. Surgery and radiotherapy 
surgical removal of the tumour often forms the basis of treatment for breast cancer, and 
many patients also receive radiotherapy to the chest wall or axilla. The modified radical 
(Patey) mastectomy involves removal of the breast and the axillary nodes, but the 
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pectoralis major and often the pectoralis minor muscles are preserved and internal lymph 
nodes are left in situ. 
The physical and psychological impact of mastectomy can be severe (Sacks et al., 1993), 
and surgical techniques which aim to preserve the breast have been developed. 
Conservative surgery encompasses a number of techniques. Lumpectomy is a technique 
in which the palpable tumour is excised and an attempt to obtain tumour-free margins is 
routinely made. More extensive techniques include wide excision and segmentectomy 
and involve the loss of more breast tissue in an attempt to clear the tumour margins. 
Radiotherapy is used to sterilise microscopic tumour deposits at the site of surgery and 
axilla, often after conservative surgery (Sacks et al., 1993). Advanced cancers may be 
treated with radiotherapy alone for palliative reasons (Rodger et al., 1994). 
Early trials of conservative surgery plus radiotherapy found a survival disadvantage 
compared to mastectomy, but the radiotherapy doses used were inadequate by modern 
standards (Rubens, 1992). More recent trials have identified no survival difference 
between the two types of surgery, but found increased risks of recurrence after 
conservative surgery (EBCTCG, 1994, Fisher et al., 1995, Riley et al., 1995). 
The cosmetic advantage of breast preservation can be offset by fears of recurrence, and 
psychiatric morbidity does not appear to be influenced by the type of surgery performed 
(Maguire, 1994). Risk of recurrence has been linked to incomplete tumour excision, the 
presence of an in situ component, vascular or lymphatic invasion, and high tumour grade 
(Dixon, 1995). Concern over recurrence rates following conservation surgery have been 
raised (Benson, 1996), with the suggestion that conservative techniques should be 
restricted to small, uni-focal tumours (<2cm), with complete clearance of the tumour 
margins. The perception that conservative surgery is better for patients was 
demonstrated by the quality standard set by the NHSBSP in 1992 that >50% of women 
with a tumour <=15mm should receive conservative surgery, but the need for complete 
tumour excision was stressed (NHSBSP, 1992). The need for surgical stringency has 
been addressed in guidelines from the BASO group (BASO, 1995) for surgeons treating 
symptomatic breast cancer. Use of reconstructive surgery has risen by more than 5-fold 
since 1992 (Watson et al., 1995), although such techniques are not universally practised. 
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The recent BASO guidelines recommend that a minimum of four axillary nodes should 
be sampled at diagnosis (BASO, 1995), while the TNM staging system recommends that 
at least 6 axillary nodes are sampled (UICC, 1992). Various methods of management of 
the axilla are still in use, ranging from a "watch" policy" to dissection, clearance and/or 
radiotherapy. Axillary staging is still not always carried out. Axillary dissection may be 
performed to level I, II or III of the axilla. Evidence that axillary irradiation reduces 
recurrence rates in women undergoing conservation surgery has been found repeatedly 
(Bundred et al., 1994). A recent meta-analysis comparing axillary clearance with 
radiotherapy identified no survival difference between groups, but fewer recurrences in 
those receiving radiotherapy (EBCTCG, 1995). 
Side effects from radiotherapy include desquamatisation, nausea, and fatigue. 
Complications may result from intervention at the axilla, particularly if a level II or III 
clearance and irradiation are used. Nerve and muscle damage can be caused by surgery 
or irradiation, giving rise to conditions including brachial plexopathy (Spittle, 1995). It is 
anticipated that the peak incidence of radiation induced plexopathy has been reached due 
to changes in techniques in since 1970 (Maher, 1995). Lymphoedema of the arm is most 
severe when resulting from axillary recurrence, but can result from combined high-level 
dissection and radiotherapy. Around 30% of those receiving radiotherapy after a level II 
clearance experience lymphoedema, and radiation in addition to surgery should be 
avoided after level III dissection (Bundred et al., 1994), and avoided or spread out over 
a long period where reconstruction is planned (Watson et al., 1995). 
ii. Systemic therapy 
Systemic therapies have been developed in attempts to eliminate micro-metastatic 
deposits in patients with apparently localised disease, to reduce symptoms and improve 
survival of patients for whom surgery is unsuitable and to shrink large tumours 
pre-operatively in order to facilitate effective surgery. Systemic therapy is used as both a 
primary intervention, and as an adjuvant to locoregional surgery or radiotherapy. 
Adjuvant therapy preserves prognostic data at diagnosis, but the benefit to individual 
patients is hard to monitor. Primary tumour-shrinking treatment does allow direct 
assessment of progress and may reduce the impact of surgery, but involves loss of 
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prognostic-data. Commonly used systemic therapy can be divided into cytotoxic and 
endocrine (hormone) therapy. A number of trials have examined use of immune 
therapies, but none has identified a significant benefit from these drugs in terms of 
recurrence-free or overall survival (EBCTCG, 1992). 
a. Cytotoxic chemotherapy 
Many cytotoxic agents have been used for breast cancer, including alkylating agents and 
anthracyclines. Combinations such as Cyclophosphamide, Methatrexate, and 
Fluorouracil (CMF) are more effective than single agents at delaying recurrence, 
especially in poor-prognosis patients (EBCTCG, 1992). In this trial the proportional 
reduction in annual mortality for patients >= 50 years with stage '2' disease was 12% 
compared to patients not receiving CMF, and for patients <50 years, 30%. Cytotoxic 
therapy may be useful for rapidly progressive cancer (Rodger et al., 1994), but the 
benefits of cytotoxic drugs must be weighed against side effects such as nausea, alopecia 
and induction of menopause. In patients wishing to undergo reconstructive surgery 
cytotoxic chemotherapy should only be given after the wound has healed and only if 
there are no signs of infection (Watson et al., 1995). Oophorectomy, which is only of 
benefit to younger women, produces similar survival benefit to polychemotherapy, can 
be achieved by surgery, irradiation or hormonal manipulation, but is also associated with 
unpleasant side-effects including induced menopause and osteoporosis (Richards, 1994). 
b. Hormone therapy 
The most commonly used hormonal agent for early disease is Tamoxifen, which 
although predominantly an oestrogen antagonis tic, has some agonist properties. A 
reduction in mortality of 20% was found for middle aged women with stage 2 tumours 
treated with Tamoxifen (EB CTCG, 1992). A recent meta-analysis concluded that, 
although of more benefit in oestrogen receptor-rich tumours, a smaller benefit could also 
be achieved in receptor-poor tumours. Tamoxifen is considered to be of benefit for all 
ages (Richards, 1994), and may be used as primary treatment and an adjuvant in patients 
with early breast cancer. Combined polychemotherapy and Tamoxifen has been found to 
be more effective than either regimen alone in terms of relapse-free survival (EBCTCG, 
1992), but a meta-analysis of quality-adjusted survival revealed no benefit for those 
receiving both therapies compared to Tamoxifen alone, a finding which authors attribute 
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to side-effects associated with chemotherapy (Gelber et al., 1996). A number of other 
hormonal agents have been developed including aromatase inhibitors which are used in 
postmenopausal women with advanced disease (Zeneca Pharma, 1995). 
iii. 
There is currently no consensus of opinion on the optimal treatment for in situ cancer. 
One trial comparing lumpectomy vs lumpectomy plus radiotherapy identified a reduced 
risk of non-invasive or invasive ipsilateral cancer in those given radiotherapy, and 
authors suggest conservation surgery with radiotherapy may be more appropriate than 
mastectomy (Fisher et al., 1993). Recent recommendations on the treatment of DCIS 
(Page et al., 1995) include excision of tumours <4cm and mastectomy if >=4cm or 
widespread DCIS, postoperative radiotherapy if comedo-type DCIS, and possible use 
of Tamoxifen. The NHSBSP is currently undertaking a trial of patients with screen 
detected DCIS to identify the most appropriate treatment options (NHSBSP, 1989). 
1.3.5 
i. Consensus treatment guidelines 
In 1983 a survey of 766 consultant surgeons in England revealed variations in clinical 
practice (Gazet et al., 1985). Use of surgery varied; over 70% of patients underwent 
mastectomy, and over 10% of surgeons never performed conservative surgery. Use of 
radiotherapy and chemotherapy differed and although use of endocrine therapy was 
common, criteria used to select women for treatment varied. In 1986 the Kings Fund 
convened a panel of experts to set guidelines on treatment and the organisation of breast 
cancer services (Kings Fund 1986). A summary of the guidelines is shown in Table 1.2. 
A survey in 1991 examined the impact of the King's Fund guidelines (Morris et al., 
1992). The authors found that use of conservative surgery had increased, that surgeons 
discussed treatment options with patients more often, and that access to counselling had 
improved since the original 1983 study. However, an investigation of patients treated in 
1986 at two London teaching hospitals found that clinical practice still differed from the 
guidelines (McCarthy et al., 1991). For example, only 43% of patients had axillary node 
sampling or clearance and few women under 50 years received cytotoxic therapy. A 
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recent study from the South East found that treatment varied widely (Choiullet et al.. 
1994). Axillary surgery was carried out in only 46% of cases. The authors concluded 
that, five years after the King's Fund conference, some of the recommendations had not 
been absorbed into common practice. This situation is similar to that in the United States 
where, although rates of conservative surgery are rising, there are large differences in 
rates between areas (Farrow et al., 1992), and in a study of the effect of hospital type on 
survival from breast cancer, use of recommended breast conserving surgery was greater 
amongst teaching rather than non-teaching hospitals (Lee-Feldstein et aI., 1994). 
ii. 
The organisation of cancer care has been examined in relation to survival by a number of 
studies (Stiller, 1994). Finnish women living near hospitals with radiotherapy facilities 
enjoyed better survival after adjustment for age and stage compared to those living 
elsewhere (Karjalainen, 1990). Survival for women treated at UK teaching hospitals was 
The organisation of cancer care 
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better than for those at non-teaching hospitals after adjustment for age, stage and type of 
operation (Basnett et al, 1992) and a study from the United States identified a survival 
advantage for patients treated at large community hospitals compared to smaller 
hospitals (Lee-Feldstein et al., 1994). It has been hypothesised that this survival 
advantage results from the better treatment provided by specialists in multi-disciplinary 
teams which treat a large number of patients and have access to new or better treatment 
regimens. One study identified a reduction in risk of dying for those treated by specialists 
after adjustment for age, tumour size, socio-economic status, and nodal involvement 
(Gillis and Hole, 1996). No treatment data were available in this study, but the authors 
suggest that the observed survival advantage may reflect differences in treatment. 
A recent study identified a survival benefit for those treated by clinicians with an annual 
workload of >30 new cases/year (Sainsbury et al., 1995b), and caseload was found to 
have a significant influence on survival after adjustment for age, nodal status, grade, 
social class and treatment regimen. One Italian study, however, failed to identify any 
benefit in terms of mortality rates according to caseload (Bofetta et al., 1993). It is thus 
questionable whether caseload alone is adequate as an indicator of multi-disciplinary 
care provision (Baum 1996, Sikora, 1996), although in one study surgeons with a high 
caseload were more likely have a "special interest" in breast cancer, and were more 
likely to use adjuvant treatment (Sainsbury et ai., 1995a). 
The validity of surgical caseload as an indicator of high quality multi-disciplinary care is 
currently a controversial issue. The Calman-Hine report (HMSO, 1995) set out a 
strategy for reorganising cancer care in the UK, focusing on the establishment of Cancer 
Centres and Cancer Units in which multi-disciplinary teams with site specialisation will 
operate. In response to the Calman-Hine report a Clinical Outcomes Group (COG) was 
set up to focus on the diagnosis and management of breast cancer, including 
recommendations on diagnostic facilities, treatment, follow-up and palliative care, and 
stressing the importance of the establishment of specialist breast teams (NHS Executive, 
1996a). The COG Report recommended that all breast referrals should be to a specialist 
breast team which deals with at least 100 new cases per year. The British Breast Group 
(BBG), however, although advocating the management of breast cancer by specialist 
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teams, recommended a higher caseload of 150 cases/year as a realistic minimum for a 
specialist breast team, with a level of 50 cases/year being set for unusual "highlands and 
islands" areas (BBG, 1994), a view endorsed by BASO (BASO, 1996). On the basis of 
the limited evidence available, higher patient throughputs are believed by the COG to be 
associated with greater diagnostic accuracy, better quality surgical and non-surgical 
treatment, and better survival rates (NHS Executive, 1996a, 1996b). 
1.4 SCREENING FOR BREAST CANCER 
Concerns over high breast cancer mortality in the UK raised the possibility of 
introducing a population-based screening programme. A variety of screening techniques 
were studied in the 1960s and 1970s, and results suggested that detection of 
pre-symptomatic cancer could be achieved by mammography. To assess the feasibility of 
a programme the Department of Health appointed a committee to consider the available 
evidence. The committee, chaired by Sir Patrick Forrest, produced a report of findings 
(the "Forrest" report, HMSO, 1986), which was updated in 1991 (NHSBSP, 1991). 
1.4.1 
Randomised controlled trials assessed the impact of screening on breast cancer mortality 
by comparing mortality in those invited with that in uninvited populations. Data from the 
most important studies of screening by mammography are summarised in Table 1.3. 
Evidence from studies of breast cancer screening 
For women aged 50-74 years, the overall reduction in mortality in those invited was 
24% (RR 0.76 95% CI 0.67 - 0.87). Assuming that the underlying risk of breast cancer 
death was equal in attenders and refusers, the mortality reduction in those screened was 
estimated at 31% (Wald et al., 1994). For women aged 40-49 years the mortality drop 
was 16% (RR 0.84 95% CI 0.67 - 1.06) and was not statistically significant. 
Data from population-based studies were also considered. In a number of studies 
screening was offered to defined populations and the impact of screening assessed by 
comparing the odds of screened women dying from breast cancer with those of 
unscreened women. Data from these studies are summarised in Table 1.4. The reduced 
risk of death found in population-based studies suggest that screening can reduce 
mortality, but may be confounded by the "healthy screenee" effect, in which women least 
likely to die from breast cancer selectively attend for screening. 
1.4.2 
The Forrest Committee concluded that criteria set out by Wilson and Jungner in 1968 
were met sufficiently by breast cancer screening by mammography and recommended 
that there should be a breast screening programme in the UK, and that 
The NHS Breast Screening Programme 
the screening test should be single view, medio-lateral oblique mammography 
women aged 50-64 years should be routinely invited, women of 65 or more should 
be screened on demand, but those <50 years should not be eligible for screening 
the screening interval should be 3 years but kept under review 
specialist, multidisciplinary assessment teams should be used to carry out diagnosis 
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a-screening record system should be developed to identify, invite and recall 
women, to record attendance and to monitor the screening process 
quality control arrangements should be made between and within centres so that 
an acceptable standard of mammography is maintained 
The NHSBSP became operational in 1988, with services launched across the UK in a 
staggered introductory period lasting until 1992. To reflect the aims of the NHSBSP, 
mortality in invited women was chosen as a Health of the Nation (HoN) target of a 25% 
mortality reduction in women aged 50 - 69 years (HMSO, 1992, Department of Health 
(DOH), 1993), although monitoring changes in mortality in women aged 55 - 69 years is 
preferred by the NHSBSP (Quinn and Allen, 1995). The HoN target mortality rate has 
recently been lowered to account for a background fall in breast cancer mortality which 
began prior to 1988 (Quinn and Allen, 1995). The mortality rate in the baseline year 
1990 was estimated at 95.1/100,000, giving rise to the original target of 71.3/100,000 
(HMSO, 1992). The 1991 census revealed that the actual mortality rate in 1990 was 
lower at 93.4/100,000, and thus the current HoN target is 70.1/100,000 (DOH, in 
press). The operational procedures used by the NHSBSP are summarised in Figure 1.4. 
i. Identifying eligible women and issuing invitations 
The Forrest Committee concluded that women aged 50 to 64 years should be eligible for 
routine screening and that older women may receive screening on demand. Women 
under 50 years are not eligible, with evidence concerning the effectiveness of screening 
in this age group being contradictory (Margolese, 1996). An overview of five Swedish 
trials identified a non-significant 13% mortality reduction in women aged 40-49 years 
after 8 years (Tabar et al., 1993). A meta-analysis of seven studies identified a 
non-significant mortality reduction of 10 - 15% in the screened groups for 40-49 year 
olds (Smart et al., 1995), but analysis of false positive results from Stockholm concludes 
that the potential negative aspects of screening were substantial for younger women 
(Lidbrink et al., 1996). In order to explore this further, the NHSBSP "age" trial began in 
1991, recruiting 65,000 women aged 40 and 41 years for annual screening. An 
age-matched control group is being monitored to identify differences in breast cancer 
incidence between the groups. The trial will run for 15 years and women will be 
followed up to identify differences in mortality, Currently women aged from 65 years 
upwards may be screened on demand, but are not routinely invited. The charity Age 
Concern is, in conjunction with the NHSBSP, raising awareness of breast screening in 
this age group (NHSBSP and Age Concern, 1996). The possibility of extending the 
routine screening age up to 69 years is being explored at two pilot sites in the UK, which 
were set up in 1996 and are due to run for three years before any results are available. 
The population registers used to identify eligible women are held by District Health 
Authorities (DHAs) which have incorporated the functions performed by the former 
Family Health Services Authorities (FHSAs). The small degree of inaccuracy of these 
lists (Bowling et al., 1989; Bickler et al., 1993) means that a small proportion of eligible 
women are not invited for screening. A basic "Forrest" unit screens around 12,000 
woman a year, staggering invitations over the three year round. Women are invited in 
batches, usually according to GP practice. The process is initiated by a request from the 
screening unit to the FHSA for a Prior Notification List (PNL) providing details of 
eligible women. The PNL is sent to GPs for checking so that inaccuracies are corrected 
and women for whom breast screening is contraindicated can be temporarily or 
permanently excluded from the programme. The checked PNL is returned to the FHSA 
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or unit and used to produce invitations specifying the date, time and location of a 
screening appointment. Most units operate from a static site based at a hospital, and also 
have access to a mobile unit which visits a number of sites in the catchment area to 
reduce the travelling distances for women attending. 
ii. Basic screening method 
The Forrest Committee recommended that single view, medio-lateral oblique 
mammography should be used. However, almost half the 83 units operational in 1993 
used two view mammography, in which a second cranio-caudal view is taken, 
throughout the prevalent round. Analysis of results from programmes using single view 
compared to those using two view mammography revealed a significantly higher cancer 
detection rate in those using two view screening (Moss et al., 1995). A randomised trial 
of one versus two view screening confirmed that two view screening is more effective 
for identifying breast cancers (Wald et al., 1995). All units have been required to offer 
two view mammography to women attending for their first screen from August 1995. 
Women returning for subsequent screens are offered single view rnammography. 
Independent double reading of screening mammograms has been performed by some 
units but is not possible at many sites due to lack of staff. The benefits of double reading 
are disputed, with one study concluding that double reading produces only a modest 
increase in cancer detection rates (Ciatto et al., 1995), but another that it not only 
improves the cancer detection rate but is also less costly than a single reading policy 
(Brown et al., 1996). 
iii. The screening result 
Results of the screening mammogram are normally sent to the woman and her GP within 
two weeks. Over 90% of women are informed that the screening mammogram was 
normal. A few women are asked to return for a repeat mammogram due to a technical 
fault. A quality standard of <3% of all films requiring technical recall was set in 1992 
(Muir Gray, 1991). Less than 10% of women are recalled for assessment due to an 
abnormality on the screening film. Although not diagnostic of cancer, women are often 
distressed by the request for reattendance and clear information must be provided 
explaining the implications of recall (Austoker et al., 1994; Ong et al, 1996). 
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iv. Assessment procedures 
Assessment may involve a number of different investigations, usually from a specialist 
multi-disciplinary team which should include a radiologist, radiographer, pathologist, 
surgeon and breast care nurse. Repeat X-ray films are taken, and a physical examination 
performed for palpable lesions. Ultrasound may be employed if a cyst is suspected. In 
some units fine needle aspiration (FNA) is used to investigate possible cysts, and 
cytology of specimens obtained using FNA can be diagnostic. Suspicious lesions may 
have a fine-needle ("core", "trucut" or "wide bore needle") biopsy from which a 
histological diagnosis can be made. It is sometimes necessary to perform a surgical open 
biopsy, and X-ray guided localisation may be needed to locate impalpable lesions. In 
1993 only 5.5% of women screened were referred to assessment, and 0.8% underwent 
open biopsy (NHSBSP 1995e), rates which are lower than the estimates of 10% and 
1.5% respectively made before the introduction of screening (Austoker et al., 1988). 
These low rates are largely due to use of non-invasive diagnostic techniques. Over 80% 
of women are informed that the assessment proved negative and are placed on routine 
recall. For some women the result of assessment will be a diagnosis of breast cancer. A 
small number of women have unequivocal results after assessment, and are placed on 
short-term "early" recall, being re-invited for screening after 3 to 12 months. 
V. Treatment 
Referral for treatment may be undertaken by the woman's GP, but usually the screening 
unit refers women to a specialist breast cancer treatment team. The NHSBSP has set 
quality standards to ensure that over-treatment is avoided and that conservative surgery 
is used when appropriate. A mixture of radiotherapy, chemotherapy and hormone 
therapy is often used in addition to surgery. All women should receive information on 
treatment options and where appropriate should be offered a choice of treatment. 
vi. 
The Forrest Report recommended a 3 year screening round but specified that further 
research in this area was required. The NHSBSP is currently undertaking a trial to 
compare the effect of annual screening with routine 3 year screening. Eligible women are 
allocated a unique identifying number by the unit which is maintained throughout the 
The call and recall system 
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period of eligibility for routine screening. The call and recall system operates by 
identifying eligible women every 3 years based on age specifications set by the screening 
unit. The unique identifier allows previous screening history to be identified. It is 
essential that the invitation batch order is maintained so that women are re-invited on a 
3-yearly basis. The need to adhere to a 3-yearly round is demonstrated by a recently 
suggested radiological quality standard of >90% of women to be re-invited within 2 
months of the 3-year anniversary (Radiological Big ' 18', personal communication). 
1.4.3 The Quality Assurance system 
The Forrest Report stated that consistent high quality results will require a quality 
assurance (QA) programme. Following NHS reforms in 1996 QA services are purchased 
by lead purchasers representing Health Authorities in each of the eight regions in the 
UK. Specific aims of QA include provision of information about the NHSBSP, 
participation in evaluation and development, collection and review of data, organisation 
of multidisciplinary visits to units to assess performance, identification of problems, and 
monitoring remedial action. The QA system embraces surgery, radiology, pathology, 
medical physics, radiography, breast care nursing, health promotion, screening office 
administration and evaluation. The communication structure of the QA system outlined 
in Figure 1.5 is reproduced from QA Guidelines published in 1995 (NHSBSP, 1995c). 
Local QA services are focused at quality assurance reference centres (QARCs) led by a 
QA manager responsible for co-ordinating the activities of a QA Team. The QA Team 
consists of representatives from each of the professional groups who represent the 
interests of that discipline in the QA Team, advise the QA Manager on matters relevant 
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to their profession and participate in the National Co-ordinating Groups ("Big 18s") 
shown in Figure 1.5. 
Regional QA Team meetings provide a forum for discussion of QA issues and may be 
attended by invitation by unit directors, purchasers or other interested parties. Members 
of the QA Team also attend multidisciplinary visits to units at which discussions with 
representatives of each professional group allow assessment of quality, identification of 
problems and an opportunity to acknowledge good working practices. 
1.4.4 Evaluation of the NHSBSP 
1.4.4.1 Monitoring progress 
Breast screening is a multi-stage, multi-disciplinary process and outcome measures 
which assess the performance of each process are required. The progress of the 
NHSBSP can be assessed at three levels:- 
+ level 1 - changes in mortality due to screening 
level 2 - calculation of values for programme sensitivity and specificity 
level 3 - calculation of surrogate outcome measures 
Level I The aim of screening is to cause a fall in breast cancer mortality, but 
monitoring mortality alone does not provide a simple means of evaluating the success of 
screening. Breast cancer mortality has begun to fall in the UK (Quinn and Allen, 1995; 
Beral et al., 1995), but the degree to which screening is responsible for this is disputed 
(Wright et al., 1995), and there are other factors, including increased use of adjuvant 
hormone therapy, which are likely to have contributed to such a change. Identification of 
a significant mortality drop resulting from population based screening is complicated by 
the absence of a control population and confounded by an underlying fall in mortality 
(Quinn and Allen, 1995; Wright et al., 1995). Evidence from randomised controlled 
trials suggests that any reduction in mortality due to screening is unlikely to be apparent 
for 7 - 10 years after the introduction of screening and quantifying. the contribution of 
the NHSBSP to any drop in mortality will involve complex adjustments to allow for 
confounding (Day et al., 1989). Calculations such as these require aggregated data and 
thus should be undertaken at national and regional, rather than unit level (Knox, 1988). 
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Level 2 Calculations of sensitivity and specificity provide useful information but 
require large sets of standardised data (Greenstein et al., 1995). Data are difficult to 
collate due to the staggered start of screening and variation in round length at different 
units. The calculation of sensitivity requires knowledge of interval cancer rates. It has 
been assumed that interval cancers arising symptomatically in the 12 months after a 
negative screen can be used to represent false negative test results (NHSBSP, 1993a). It 
is, however, possible that such cancers began to develop after the negative screen, and 
that some genuine "missed" cancers become symptomatic after 12 months has elapsed. 
Level 3 The evaluation methods currently applied at national, regional and unit 
level involve the production of outcome measures which act as surrogate endpoints. A 
range of outcome measures and quality Standards has been developed by the QA system. 
Outcome measures produced at unit and regional level and provide information about 
the progress of the NHSBSP to those working in the programme, to purchasers and host 
trusts. Table 1.5 summarises the outcome measures used to assess whether the 
requirements of a successful programme are being met. 
For outcome measures to be useful they should be defined unambiguously and calculated 
consistently. High quality data must be available, and where data are available from 
multiple sources they must be consistent. Everyone using outcome measures must 
interpret them correctly, applying up to date and relevant standards, and making year on 
year comparisons to identify trends. 
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1.4.4.2 The cost effectiveness of the NHSBSP 
The annual cost of running a screening programme was estimated in 1986 to be £18 
million. The Forrest Report used evidence from a cost-utility analysis in which the cost 
per quality-adjusted life year was estimated at £3,400, and concluded that the benefits of 
screening justified the costs. More recently there has been disagreement over the 
cost-benefit balance of breast screening (Baum, 1995; Wright et al., 1995). 
In any screening programme there is trade off between risks and benefits. The benefits, 
including mortality reduction, depend on accurate detection of early cancers, 
identification of normal women and use of effective treatment. The risks of surgery can 
be minimised by avoiding unnecessary open biopsies for benign tumours, and by 
pre-operative diagnosis. These aims are reflected in quality standards set by the 
NHSBSP, and the monitoring undertaken by the QA service aims to ensure that 
unnecessary procedures are avoided. 
Mammography requires compression of the breast, and can be painful, although this was 
not reflected in the high attendance achieved in screening trials (Hurley et al., 1992). 
Possible causes of psychological morbidity include anxiety if recalled and increased 
length of time with knowledge of diagnosis (Hurley et al., 1992). A degree of anxiety 
following positive screens is inevitable, but can be reduced if the information needs of 
women are respected (Austoker et al., 1995). 
Risks resulting from breast cancer screening include overdiagnosis and the detection of 
length bias cancers. To what extent screening detects "length bias" cancers which would 
never become life-threatening is difficult to ascertain. The selective detection of such 
cancers leads to over-treatment and unnecessary anxiety, and reduces the ability of 
screening to reduce mortality. During the prevalent screen it is expected that more 
cancers are detected than would arise symptomatically in this time, and that some of 
these will be large, slow growing tumours (Day et al., 1989). This has been verified, but 
after subsequent screens the excess of cancers disappears suggesting that overdiagnosis 
is confined to the prevalent screen (Peeters et al., 1989; Tabar et al., 1992). 
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One issue yet to be resolved is the suitability of the three year screening round, which 
some believe to be too long, resulting in calls for a shorter two year round (Woodman et 
al., 1995; Day et al., 1995a, Asbury et al., 1996). The risk of breast cancer rises with 
age and thus screening should be repeated at intervals. The Forrest Committee 
recommended a three year screening round based on evidence available at the time, but 
recognised the need for further research in this area. Symptomatic cancers presenting 
after a negative screen (interval cancers) may indicate low sensitivity, or may suggest 
that a shorter interval between screens may be required. Although the incidence of some 
interval cancers is inevitable, minimising their occurrence is vital to the success of 
screening. The current definition of an interval cancer used in the collation of national 
statistics is a histologically confirmed, invasive breast cancer diagnosed within 36 
months of a normal screen. As interval cancer rates are used as a quality assurance 
standard for the NHSBSP, it is essential that interval cancers are uniformly identified and 
recorded and that radiological classification is accurate and complete. Current definitions 
do not account for a variety of factors which may influence interval cancer rates, and 
radiological classification is frequently unavailable for analytical purposes. 
1.4.4.3 The cancer registration system and screening evaluation 
In the UK a national network of cancer registries collect data on the incidence and 
characteristics of cancers occurring in the population, and submit a standard data set to 
ONS for collation of national cancer statistics. Although the current cancer registration 
system was established nation-wide in 1970, the data collected by different registries 
differed (UKACR, 1994). The WMCIU collects data from multiple sources, including 
pathology reports, and records details of treatment received. In 1993 a Minimum Data 
Set for Cancer Registration (MDSCR) was introduced (EL(92)95 Annex B) setting out 
requirements for the data to be collected by cancer registries and sent to ONS. In 
anticipation of the divestment of cancer registries from the old Regional Health 
Authorities to Lead Purchasers in 1996, a core contract for cancer registration 
(EL(96)7) was issued to ensure that the requirements of the MDSCR are maintained. 
Lack of TNM staging for breast cancers recorded at cancer registries has already been 
mentioned. The MDSCR covers many aspects of cancer registration, including 
timeliness and reliability, and recognises the importance of prognostic data by setting 
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standards for the proportion of certain cancers with staging data available. For breast 
cancer a minimum standard of 30% was set, with a desirable target of 80%. Whether 
these targets are met depends not only on efficient data supply to cancer registries, but 
on whether staging data are collected and stored in an assessable form within Trusts. 
Nonetheless, cancer registries in the UK are currently a unique source of routinely 
collected, population based data for evaluation of breast cancer. 
Cancer registries have an essential role to play in evaluating the NHSBSP (Bull et al., 
1989). The NHSBSP produced guidelines on the utilisation of breast cancer data, 
stressing the need for communication and data exchange between the NHSBSP and 
cancer registries (NHSBSP, 1993b). Categories were provided by the NHSBSP into 
which breast cancers arising in women eligible for screening would fall - screen detected 
cancers, interval cancers, cancers in lapsed attenders, cancers in non-attenders and 
cancers in the uninvited. It is only possible to categorise breast cancers in this way with 
the co-operation of both the NHSBSP and cancer registries. The incidence and 
characteristics of cancers in these groups provides insight into the success of screening. 
Examination of the prognostic characteristics of breast cancers in relation to their 
screening history can provide early indicators of success for the NHSBSP (Day et al., 
1989; Bull et al., 1991). For screening to succeed the prognosis of screen detected 
cancers must be favourable, as a fall in mortality due to screening is likely to be preceded 
by a fall in the rate of advanced disease in screen detected cancers. Studies have shown 
that screen detected cancers are often small with negative axillary nodes (Duffy et al., 
1991; Tabar et al., 1992; Moss et al., 1994), and have more favourable biological 
features than symptomatic cancers (Klemi et al., 1992; Crisp et al., 1993; Hakama et al., 
1995; Rajakariar et al., 1995). By combining data from the NHSBSP and cancer 
registries it is not only possible to examine the prognosis of screen detected cancers, but 
by comparing these cancers with those found outside the NHSBSP, it is possible to 
assess the likely impact of screening on mortality. However, missing and unreliable 
staging data can pose a serious limitation to this type of population-based assessment the 
NHSBSP. 
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For screening to succeed, the majority of breast cancers in the eligible population should 
be detected by screening. However, in a recent study of breast screening in the South 
East Thames area, only 1331 of the 4202 (48%) cancers in eligible women examined 
were screen detected (Garvican et al., 1996). If the high proportion of cancers 
diagnosed outside the screening programme in the South East were to be combined with 
a higher degree of aggressiveness in these cancers compared to those found by 
screening, the impact of screening on breast cancer mortality will be smaller than 
expected. The incidence of breast cancers outside the NHSBSP in women eligible for 
screening provides important information about the programme. In particular, the high 
rates of interval cancers observed in the NHSBSP suggest low programme sensitivity, 
and/or that the screening round length is too long (Woodman et al., 1995; Day et al., 
1995a, Asbury et al., 1996). Other breast cancers diagnosed outside the programme 
could signal other significant problems. High incidence rates in lapsed attenders, who 
have previously attended but defaulted an appointment prior to diagnosis, would suggest 
that the screening experience was unacceptable, while high incidence in the uninvited 
would indicate inadequacy in population coverage. 
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1.5 AIMS OF THIS INVESTIGATION 
There is much activity currently being directed towards improving the outcome for 
cancer patients in the UK, including women with breast cancer. The impact of the NHS 
Breast Screening Programme (NHSBSP), the reorganisation of cancer services 
following the Calman-Hine report, and improvements in treatment in response to 
guidelines issued by BASO and the NHSBSP must be evaluated. Cancer registries are 
currently the only source of the routinely collected population-based data that such 
assessments require. The NHSB SP routinely records data describing screen detected 
cancers and thus can act as additional data source. However, the validity of routinely 
collected breast cancer data for such assessments must be established. The first objective 
of this thesis was to audit prognostic data including stage recorded for breast cancers at 
the WMCIU and by the NHSBSP, in order to assess whether these data are of 
sufficiently high quality to be useful. Additional aims of the audit were to identify 
possible causes of any inadequacies in the data, and to suggest solutions. Tumour stage 
is of particular importance in evaluating breast cancer as it is recognised as a highly 
significant prognostic factor. The reported incompleteness of tumour stage recorded at 
cancer registries thus imposes a serious constraint on the utility of recorded data. In an 
attempt to resolve this difficulty the development of a staging algorithm as a possible 
means of allocating stages to breast cancers at the WMCIU was explored. 
The West Midlands represents approximately one tenth of the UK population and thus 
provides a large study population for ecological studies. The recognition of patterns of 
disease within a population is essential if resources aimed at reducing mortality are to be 
effectively targeted. The second objective of the thesis was to produce an overview of 
temporal and geographical patterns of disease in the West Midlands, and to focus in 
detail on the tumour and patient characteristics of breast cancers in the region. The 
major prognostic factors for breast cancer have been established by a number of studies, 
including tumour stage, grade, and type of treatment. This study attempted to confirm 
the significance of established prognostic factors in the study group in order to identify 
those factors which, by manipulation, could bring about improvements in survival for 
breast cancer patients in the West Midlands. 
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Use of optimal treatment is crucial if mortality from breast cancer is to be reduced, and 
current guidelines from BASO and the NHSBSP aim to improve treatment. Monitoring 
the degree and speed with which such guidelines change clinical practice will be 
essential, but it is too soon to tell whether they have had any effect. The first guidelines 
on the management of breast cancer in the UK were issued by the King's Fund in 1986. 
Although now superseded, examination of treatment pre- and post-dating the King's 
Fund guidelines allows assessment of the ability of treatment guidelines to alter clinical 
practice. Evidence from elsewhere in the UK suggests that treatment for breast cancer 
improved following the availability of the King's Fund guidelines, although sub-optimal 
treatment was still common after 1986. An aim of this study was to examine the 
treatment recorded for breast cancers diagnosed in the West Midlands in 1983 and 1987, 
spanning the publication of the King's Fund guidelines, in order to examine treatment 
patterns across the region and identify any changes in clinical practice. The study also 
aimed to establish an audit process to facilitate the routine performance of future studies 
and provide baseline data against which any improvements in treatment following recent 
guidelines could be measured. 
The multi-disciplinary Clinical Outcomes Group (COG) has recently issued a 
recommendation that breast cancer care should be delivered within high caseload 
surgical teams on the assumption that treatment from surgeons with a high caseload 
translates into better patient outcomes. However, there is only limited evidence for a 
positive relationship between high patient throughput, better treatment and improved 
survival. A further aim of this study was thus to assess whether any differences were 
apparent in recorded treatment according to surgical caseload, and to examine whether 
any survival differences according to surgical caseload could be identified. 
The evaluation of the NHSBSP is hampered by the lack of a control population, and 
analysis of the survival for women with screen detected cancer compared to cancer 
detected symptomatically will always be confounded by lead time bias, It is essential that 
other means of predicting the impact of screening on the population are identified and 
routinely undertaken. Although screening may bring about a significant fall in mortality 
for women with screen detected cancer, unless these cancers make up a large proportion 
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of breast cancers in women eligible for screening, the ability of the NHSBSP to bring 
about a significant mortality drop in the population will be reduced. Despite the 
importance of this type of evaluation in assessing the likely impact of the NHSBSP, 
currently very little research in this area has been published. One objective of the 
investigation was to develop a means by which breast cancers diagnosed in women 
eligible for screening could be categorised according to their screening history. This 
allows the proportions of cancers detected by screening and outside the programme to 
be identified, and in addition, allows the prognostic characteristics of cancers according 
to screening history to be examined, providing vital insight into the likely impact of the 
NHSBSP in the region. 
In recent years attention has been focused on the occurrence of interval breast cancers in 
the NHSBSP, which may indicate poor programme sensitivity and/or that the screening 
round is too long. Although important decisions about the future of the NHSBSP, such 
as a potential shortening of the round length, utilise interval breast cancer data, the 
definition and interpretation of these cancers remains unclear. In order to explore this 
issue an examination of these cancers was included in the study. 
The NHSBSP represents a major commitment of NHS resources and it essential that the 
beneficial effects of screening are maximised. The NHSBSP Quality Assurance (QA) 
system was established to ensure a high quality of service for the programme, and has 
devised a number of outcome measures to act as performance indicators and markers of 
likely success for the programme. It is essential that these outcome measures provide a 
valid indication of the performance of the programme. A further aim of the thesis was to 
assess these outcome measures and their associated quality standards, using data from 
the West Midlands to identify ways in which the validity of these outcome measures 
could be improved. 
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CHAPTER TWO 
_ -  
DATA SOURCES AND METHODS 
2.1 DATA SOURCES 
Most of the data presented in this thesis were derived from records held at the WMCIU. 
Screening histories were obtained from the West Midlands NHSBSP in the form of data 
relating to individuals, and from standard statistical reports collated by the NHSBSP 
computer record system. Published data were obtained from the Office for National 
Statistics (ONS) formerly the Office of Population, Censuses and Surveys (OPCS), the 
Department of Health (DoH), and from other European and UK cancer registries. 
2.1.1 Data from ONS, DoH and other cancer registries 
This thesis is primarily concerned with female invasive breast cancer, defined by the 
International Classification of Diseases (9th revision) as 1740.0 - 174.9 (WHO, 1977). 
Baseline Health of the Nation data were obtained from the Public Health Common Data 
set (HMSO, 1993). Survival data from other UK cancer registries were obtained from 
published reports (Yorkshire Cancer Organisation, 1995; Scottish Cancer Intelligence 
Unit ,1993, West Midlands RHA and WMCIU, 1996; Centre for Cancer Epidemiology , 
Manchester, 1992; Cancer Epidemiology Unit, University of Bristol, 1995; Thames 
Cancer Registry, 1994). Mortality data for the West Midlands for 1981-92 were 
obtained from ONS and used to derive mortality rates. Some of the data presented in the 
overview of breast cancer in the West Midlands in Chapter Four were calculated for the 
1995 Annual Report of the West Midlands Director of Public Health (WMRHA, 1996). 
The incidence of female invasive breast cancer was derived from registrations at the 
WMCIU. The incidence of female in situ breast cancer, defined by ICD9 233.0, and of 
male breast cancers defined by ICD9 175, were also determined for comparison. 
Numbers of deaths from breast cancer in the West Midlands by age, year and DHA were 
obtained from ONS. Estimates of the resident mid-year female population in each West 
Midlands DHA by five year age group and year were obtained from the Information 
Department of the WMRHA. 
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2.1.2 
The WMCIU has been population based since 1957, covering a fixed geographical area 
defined by the former West Midlands RHA, with a current population of over 5.3 
million. Data are derived from multiple sources including pathology reports, hospital 
discharge summaries, notifications from medical records departments, consultants and 
GPs, post mortem reports and death certificates. Upon receipt of details of a cancer, 
identifying details are used to ascertain whether the cancer is already registered. If a 
previous registration exists, tumour details are compared to decide whether the new 
tumour is a recurrence of a previously registered primary tumour, or is a new multiple 
primary tumour. Details of recurrences are added to the primary registration. If a 
previous registration exists, or if the cancer is a multiple primary tumour, a new 
registration is created, and personal identifiers, the anniversary date and the site of the 
cancer recorded. Use of multiple sources enables the WMCIU to record prognostic 
information using rules which differ between cancer sites. Up until 1994 data were held 
on the PDPl 1 computer database. In 1994 a new system - the Generic Registration And 
Cancer Epidemiology database (GRACE) - was introduced. 
Prognostic data recorded at the WMCIU for breast cancers include the TNM stage, 
tumour size, the status of the axilary nodes, the extent of disease, the presence or 
absence of metastases, tumour grade and histology. Patient related information including 
personal identifiers and date of birth are also recorded along with address details 
including the postcode which may be used to allocate indicators of material deprivation. 
Treatment data describing surgery, radiotherapy, hormone therapy and chemotherapy 
are supplied to the WMCIU by hospital medical record departments and radiotherapy 
clinics and are recorded with dates regardless of the time since diagnosis. 
2.1.3 
Directly age standardised incidence and mortality rates were calculated using the 
Standard European Population as a reference, and 95% confidence intervals (CIs) were 
constructed using the methods described by Boyle and Parkin (Boyle and Parkin, 1991). 
Directly standardised rates for each DHA were compared to regional rates to produce 
Standardised Incidence Ratios (SIRs) and Standardised Mortality Ratios (SMRs). 95% 
Data recorded by the WMCIU 
Calculation of incidence and mortality rates 
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CIs were constructed, and DHAs with an SIR or SMR with a 95% CI not including 100 
were considered to differ significantly from the region. Maps demonstrating variations in 
incidence, mortality and survival across DHAs and NHSBSP breast screening unit 
catchment areas of West Midlands were produced with the assistance of Geographical 
Information System Project staff at the WMCIU. 
2.1.4 Data recorded by the NHSBSP 
Details of screening episodes are entered onto the computer record system at each 
screening unit. For nine of the ten units in the West Midlands this record system is the 
Oxford National Breast Screening System (NBSS). One unit uses Kodak software, but 
the data items collected are identical to those on the NBSS. Diagnostic details including 
histology, tumour size, grade and nodal status are recorded, but stage is not recorded by 
NHSBSP. Details of treatment and follow-up are also recorded and used in the 
calculation of outcome measures. Screening units are required to submit reports 
detailing screening activity over each 12 month period to the DoH. These "Körner" data 
are collated onto "KC62" reports by software supplied to the units. In addition 
specialised reports are available which detail histological and surgical data. All data 
supplied by West Midlands units for this study were anonymised prior to presentation. 
2.1.4.1 KC62 reports 
Data for the period 1 April 1994 to 31 March 1995 were provided by all ten units using 
the KC62 version 2.8 report. The format of a KC62 Version 2.8 report is shown in 
Appendix Two. Version 2.8 operates on a cohort basis so that women in each table may 
be followed from screening to the final outcome, allowing data quality checks to be 
calculated by cross-reference within and between tables. The increasing use of diagnostic 
cytology was recognised in this version by detailing cytological procedures separately 
from diagnostic histology. Unfortunately all histology procedures are grouped so that it 
is impossible to separate open biopsies from non-surgical procedures, Unlike previous 
versions of the report, outcome measures are calculated by the KC62 report. 
2.1.4.2 Histological QA (HQA) reports 
The histology QA (HQA) report was developed by the NHSBSP to provide pathological 
data for screen-detected and interval breast cancers. The format of an HQA report is 
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shown in Appendix Two. Prognostic data such as invasive status, tumour histology, size, 
grade, nodal status and presence of vascular invasion are reported. The method used to 
identify women for inclusion in HQA reports differs from that used by KC62 reports 
version 2.8. Data for 1992-95 were supplied by the 9 West Midlands units which 
support the HQA software. The unit with Kodak software was unable to produce these 
additional reports. HQA reports provide data describing screen detected cancers and 
interval cancers but as many units in the West Midlands were not routinely recording the 
characteristics of interval cancers on their computer system at the time of investigation it 
was not possible to investigate interval cancers from HQA reports. 
2.1.4.3 Surgical QA (QASS) reports 
The surgical QA summary (QASS) report was developed by the NHSBSP to provide 
surgical data with which to assess the programme. The format of a QASS report is 
shown in Appendix Two. Details of diagnostic biopsies, treatment stratified according to 
choice of surgical treatment (conservative surgery or mastectomy) and size are provided. 
Surgical outcome measures (NHSBSP 1992, NHSBSP, 1996b) focus on the need to 
minimise the weight of benign biopsies, promotion of conservative surgery for small 
tumours, and minimising the use of open surgical biopsy. Data for 1992-95 were 
supplied by the 9 West Midlands units which support the QASS software. The unit with 
Kodak software was unable to produce these additional reports. 
2.2 
_-  
METHOD ONE: INVESTIGATION OF DATA AVAILABILITY 
AND VALIDITY AT THE WMCIU 
An audit of staging and tumour characteristic data at the WMCIU 2.2.1 
An audit of staging and tumour characteristics data at the WMCIU was undertaken to 
assess the quality of routinely recorded prognostic data. Data held on the old PDP11 
database, and in case notes kept at the WMCIU, were reviewed in relation to TNM 
stage and stage components, tumour size, the status of axillary nodes, disease extent, 
and the presence or absence of metastases. Figure 2.1 describes the pathways of data 
transfer under investigation. 
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The 251 1 female breast cancers registered at the WMCIU in 1983 were selected as the 
study population. The prognostic data under review had originally been abstracted onto 
the PDP11 database. The coding instructions available at the time of original abstraction 
onto the PDP11 were suggested to be insufficiently detailed and sometimes not adhered 
to. Using the available documentation, and after discussions with staff at the WMCIU, 
rules which applied to the use of codes on the PDP11 were compiled and are provided in 
Appendix Three. The suspected inconsistencies in interpretation of data and in the use of 
codes on the PDPI 1 were confirmed in these discussions, Some fields on the PDP11 
were used to record several types of data. In addition, ambiguities in the data on the 
PDP11 resulted from non-adherance to or misunderstanding of the coding rules so that a 
single code was used to record more than one thing e.g., one code was used to record 
either the presence of negative axillary nodes or that nodal status was unknown. The 
introduction of a new WMCIU database, GRACE, in 1994 allowed problems in the 
structure of the PDPl 1 to be eliminated, and the abstraction rules used to record breast 
cancer data on the PDP11 to be reviewed. An independent database and coding system 
were developed for the review. The review database also held data imported from the 
PDP 1 1, which were translated for analysis using the rules in Appendix Three. 
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Where TNM stage, or IT', Tu' or 'Ml components were recorded in the case notes they 
were transcribed onto the review database. Tumour characteristic data in the notes were 
recorded using rules described in Appendix Four. 
The review database was designed with three fields for size, one for each of three 
sources - pathological, radiological, and clinical. An additional field was provided to 
record the size considered the most accurate. This "best'' size was selected so that 
pathological size was selected preferentially, followed by radiological and then clinical 
s i e .  The "best" size should have matched that on the PDP11 if data transfer was 
complete and accurate at the original abstraction. 
For the review, one field was provided to record nodal status and a second to record 
mobility. Pathological data were used in preference to clinical, and an additional code 
was included to identify cases for which the status of the nodes was not reported despite 
pathological sampling. The mobility of nodes was recorded as mobile, fixed or unknown. 
To allow comparison of data from the PDP11 and the review, clinical and pathological 
data held on the PDP11 were combined to give a PDP1 i "best" nodal status, with 
pathological data taking precedence over clinical data. Nodes considered suspicious "at 
operation" but with no investigations reported were considered clinically positive. 
The following codes were available on the review database to record disease extent 
i. in situ 
ii. limited to the site of origin 
iii. invading neighbouring structures 
iii. probably limited to site of origin 
v. possibly invading neighbouring structures 
vi. insufficient information 
Two new fields were created, one to record the presence of multiple lesions, and a field 
to record why a tumour was not treated including "found at post mortem ". 
For. the review a single metastases field was provided and data recorded so that any 
positive site produced a positive code even if other sites were negative. The need for 
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comparison between clinical and "at operation" fields was eliminated by use of a 
hierarchical selection process, with "within site'' variation defined differently to "between 
sites" variation. 
within site Pathological data were selected in preference to clinical data for a single 
site. For example, a clinical skin metastasis subsequently found on biopsy 
to be benign would be recorded as a pathoiogically negative result 
between sites If more than one site was mentioned, positive data took precedence 
For example, a cancer with clinical skin metastasis that proved to be 
pathologically negative, but with clinical bone metastasis without 
pathology would be recorded as clinically positive 
This avoided misclassification resulting from a negative pathology at one site in the 
presence of clinically positive metastases at another site. For the review suspicion of 
metastases was also recorded, and was retained in the clinical metastases field on 
GRACE. This code was appropriate for cases where symptoms associated with 
metastases were mentioned, but no investigations were carried out, e.g. patients 
presenting in poor health with suspicious symptoms such as back ache, and allowed an 
assessment of how abstractors had interpreted suspicious symptoms. Similarly to local 
nodes data, "best" metastases data were identified from the PDPI 1. This process 
selected "at operation" data in preference to clinical data within site, and positive data in 
preference to negative data between sites. An important addition was that cancers 
without data referring to metastases were assumed to be free of metastases. 
2.2.2 
Quality assurance measures were calculated in relation to transfer of data from the notes 
to the PDP 1 1. The formulae used to calculate measures are provided in Appendix Five. 
1. Completeness Completeness of transfer describes the proportion of 
Quality assurance measures assessing data transfer 
cancers with data in the notes for which data were present 
on the PDP11, regardless of the accuracy of transfer 
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ii. Accuracy Accuracy describes the proportion of cases with data in 
the notes and the PDP11 for which the data were 
consistent 
_ -  
iii. Mismatched data Calculated for tumour size only. Mismatched data 
describes the proportion of cases with a size in the notes 
which was inconsistent with the size on the PDP11 
The proportion of added data indicates the proportion of 
cases for which data on the PDP11 did not originate in 
the notes 
iv. Added data 
2.2.3 
A possible means of allocating stage at the WMCIU was to combine the separate 
tumour characteristics incorporated in the TNM system. The study group defined in 
section 2.2.1 for an audit of staging data was also used to assess the feasibility of a 
staging algorithm. The construction of the TNM staging system is described in Appendix 
One. Four staging algorithms, shown in Appendix S i x ,  were written for the package Epi 
Info (Dean et al., 1990) combining tumour characteristics using a protocol based on the 
TNM system. Figure 2.2 describes the steps used to allocate stage. 
Each algorithm contained a different combination of assumptions about the data, and 
their validity was examined by analysis of survival in order to identify the most valid 
algorithm. No attempt was made to stage the 16 cancers identified at post mortem, and 
the 33 registered from death certificate only. 6 confirmed sarcomas were excluded. 413 
tumours were clinically diagnosed as breast cancer but had no histology recorded. Only 
6 of 2049 (0.3%) histologically confirmed cancers were non-carcinomas, and it was thus 
considered unlikely that many of these 413 cases were not carcinomas. All cancers 
without histological confirmation were assumed be carcinomas and included in the 
study. Tumours with in situ histology or Paget's disease without underlying carcinoma 
were allocated Tis. The data available were not sufficient to allow categorisation beyond 
the main TNM components, and no attempt to allocate sub-classifications of 'T' or 'N' 
components was made. The "best" tumour sizes identified during the review were used 
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Design of a staging algorithm 
to allocate hybrid clinical/pathological T/pT components. Although 6 ‘N3' components 
were recorded in the notes, no data describing internai mammary lymph nodes, which 
indicate an 'N3', were found during the review, and N3 was not incorporated into any of 
the algorithms. Cases were allocated MO if evidence that metastases were absent was 
reported, or if no mention of metastases was made. These assumptions are similar to 
those used elsewhere (Chouillet et al., 1994). 
_ -  
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2.2.3.1 
Limitations imposed by data completeness and quality dictated that three further 
assumptions be incorporated into the staging algorithms. Each algorithm incorporated a 
different combination of assumptions. The different combinations and the predicted 
influence on survival by stage of incorrect assumptions are shown in Table 2.1. 
i. Disease extent 
The review system provided two codes to indicate invasion beyond the site of origin. 
The first code indicated definite tumour extension. The second code indicated equivocal 
evidence of tumour extension. Two versions of the algorithm were created, one using 
both codes as criteria for a 'T4' (Algorithm 1), and the other only using the "definite" 
code (Algorithm 2). Algorithms 1 and 2 were identical in all other respects. 
ii. Mobility of local nodes 
Of 909 cancers with positive local nodes, 36 had mobility specified. Algorithm 2 was 
designed so that local nodes of unknown mobility were assumed mobile, and assigned 
‘N1'. Algorithm 3 assumed that local nodes of unknown mobility were fixed, and 
assigned ‘N2'. Algorithms 2 and 3 were identical in all other respects. 
iii. 
46 cancers had evidence suspicious of metastases. In Algorithm 2 such evidence was 
assumed to be positive and assigned 'Ml'. Algorithm 4 assumed that such cases were not 
metastatic and assigned 'MO'. Algorithms 2 and 4 were identical in all other respects. 
Assumptions used differently by the four staging algorithms - 
Clinical suspicion of distant metastases 
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2.2.3.2 
Al cases except those diagnosed at post mortem or registered from a death certificate 
only (DCO cases) were allocated a stage using each of the four staging algorithms. 
Cause specific survival was calculated using the Kaplan Meier function provided by 
SPSS for Windows (SPSS Release 6.0). Survival was calculated in months from 
diagnosis and cases were followed from diagnosis to the end of the study, defined as 
3 1st December 1994, at which point those still alive were censored. Deaths fiom breast 
cancer were identified using the cause of death recorded on the death certificate. Deaths 
for which breast cancer was the primary cause (1 153 deaths), and those with breast 
cancer present at the time of death but not the primary cause (146 deaths) were counted 
as events. Deaths from other causes were censored on the date of death. 
Selection of the most valid staging algorithm 
_ -  
Since stage has a natural order, tests were used to assess whether a significant trend in 
survival existed across stages. Chi square tests for equality of survival by stage were 
performed. The influence of each algorithm on survival by stage was assessed. These 
analyses examined whether, for example, stage '2a' from Algorithm 1 had a significantly 
better or worse survival experience than stage '2a' from Algorithm 2. Rather than 
examining survival stratified by stage, an analysis was designed that examined survival 
for each stage stratified by algorithm. Survival analyses were performed based on the 
instances of each stage according to the algorithm by which it was produced. The 
following criteria were used to identify the algorithm that was most valid and useful 
stages must fall into the correct order according to survival 
stages must display a statistically significant trend in survival 
sufficient cases should be staged for the algorithm to be of practical use 
The selection process was based on pair-wise comparisons summarised in Table 2.2. 
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2.3 METHOD TWO: AN EXAMINATION OF BREAST CANCERS 
DIAGNOSED IN 1983 AND 1987 
_ -  
Female breast cancers registered at the WMCIU in West Midlands residents which were 
diagnosed in 1983 and 1987 were used as the study populations in investigations of 
prognostic characteristics, treatment and survival. The 2.7% of cases diagnosed in 1983 
and 8.4% of cases diagnosed in 1987 for which the case notes could not be located at 
the WMCIU, for which no age or date of birth was available, or for which no DHA of 
residence or postcode was available were excluded. 
2.3.1 
Breast cancers in the study populations were characterised in terms of age at diagnosis, 
DHA of residence, level of material deprivation, stage at diagnosis, tumour grade, 
tumour histology, treatment type and the annual caseload of the treating surgeon. 
Age at diagnosis was grouped into three bands <50 years, 50 - 69 years, and 70 years or 
older. The <50 year age group was assumed to be made up of mainly pre-menopausal 
women, whereas the oldest group was assumed to be mainly post-menopausal. The 
middle group was assumed to be a mixture of pre-, peri- and post-menopausal women. 
The District Health Authority (DHA) of residence was used to partition the data into 
geographical areas within the West Midlands. The boundaries of the 15 DHAs in 
existence in 1994-95, the period in which much of this work was undertaken, were used, 
although mergers have since taken place. Similarly the 14 Regional Health Authorities 
(RHAS) in existence in 1995 have been used to describe inter-regional differences 
although these were reorganised in 1996. 
Townsend scores (Townsend et al., 1982) were used as an indicator of material 
deprivation. Townsend scores were derived from four data items collected during the 
1991 census; access to a car, employment status, degree of overcrowding, and type of 
housing tenure. Each enumeration district was allocated a score based to these variables 
according to the protocol devised by Townsend (Townsend et al., 1982) to provide a 
quantitative measure of material deprivation. In this study level of deprivation for cases 
in the study group was estimated from that of the enumeration district of residence, 
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Definition of patient and tumour characteristics 
which were in turn identified using the postcode of residence. Townsend scores 
allocated to cases diagnosed in 1983 were banded into quintiles to provide five 
deprivation levels. The cut-off scores identified in this process were used to allocate 
deprivation levels to cases diagnosed in 1987. 
The staging algorithm selected by the method described in section 2.2.3.2 was used to 
assign stage at diagnosis. For some purposes stages were grouped into three levels - 
"early" (stages 'O', '1' and '2a'), "locally advanced" (stages '2b' and '3’, and "metastatic" 
(stage '4'). Tumour histology was assigned according using the International 
Classification of Diseases Morphology codes (WHO, 1977) recorded at the WMCIU. 
The histology groups allocated for the purposes of the investigation are shown in Table 
2.3. Special types of invasive carcinoma were defined as medullary, tubular, mucoid, 
cribriform, papillary and adenoid cystic carcinomas. 
Tumour grade was obtained direct fiom pathology reports during the audit of data for 
cases diagnosed in 1983. For cases diagnosed in 1987, grade was obtained fiom data 
recorded on GRACE. Some of the data on GRACE had been imported directly from the 
PDP11, and the method previously used to store grade on the PDP11 necessitated 
grouping grade into two groups - "good" (grade I or II), and "poor'' (grade III, and 
tumours described as anaplastic or undifferentiated). 
2.3.2 Treatment data 
2.3.2.1 Definition of treatment types 
The treatment data included in analyses were restricted to therapy given within six 
months of diagnosis. The term "conservative surgery" was used to describe all variants 
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including lumpectomy and wide local excision. "Mastectomy" is used to describe all 
variants of mastectomy. The term non-surgical oncology encompasses radiotherapy, 
hormone therapy and cytotoxic chemotherapy. Non-surgical therapy data simply 
described whether or not treatment was recorded. The treatment recorded for each 
patient was described using two treatment variables described in Table 2.4. 
The data did not allow for determination of axillary node clearance, whether 
oophorectomy had been performed or the agents and dosages used in chemotherapy. 
2.3.2.2 Identification of surgical caseload 
A method similar to that used by Sainsbury (Sainsbury et al., 1995b) was used to 
identify surgical caseload. Data for two three-year periods were examined. Caseload of 
relevant surgeons was estimated from the number of new breast cancers treated from 
1982 to 1984. The number treated within 6 months of diagnosis by each surgeon was 
counted, and an annual rate calculated. The process was repeated for cases diagnosed 
from 1986 and 1988 to calculate the caseload for surgeons treating new cases in 1987. 
Patients having surgery were classified according to the caseload of the surgeon, and if 
both conservative surgery and mastectomy were performed, on the basis of the surgeon 
performing mastectomy. 
2.3.2.3 
The Kings Fund guidelines provided guidance on use of diagnostic and staging 
techniques, provision of advice and counselling, and discussing treatment choices with 
Comparison of treatment with the King's Fund guidelines 
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patients. Changes in treatment patterns from 1983 to 1987 were investigated in order to 
assess whether the following guidance was acted upon 
_ -  
age, menopausal status and stage should be considered when allocating treatment 
mastectomy and conservative surgery are of equal survival benefit, but 
mastectomy should be used for extensive disease 
patients with extensive disease should be offered adjuvant therapy 
conservative surgery should be followed by radiotherapy to reduce the risk of 
recurrence 
cytotoxic chemotherapy is most effective for women aged <50 years 
hormone therapy is most effective in over women over 50 years, but may be of 
benefit in reducing recurrence rates in all ages 
A further recommendation was that care should be delivered by multi-disciplinary 
specialist teams. Whether or not cases were treated by a multi-disciplinary team could 
not be ascertained from data held at the WMCIU, but the surgical caseload was 
examined to identify changes which could be related to multi-disciplinary working, and 
also to allow examination of whether any survival benefit with increased caseload was 
apparent as has been found elsewhere (Sainsbury et al., 1995b; Gillis and Hole., 1996). 
2.3.3 Survival analysis 
Breast cancers diagnosed at post mortem or registered from a death certificate only 
were excluded from analyses of survival. 
2.3.3.1 Univariate analysis of survival 
Software designed by Hakulinen and Abeywickrama (Hakulinen et al., 1985) was used 
to calculate five year relative survival rates using the 1981 England and Wales life table 
as the comparison group. Cases were stratified according to year of diagnosis, and by 
age group, DHA, level of deprivation, stage, grade, histological group, treatment type 
and surgical caseload. All causes of death were included in analyses, and live cases were 
censored on 3 1st December 1994. Ascertainment of deaths was assumed to be complete 
at the censor date, and no cases were withdrawn from the data set. Statistical testing of 
variation in survival was performed using the log rank test supplied in the software. 
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2.3.3.2 
me influence of multiple factors on survival was assessed using Cox proportional 
hazards modelling (Cox, 1972). Tests of statistical significance were set at the 5% level. 
SPSS software (SPSS release 6.0) was used to examine the 1041 invasive breast cancers 
in the combined study populations for which stage, grade and Townsend score were 
available. All factors were entered as categorical covariates. Plots of log[-log survival] 
for cases stratified according to each covariate were constructed and did not suggest 
that the assumption of proportionality was contravened. The categories used for all 
variables except treatment were the same as for univariate analysis. In addition, year of 
diagnosis was entered as a covariate. 
To simplify analyses treatment type was described in one covariate combining surgical 
and non-surgical therapy. Conservative surgery and mastectomy were grouped as 
"surgery". Those with non-surgical treatment only or without any treatment were 
combined into a category representing those with least intervention. Surgical cases were 
grouped into those with surgery alone, and those that had recorded adjuvant therapy. 
Cases with adjuvant therapies were further classified into four groups - those with 
hormone therapy only, with radiotherapy only, with radiotherapy and hormone therapy, 
or with chemotherapy either alone or in combination with other adjuvant therapies. 
Models were created for all cases, and for each stage separately, using two methods. 
Models in which each covariate was entered singly were produced to assess the 
significance of each covariate. To assess the impact of adjusting for stage, this process 
was repeated with a baseline model including stage. Overall models were produced 
using forward stepwise conditional selection. Selection for entry depended on the global 
Chi square, with the significance level for entry set at <0.05. Covariates in the model 
with a probability of the likelihood ratio statistic of >= 0.1 were rejected. Relative risks 
for each covariate were described by comparison with a reference category. 
Multivariate analysis of survival 
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2.4 METHOD THREE: DERIVATION AND INTERPRETATION OF 
SCREENING HISTORIES FOR BREAST CANCER 
2.4.1 Identification of screening histories 
A test population was identified as all female breast cancers registered at the WMCIU 
resident in the catchment area of the Warwickshire, Solihull and Coventry breast 
screening unit. The catchment area of this Screening Service includes about 20% of the 
female population in the age group eligible for screening, and was thus considered to 
constitute a sample large enough to be reasonably representative of the region. 
Screening activity in the prevalent screening round (17th April 1989 to 31st March 
1992) was considered. Over this period more than 80,000 women were invited, and over 
62,000 attended for screening. 
A retrospective analysis was devised to identify and categorise breast cancers which 
might have been detected by screening in the prevalent round. It was necessary to define 
a time limit, starting at the time of screening, beyond which a cancer arising 
symptomatically could not have been detected at the original screen. This time depends 
on the average sojourn time of breast cancer, i.e., the length of time that a cancer is 
detectable pre-clinically. The mean sojourn time for breast cancers in women aged 50-69 
years was estimated from the Swedish Two Counties Study to be 4.12 years (Paci et al., 
1991). This means that, on average, a breast cancer is detectable pre-clinically for 4.12 
years, and that a cancer detected symptomatically could have been found by screening 
for the previous 4.12 years. In this investigation the limit was set at five years in 
accordance with the NHSBSP statistical KC62 version 2.8 report in which women who 
have been screened before are divided into those screened less than, or more than five 
years previously. Cancers arising more than 5 years from the last screen were excluded. 
Woman were designated as eligible for having their cancer detected by screening if the 
cancer was diagnosed when aged 49-68 years, and if invited, diagnosis was within five 
years of the last invitation. Screening histories were located using surname, forename, 
date of birth and postcode to identify registration and screening details at the unit. 
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Cancers diagnosed before the unit was operational, in women registered at neighbouring 
units, or that were detected following a screen or invitation in the second or third round 
were excluded. Cancers were classified using the scheme in Figure 2.3. A cancer in a 
lapsed attender cannot arise until a woman has attended and been invited again, and thus 
could not be identified immediately after the prevalent round. The term "lapsed attender" 
is also used by the NHSBSP to describe cancers arising symptomatically at >=36 months 
from the last negative screen in women no longer eligible for a routine invitation. In this 
investigation such cancers were termed "late invitation" interval cancers and comprised 
those cancers arising at >=36 months in women no longer eligible for a routine 
invitation, and cancers arising in women re-invited at >=36 months from the last screen 
but in whom the cancer arose prior to re-invitation. 
a. 
Cancers diagnosed from 17th April 1989 to 31st March 1992 in women aged 50-64 
years, resident in the catchment area, of whom no details were identified at the unit or 
other units in the West Midlands. 
Cancers in women not registered at the unit 
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b. 
Cancers in women registered at the Unit, who did not attend an invitation between 17th 
April 1989 and 31st March 1992 because they had been excluded by their GP, or 
because the invitation post-dated a diagnosis of breast cancer between 17th April 1989 
and 31st March 1992. In both cases diagnosis occurred in women aged 50-64 years. 
C. Cancers in non attenders 
Cancers in women registered at the unit, that arose after a non-attendance, in women 
that received their last invitation between 17th April 1989 and 31st March 1992 aged 
50-64 years. This category was sub-divided into cancers diagnosed at <36 months and 
>=36 months from the last invitation. Cancers diagnosed at >60 months from the last 
invitation were excluded. 
d. Screen detected cancers 
Cancers detected at screening between 17th April 1989 and 31st March 1992 in women 
aged 50-64 years. This category was sub-divided into cancers detected at routine 
screens and those detected at screens resulting from self or GP referral or early recall 
within the first round. 
Cancers in those not screened 
e. 
Cancers arising after a negative screen, in women attending their last negative screen 
between 17th April 1989 and 31st March 1992 aged 50-64 years who had either not 
received their next appointment or had not had the opportunity to attend the 
appointment. This category was sub-divided into cancers diagnosed <36 months (el 
intervals cancers) and >=36 months (e2 "late invitation" interval cancers) from the last 
negative screen. Cancers diagnosed at >60 months from the last screen were excluded. 
2.4.2 Examination of the definition and classification of interval cancers 
Interval and "late invitation" interval cancers identified by the method described were 
selected for further examination. The interval time was calculated as the time from the 
last negative screening mammogram to the histological confirmation of the cancer. 
Histological classification is vital as breast lumps may be lymphomas or metastatic 
disease. Paget's disease without underlying invasive disease was classified as in situ. 
Cancers were classified as "core" or "non-core" according to the criteria in Table 2.5. 
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Interval and "late invitation" cancers 
The criteria include cancers arising in women at higher than normal risk and those 
presenting symptomatically in women on early recall but do not include cancers detected 
at early recall. Cancers diagnosed more than 36 months from the last screen ("late 
invitation" intervals) were excluded. 
Radiological classification of the 2 13 "core" intervals was undertaken by Consultant 
Radiologists working in the West Midlands programme. Screening films were loaded 
onto a multi-viewer with negative films in a ratio of interval : normal of 1:2. The viewer 
was read by the visiting radiologists and by home radiologists. Screening films were 
identified as "positive" if two radiologists would have recalled the case, and if the area of 
suspicion corresponded to the position of the cancer, based on diagnostic mammograms. 
Classifications were allocated using the rules in Table 2.6. 
Based on the Northern region scheme (Simpson et al., 1995) cancers without 
mammograms from the time of diagnosis were classified as "false negative" if the 
screening films were identified for recall when reviewed, and "not false negative" if the 
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screening films were passed as negative. A small group of "unclassifiables" still remained 
for which insufficient surgical or pathological data were available. A method similar to 
that used by Peeters (Peeters at al, 1989) was employed to estimate the effect of 
screening at 2 years. It was assumed that false negative cancers presenting in the third 
year would be detectable at 2 years and that occult cancers could not be screen detected 
at any point. The "not false negative" group were assumed to be made up 
proportionately of true and occult cancers. No assumptions were made concerning 
unclassifiable cancers, which were retained in the denominator of calculations of the 
proportion detectable. The rate of true intervals becoming detectable in each 12 month 
period after a negative screen was assumed to remain constant and was estimated as the 
rate arising in the first 12 months. The true intervals becoming detectable in the third 
year after screening was assumed to be made up of some cancers which had been 
detectable at less than 24 months (which could have been found if screening had 
occurred at two years) and some that only became detectable after 24 months. The 
annual rate of true intervals was used to estimate the proportion of the true intervals 
detected in the third year that were detectable at two years. The number of "detectable" 
cancers arising in the third year (the sum of the false negative and detectable true 
intervals) was used to estimate the proportion detectable by screening at two years. 
Routine screening activity data for 1989 - 1995 were obtained from KC62 reports and 
used to calculate Standardised Detection Ratios (SDRs) for 50 - 64 year olds. This age 
standardisation technique calculates the ratio of the observed invasive cancers to the 
number expected based on the results of the Swedish Two-County Study, an SDR of 1 
indicating parity with the Swedish study (Blanks et al., 1996a). 
Diagnostic and screening details of 155 women with a cancer detected at their incident 
second round screen, who also attended in the first round, were used to calculate 
individual round lengths for women. All 155 women had been found to be screen 
negative at their first screen, placed on routine recall, and arrived at their second screen 
at which cancer was detected as a result of routine invitation. The proportion of women 
re-invited at 36 months or more from the last screen was assessed. 
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The expected underlying incidence of invasive breast cancer in 1992 in the population 
covered by the screening unit was estimated for 50-64 year olds using cancer 
registration data for 1981 to 1987. The pre-screening trend in incidence rates in this age 
group was extrapolated by linear regression to calculate the expected rate in 1992. 
2.4.3 
Prognostic data with which to assess the impact of screening were investigated using 
five groups of cancers identified by the method described in section 2.4.1. Histology, 
tumour size, nodal status, and grade were examined. Data were derived from pathology 
reports held at the WMCIU if available, but if absent, data recorded by the unit for 
screen detected cancers and some of the interval cancers were used. 
Assessment of prognostic data in relation to screening history 
The characteristics of prevalent round, screen detected breast cancers, interval breast 
cancers, cancers in non-attenders, and second round incident screen detected cancers 
were examined. Breast cancers registered at the WMCIU which were diagnosed in 1987 
in women aged 50 - 64 years provided a pre-screening symptomatic control group. 
Prevalent screen detected cancers were included only if found at routine screens. 
Cancers detected at early recall, or after GP or self referral were excluded as there were 
too few in these groups to permit detailed analysis. Cancers in non-attenders were 
included if diagnosis occurred within 36 months of the last invitation. Interval cancers 
identified as "core" intervals by the method described in section 2.4.2 were examined. In 
addition, 156 incident (re-screen) screen detected cancers from the second screening 
round were examined. 
Pathological tumour size and nodal status were used in preference to clinical data which 
were used in the small number of cases for which pathological data were unavailable. 
Tumour sizes were excluded if the excision margins were not clear, if the tumour was 
not excised in one piece, or if pre-operative therapy was recorded. Nodal status was 
classified as negative or positive, and a third category indicated the presence of distant 
metastases including distant nodes. The proportion of in situ breast cancers, lobular 
carcinomas and special types in each post-screening group was compared with that in 
the control group. To examine the significance of the differences between proportions 
Chi square tests with Yates correction were performed. The distribution of cases by size, 
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nodal andmetastasis status in each group was compared with that of controls, and the 
significance of differences in distributions was tested using the Mantel-Haenzel Chi 
square test for linear association. 
2.5 METHOD FOUR: ASSESSMENT OF THE OUTCOME MEASURES 
USED BY THE NHSBSP 
The NHSBSP has devised a number of outcome measures with which to assess the 
performance of the Programme. Table 2.7 describes some outcome measures calculated 
from KC62 reports. Quality standards have been set in relation to these outcomes. As 
the NHSBSP has developed new measures have been introduced, some measures have 
been withdrawn and changes in the definitions of measures and in the standards set have 
occurred. The rationale on which these standards are set is that, to achieve results 
comparable to the Swedish Two Counties Study, the NHSBSP must achieve equivalent 
or better interim screening characteristics. The measures defined in 1988 (NHSBSP, 
1988) set a single standard for each outcome, as all units were in the prevalent round. 
Standards were set at a level that should have been met by all units. The 1993 Objectives 
for the Breast Screening Programme (NHSBSP, 1993b) introduced standards split into 
"acceptable" and "achievable" levels. An acceptable standard was set as the minimum to 
be attained. Achievable standards were set at a level already achieved by 25% of units 
and provided a target to be aimed at. The 1996 Quality Standards (Radiological Big ‘18’, 
personal communication) have changed the terminology. A "minimum" standard is set a 
level at which, if not met, remedial action must be taken. "Expected standards" are set at 
a level which should be attained at all units. 
Data were obtained from KC62 reports supplied by the ten screening units in the region 
for the period 1 April 1993 - 31st March 1994. Outcome measures are presented in 
relation to the current quality standards in order to identify and discuss the difficulties 
associated with using the currently recommended outcome measures. In addition, 
treatment data for 1992 to 1995 provided by QASS reports supplied by nine screening 
units are used to assess some of the treatment outcome measures used by the NHSBSP. 
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CHAPTER THREE 
RESULTS: THE AVAILABILITY AND VALIDITY OF ROUTINELY 
_ -  
COLLECTED PROGNOSTIC DATA 
3.1 INTRODUCTION 
The validity of data is defined by IARC as the proportion of cases with a given 
characteristic recorded which truly has the attribute (Parkin et al., 1994). It is essential 
that data recorded at the WMCIU and by the NHSBSP are both complete and valid if 
they are to be used in the assessment of breast cancer. In this chapter the results of studies 
are presented which address the need for high quality prognostic data by assessing breast 
cancer data routinely recorded at the WMCIU and by the NHSBSP in the West Midlands. 
To undertake studies of survival and to identify stage shift resulting from early diagnosis, 
complete and accurate staging data are required. Ideally TNM stage would be recorded 
for all breast cancers at diagnosis and supplied to the WMCIU. Complete and accurate 
transcription would then result in a fully staged database. If valid data describing tumour 
characteristics were available it would also be possible to confirm the validity of stages by 
comparison with tumour characteristics. A review of prognostic data held at the WMCIU 
is described, focusing on TNM staging and those tumour characteristics incorporated into 
the TNM system. The review contributed to the development of new breast cancer coding 
rules and an improved coding system for incorporation into the WMCIU's new computer 
system GRACE. The design and impact of a staging algorithm as a possible means of 
increasing the proportion of cases staged for analytical purposes is also described. 
High quality prognostic data are essential to the evaluation of the NHSBSP, and must be 
available for breast cancers detected both inside and outside the screening programme. 
The prognostic data collated in HQA reports provided by West Midlands Breast 
Screening Units was assessed. The availability of prognostic data for breast cancers 
arising within the catchment area of the Warwickshire, Solihull and Coventry Screening 
Unit was examined according to screening history and compared with data recorded for 
cases diagnosed in 1987 prior to the start of screening. 
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3.2 AN AUDIT OF STAGING AND TUMOUR CHARACTERISTIC DATA 
HELD AT THE WMCIU 
2444 (97.3%) of the 2511 breast cancers diagnosed in the West Midlands in 1983 were 
eligible for analysis. A total of 67 cases were ineligible. The notes for 34 cases were not 
located, and notes for 25 cases contained insufficient clinical detail to be of use. Neither 
DHA nor postcode of residence was available for 7 cases. One case was excluded because 
neither age nor date of birth was available. 
3.2.1 Staging data 
Figure 3.1 summarises quality assurance (QA) measures for staging data which describe 
the transfer of data from case notes onto the old PDP11 database at the WMCIU. The 
QA measures shown in Figure 3.1 are reported in detail in Table A5.1 of Appendix Five 
which also provides definitions of all the QA measures presented in Chapter Three. 
Only 4.8% of cancers had stage recorded on the old WMCIU PDP11 database, and 4.1% 
had stage recorded in the notes. One or more stage components were recorded on the 
database for just 5% of cases, with a similar proportion having components recorded in 
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the notes. _ -  The availability of both full stage and stage components was thus extremely 
poor. Completeness of transfer was highest for advanced stages (stage '3' 61.8%, stage '4' 
63.2%), and lower for earlier stages. No stage 'O's, indicating in situ disease, were found 
in the case notes, so that the 26 stage 'O's recorded on the PDP11 database had been 
added by abstractors in the absence of data in the notes, and were termed "added stages". 
Accuracy of transfer was high for all stages, being 96.3% overall. Proportions of added 
stages on the PDP11 database were lowest for stage '1' and highest for stage '4', 
suggesting that addition of stage by abstractors was biased towards later stages. 
Poor completeness, high accuracy and high proportions of added data were also seen for 
'T', 'N’, and 'M’ components. Staging components for the 115 cancers without recorded 
stage but with staging components were combined using the TNM protocol to allocate 
stage. If no 'M’ component was present, 'MO' was assumed. 8 cancers were not staged due 
to insufficient data. This process increased the overall proportion staged by 113%, but the 
staged proportion was still under 10%. Thus, even if data transfer at the WMCIU had 
been 100% complete, less than 10% of cases would have had staging data on the PDP11, 
An estimate of the validity of stages added to the PDP11 database was made by 
comparison of these added stages with stages allocated by a staging algorithm, shown in 
Figure 3.2. The design of the selected staging algorithm is presented in section 3.3. 
Overall only 41.5% of the 65 added stages were consistent with the stage allocated by the 
algorithm, 35.4% were unstagable due to lack of data, and in 23.1% the stages were 
inconsistent. Agreement with the staging algorithm does not necessarily indicate that the 
added stage was correct, and no stage allocated by a clinician at diagnosis was available 
for comparison, but lack of agreement indicates inconsistency between the added stage 
and the tumour characteristics recorded in the case notes. Of cancers with added stage 'O', 
19.2% were allocated a higher stage by the algorithm and 61.5% were unstageable. Lack 
of data describing status of the local nodes was responsible for most of the unstaged 
cases. For cancers with an added stage '4', 60% were in agreement with the algorithm, but 
33.3% were allocated a lower stage by the algorithm as no evidence of distant metastases 
was recorded in the notes. 
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3.2.2 Tumour characteristic data 
Summary QA measures for tumour characteristic data recorded for the 2444 cases eligible 
for analysis are shown in Table 3.1. The definitions of QA measures are provided in 
Chapter Two and in more detail in Appendix Five. Detailed descriptions of the coding 
systems used on the PDP11 database, and that developed as part of this audit, are 
provided in Appendix Three and Appendix Four respectively. 
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3.2.2.1 Tumour size 
Tumour size was recorded on the PDPI 1 for 1544 of the 2444 cases examined (63.2%), 
and valid sizes were found in the notes for 1591 (65.1%). Of "best" sizes derived from the 
notes (the definition of "best" size is provided in Chapter Two), 66.4% were pathological, 
33.2% clinical, and 0.3% radiological. No "best" size was identified for 853 cases 
(34.9%), of which 19.6% had a size incorrectly recorded on the PDP11 database, 
including 90 cases with an invalid pathological size. For prognostic purposes pathological 
size is considered most accurate, but 1387 (56.8%) cases had no valid pathological size 
recorded in the notes, of which 275 with an invalid pathological size. Reasons for 
invalidity of pathological size are described in Appendix Four. Reasons for lack of 
pathological size in the sample examined are shown in Figure 3.3, with the most common 
reason for invalidity being the presence of positive resection margins. In 367 cases 
(26.5%) without pathological size, no pathology report was available. However, in a 
further 745 cases (53.7%), a pathology report was present but size had not been recorded. 
Overall completeness and accuracy of transfer of size was high at 86.5% and 84.6% 
respectively. However, 10.8% of sizes had been wrongly added by abstractors. The 
completeness and accuracy of pathological size (89.4% and 89.7% respectively) was 
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higher than for clinical size (81.1% and 73.9%). Completeness and accuracy of transfer 
are not independent of coding changes and of the consistency with which selection of size 
for entry operated. For example, if a clinical size of 15mm and a pathological size of 
10mm were both available and valid, pathological size should have been recorded. If 
clinical size had been selected incorrectly, even if transferred accurately it would not 
match the "best" size of 10mm, giving the appearance of inaccurate transfer. 
A total of 90 invalid pathological sizes had been recorded on the PDP1 1, and furthermore, 
49 cancers with a valid pathological size in the notes had a different size recorded on the 
PDP11 which matched the clinical size in the notes. Although possibly due to chance, a 
likely explanation is that abstractors overlooked valid pathological sizes. The reliability of 
size on the PDP11 was further reduced by the finding that 18.9% of cases had no size 
recorded on the PDP1 1 database despite identification of a clinical size during the review. 
3.2.2.2 
Figure 3.4 shows local node status data recorded on the PDP11 database and in the notes. 
Local node status and mobility 
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Although local node status was recorded on the PDP11 database for 235 1 cases (96.2%), 
only 1122 (45.9%) had pathological local node status recorded in the notes, and a further 
622 (25.5%) had clinical node status recorded although pathological data were absent. Of 
the 1322 cases without pathological node data in the notes, 476 (36.0%) had a pathology 
report available but nodal status was not recorded. In 41 cases node sampling was 
recorded in the notes, but no pathology for this procedure was recorded, indicating that 
the data sent to the WMCIU were incomplete. In 700 cases (28.6%) no clinical or 
pathological data describing the local nodes were available. 
The completeness and accuracy of recording nodal status at the WMCIU was high at 
99.0% and 88.4% respectively. A problem with the data on the PDP11 database is shown 
in Figure 3.4 by the proportion of cases recorded as "clinically negative". Data on the 
PDP11 database indicated that 1026 cases (42.0%) fell into this category, but data in the 
notes revealed that only 350 cases (14.3%) could be placed in this group. Of 1026 cases 
recorded as "clinically no nodes" on the PDP11 database, 65.9% had been incorrectly 
allocated this code to indicate lack of data instead of the rarely used "no data" code. 
Local node mobility, which is required for TNM staging, was recorded on the PDP11 
database for only 125 cases (5.1%). However, just 37 cases (1.5%) had mobility recorded 
in the notes. The completeness of transfer of mobility data was 69.4%, and although 
accuracy was 100%, nearly 80% of mobility data had been added in error by abstractors. 
3.2.2.3 Disease extent 
Figure 3.5 shows that 1593 cases (65.2%) were recorded as "limited to the site of origin" 
on the PDP11 database compared to 291 cases (1 1.9%) recorded on review as "definitely 
limited" based on data in the notes. The interpretation of data in relation to disease extent 
is complex. The introduction of new coding categories allowed definite and possible 
evidence of invasion beyond the breast to be recorded. Even if "probably limited" cases 
are assumed to be limited to the breast, the "limited" proportion on the PDP11 was 
significantly higher than that in the notes (65.2% vs 48.7%, p<0.05). Conversely, if only 
"definitely invading" cancers were assumed to be invading beyond the breast, significantly 
fewer cases were "invading" on the PDP11 database (16.6% vs 23.2%, p<0.05). 
64 
Overall completeness of recording disease extent was high at 88.7%, and accuracy was 
over 80%, although calculation of accuracy was complicated by the interpretation of new 
coding categories. For ''possibly invading" cases, completeness was 82.9%. Accuracy, if 
equivalence to "invading" on the PDP11 database is assumed, was 30.0%, but when 
equivalence to the "limited" code on the PDP11 database was assumed, rose to 61.3%. 
This suggested that characteristics that were suspicious of invasion had been interpreted 
inconsistently at the original abstraction. For "probably limited" cancers, completeness 
was 91.3%, and accuracy assuming equivalence to the "limited" PDP11 code, was over 
98%. The proportion of added data was low at 7.8%. The disease extent field on the 
PDP11 database had not been used to identify in situ cancers, demonstrated by the 
observation that of the 34 in situ cancers identified, 88.2% had been coded on the PDP1 1 
database as "limited". The new coding rules allowed disease extent to be recorded for 
52.2% of cancers that had no disease extent data on the PDP11 database, including 66 
"definitely invading" cases. In a small number of cases, disease extent data were no longer 
hidden, as 45 of 61 cancers recorded as "multiple lesions" or "found at post mortem" on 
the PDP1 1 database had data in the notes. In addition, in situ cases were identified in the 
new disease extent field in addition to the use of the appropriate ICD9 code. 
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3.2.2.4 Distant metastases and distant nodes 
Identification of positive distant metastases from the PDP11 database required 
comparison of clinical and "at operation" data, which was complicated as "at operation" 
data could not be translated directly as pathological as some codes were based on 
observation at surgery only. For the review all metastatic sites were coded together, and 
clinical and pathological data were coded in one field on a hierarchical basis, making data 
analysis easier. Only 220 cases had any metastases data recorded on the PDP11 database, 
and over 77% had no data relating to metastases recorded in the notes. 31 cases (1.3%) 
had pathologically confirmed metastases, and 196 (8%) clinically positive metastases. 
Only 3 cancers had all suspected sites confirmed as negative, and clinically negative data 
were available for 269 (11.0%). A further 46 (1.9%) had suspicious symptoms such as 
back ache which had not been investigated further. Only 157 of the 227 cases with 
positive data (69.2%) in the notes had positive data on the PDP11 database, although 
accuracy was 91.4%. A total of 76 cancers with positive data had been overlooked, and 
18.7% of positive data on the PDP11 had been incorrectly added. Of 46 cancers with 
"suspicious" data in the notes, only 3 1.4% had been recorded as clinically positive on the 
PDP11 database indicating inconsistent interpretation of data. 
The recording of distant node status suffered from the same problems as those identified 
for local nodes. Only 164 cases (6.7%) had distant nodes data recorded in the notes, 
compared to 2307 cases (94.4%) with distant node status recorded on the PDP11. 
Overall, 93% of data on the PDP11 database had been added, mostly as a result of 
incorrect use of the "clinically no nodes not present" code, which was used for 95% of 
cancers on the PDP11 database. Although overall completeness was 97.5%, accuracy was 
only 61%, indicating that distant node data had been omitted on the PDP11. 
3.3 THE DESIGN AND VALIDATION OF A STAGING ALGORITHM 
Data recorded for the review were used in the development of four staging algorithms 
from which one algorithm was selected for future use. The assumptions contained within 
each algorithm, and the method by which the algorithms were tested are provided in 
Chapter Two. Programme listings for each algorithm are reproduced in Appendix Six. 
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All four algorithms staged over 63% of cancers, with algorithm 1 staging 68% and 
algorithm 4 64%. For all algorithms, survival by stage displayed a highly significant trend, 
with stage '4' showing the poorest survival. Algorithm 4 displayed the most significant 
statistics for trend, and algorithm 1 the least. Algorithm 1 showed inversion of the survival 
from stages '3b' and '3a' so that stage '3a' cancers displayed poorer survival than stage '3b'. 
This inversion of stages 3'a' and '3b' was displayed by all algorithms except Algorithm 3, 
which inverted stages '2a' and '2b'. The influence of the assumptions created differences in 
the proportion of cases that could be staged, and in the survival calculated for each stage. 
3.3.2 
Figures 3.10 - 3.15 show survival curves for each stage stratified by the algorithm used. 
For stage ‘1', survival according to algorithms 2, 3, and 4, was similar, but that from 
Algorithm 1 was slightly higher. For stage '2a' cases, survival from algorithm 3 was the 
highest, followed by algorithm 1, with similar curves for algorithms 2 and 4. For stage 
'2b', survival for those staged by algorithm 3 was much higher than for algorithms 1, 2, 
and 4, and a similar pattern was seen for stage '3a' tumours. Survival for stage '3b' was 
higher for those staged by algorithm 1 than from the other three algorithms. For stage ' 4  
tumours, survival for tumours staged by algorithms 1, 2 and 3 were identical so that only 
the curve for algorithm 1 is visible, but survival from algorithm 4 was slightly poorer. 
Survival by stage according to staging algorithm 
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3.3.3 Selection of the best algorithm 
3.3.3.1 
Algorithm 1 staged more cases than algorithm 2, with 31.8% and 35.6% unstaged 
respectively, but the assumption used in algorithm 1, that the two disease extent codes 
were equivalent was not supported. Five year survival rates for stage '3b' cases (Table 3.2) 
were 52.2% and 44.7% for algorithms 1 and 2 respectively, and a log rank test for 
difference in survival for stage '3b' from each algorithm was significant (p=0.02). 
Algorithm 1 inverted stages '3a' and '3b', and although the trend in survival across stages 
was highly significant for both algorithms it was more significant for algorithm 2. 
Algorithm 1 was thus rejected. 
3.3.3.2 
Both algorithms staged 64.5% of cases. However, the assumption that nodes of unknown 
mobility were fixed, used in algorithm 3, was not supported. Presence of fixed local nodes 
is the criterion for 'N2', with a minimum stage of '3a'. If mobile nodes were allocated ‘N2' 
this would increase the survival of stage '3a' cases. Five year survival rates for stage '3a' 
cases shown in Table 3.2 were 41% and 58% for algorithms 2 and 3 respectively, and a 
log rank test for difference in survival for stage '3a' cases from each algorithm gave a near 
significant value of 3.06 (p=0.08). In addition, the trend in survival across stages was 
stronger for algorithm 2 than for algorithm 3. Algorithm 3 was therefore rejected. 
3.3.3.3 
Algorithm 4 staged fewer cases than algorithm 2, with 36.1% and 35.6% of cases 
unstaged respectively. The assumption that suspicion of metastases was indicarive of 
positive metastases was not supported. The five year survival rates for stage '4' cases 
(Table 3.2 ) were 12.3% and 10.0% for algorithms 2 and 4 respectively, and a log rank 
test for difference in survival for stage '4' cases from each algorithm was non-significant 
(p=0.20). Despite the lack of significance, this result suggetes that cases allocated a stage 
' 4  by algorithm 2 due to suspected metastases, when allocated a lower stage by algorithm 
4, left behind cases of a poorer survival in stage '4'. Furthermore, the trend in survival by 
stage for algorithm 4 was stronger than for algorithm 2. Algorithm 2 was thus rejected. 
Comparing Algorithm 1 and Algorithm 2 
Comparing Algorithm 2 and Algorithm 3 
Comparing Algorithm 2 and Algorithm 4 
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using algorithm 4, 1562 cases (63.9%) were staged, producing an almost 13-fold 
improvement in the staged proportion, shown in Figure 3.17. The largest change (other 
than that for stage 'O' cases, of which none were recorded in the notes) was seen for stage 
'2' cases, with a 26-fold increase, the lowest increase being for stage '1' cases for which 
the algorithm brought about an 8 fold increase. For advanced stages (stages '3' and '4’, a 
12 fold increase was seen, demonstrating that, even for advanced cancers, many had not 
been staged in the notes. However, despite the algorithm 36.1% of cases remained 
unstaged including 55 cancers excluded as registrations from DCO or post mortem report, 
or non-carcinoma histology. The remaining unstaged cases had insufficient data even after 
the review of the notes. The cumulative 5 year survival rate for unstaged cases was 69%, 
midway between stage '2a' (79.2%) and stage '2b' (62.3%), suggesting that this group of 
cases contained earlier stage cases rather than a preponderance of advanced disease. 
More data items are required to allocate stages '1' to '3a' than for stages '3b' and '4'. Only 
a single data item is required to allocate stage '3b' or '4' (invasion beyond the breast or 
positive metastases respectively), but in the absence of data indicating 'T4' or 'M1', size, 
nodal status and disease extent must all be recorded. In the sample examined, 28.6% had 
no nodal status and 34.9% had no size recorded in the notes. 
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3.4 THE AVAILABILITY OF PROGNOSTIC DATA FOR EVALUATION 
OF THE NHSBSP 
3.4.1 
Prognostic and diagnostic data recorded on the computer record system at nine West 
Midlands screening units and compiled into HQA reports were examined. The format of 
HQA reports is described in Appendix Two. 
Data available from standard NHSBSP reports 
The proportion of invasive cancers of unknown size recorded at each screening unit from 
1992 - 1995 are shown in Figure 3.18. There was variation across the region, and despite 
generally falling rates, three units failed to achieve the <5% minimum standard set for 
unknown size (Radiological Big '1 8', personal communication). In addition to restricting 
analysis of prognosis, cancers of unknown size cannot contribute to the small cancer rate, 
which is one of the outcome measures used by the NHSBSP discussed in Chapter Six. 
Data describing local node status should be provided for all breast cancers detected by 
screening (NHSBSP, 1996). However, Figure 3.19 shows that many units had high 
proportions of cancers with unknown nodal status. In 1992/93 rates of cancers with 
unknown nodal status varied from 18% to 92% across the region. 
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Despite falling rates from 1992 onwards, in 1994/95 three units had nodal status recorded 
for less than 50% of invasive cancers. For screening to be effective it is recommended that 
>70% of cancers are node negative (Tabar et al., 1992), but if data are incomplete it is 
impossible to tell whether this is the case. One reason for lack of data may be that node 
sampling is performed as a secondary surgical procedure of which details are not routinely 
entered onto screening unit computer systems. 
Variation in the proportions of cases without grade recorded are shown in Figure 3.20. 
Generally falling rates from 1992 to 1995 suggest that the proportion of cases being 
graded and/or the supply of data to screening units has improved, especially, for example, 
at Units D and H. The increasing rate at Unit G is cause for concern and should be 
investigated. Tabar also recommended that at least 30% of grade III screen detected 
tumours should be <15mm (Tabar et al., 1992). However, the HQA report current in 
1996 did not strati& by both size and grade, and used the size limit <=15mm and not 
<15mm, making this outcome measure impossible to calculate. The surgical (QASS) 
report did strati& by grade and size but did not provide the <15mm group either. 
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3.4.2 THE AVAILABILITY OF PROGNOSTIC DATA IN RELATION 
TO SCREENING HISTORY 
The screening histories and the availability of prognostic data for 755 cancers in women 
invited to screening at the Warwickshire, Solihull and Coventry Breast Screening Unit 
were analysed. The allocation of screening history is described in Chapter Two and the 
prognosis and screening histories of this group of cancers is explored in more detail in 
Chapters Four and Six. In addition, data recorded for 788 breast cancers diagnosed in 
1987 in women aged 50 - 64 years were examined as pre-screening controls. Data held at 
the WMCIU and supplied by the screening unit were combined to maximise data 
completeness. The proportions of cancers in each group with histological confirmation, 
tumour size, nodal status and grade recorded are shown in Figure 3.21. 
Histological confirmation was available for all the screen detected cancers, and for all but 
1.1% of interval cancers. The proportion of cancers in non attenders without histological 
confirmation was 26.9%, higher than the 9.5% found in pre-screening controls. Even 
amongst screen detected cancers size was unavailable for 4.8% and 6.8% of prevalent and 
incident cancers respectively, despite the quality standard set by the NHSBSP of <5% of 
cancers be without recorded size (Radiological 'Big 18', 1996). 8.9% of interval cancers 
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SUMMARY 3.5 
An audit of prognostic data recorded at the WMCIU revealed that, in general, the 
accuracy and completeness of the data recorded were high, but identified several factors 
which reduced the validity of data recorded at the WMCIU. 
only 4.8% of the 2444 cases studied had stage recorded on the WMCIU database, 
and only 4.1% had stage recorded in the notes held at the WMCIU 
even when stage was derived from individual staging components found in the case 
notes, it was only possible to obtain a stage for 10% of the cancers investigated 
the accuracy of the recording of stage on the PDP11 was high at 96.3%, but only 
54% of stages in the notes were recorded on the PDP11 
45.8% of stages on the PDP11 were derived from the notes, the remainder being 
added by abstractors. Of added stages, only 40% were consistent with the stage 
allocated by the staging algorithm 
size was available for 65.1% of breast cancers, local node status for 7 1.1% and 
disease extent for 83.4% 
the completeness and accuracy of tumour characteristic data recorded on the old 
WMCIU PDP11 database was high at 87% and 85% respectively for size, 99% and 
88% for local node status, 97.5% and 61% for distant node status, 89% and 86% 
for disease extent and 67% and 91% for positive metastases 
misuse of codes for local node status occurred on the PDP11 so that cases with 
unknown nodal status were indistinguishable from those with negative nodes. 
Survival analysis for stage '2a' cases including and excluding cases with unknown 
nodal status suggested that some of these cases were node positive 
this misuse of codes limited the usefulness of prognostic data recorded on the 
PDP11. Improved coding rules and a new database structure which rectified the 
problems identified have been implemented in the new WMCIU database GRACE 
in 745 of the 1387 cases (53.7%) without a pathological size, and 476 of the 1322 
cases (36.0%) without pathological node status, a pathology report had been sent to 
the WMCIU but did not report these prognostic factors 
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A staging algorithm was designed to combine coded tumour characteristics. The 
algorithm was able to stage 63.9% of cases, a 13-fold increase in the staged proportion. 
The algorithm was able to improve the staged proportion sufficiently for use in 
examination of treatment, prognosis and survival, although its use was restricted by the 
completeness of the data, and some of the assumptions made may not always be valid. 
Analysis of the HQA data recorded by the NHSBSP revealed similar problems to those 
seen with pathological data at the WMCIU. For the screening year 1994/95 
an average of 42.1% of cases had no local node data recorded, with the rate varying 
from 10.3% to 75.0% across the region 
three screening units had no size recorded for >5% of cancers, with rates varying 
from 0% to 6.3% across the region 
five out of the nine screening units had no grade recorded for >5% of cases, with 
rates varying from 0% to 14.7% across the region 
The availability of prognostic data varied according to screening history. Histological 
confirmation and prognostic data were available more often for screen detected cancers 
detected compared cancers diagnosed outside the screening programme. 
size was available for 95.2% of prevalent, and 93.2% of incident screen detected 
cancers, 91.1% of interval cancers, 59.5% of cancers in non-attenders and 65.9% of 
pre-screening controls 
local node status was available for only 43.9% of prevalent, and 73.7% of incident 
screen detected cancers, 59.6% of interval cancers, 61.5% of cancers in 
non-attenders and 68.7% of pre-screening controls 
grade was available for 83.6% of prevalent, and 91.7% of incident screen detected 
cancers, 76.5% of interval cancers, 55.1% of cancers in non-attenders and 46.1% of 
pre-screening controls 
To facilitate the evaluation of the NHSBSP, the completeness of prognostic data must be 
improved, particularly in relation to local node status for screen detected cancers. The 
completeness of prognostic data for breast cancers diagnosed outside the programme 
needs particular attention. 
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CHAPTER FOUR 
RESULTS: AN EXAMINATION OF BREAST CANCER IN 
THE WEST MIDLANDS 
_ -  
4.1 INTRODUCTION 
This chapter describes breast cancer in the West Midlands, utilising published data and 
findings from analyses undertaken at the WMCIU. An overview is presented to describe 
the magnitude of the problem in terms of incidence, mortality, and survival from the 
disease in the region. Attention is focused on differences across the West Midlands, and 
variation by age and time trends is reported. 
The results of two studies examining breast cancer in the West Midlands are then 
presented. Patient and tumour characteristics for breast cancers registered at the 
WMCIU which were diagnosed in 1983 and 1987 are described. The prognostic 
characteristics of breast cancers in relation to their screening history are then described 
in order to assess the likely impact of screening on breast cancer in the West Midlands. 
4.2 AN OVERVIEW OF BREAST CANCER INCIDENCE, MORTALITY 
AND SURVIVAL IN THE WEST MIDLANDS 
4.2.1 Incidence 
The West Midlands had the second highest incidence of 14 Regional Health Authorities 
(RHAs) in 1988 with a Standardised Incidence Ratio (SIR) of 107 in comparison to the 
average for England and Wales. Between 1983 and 1987, in the five years before the 
introduction of screening, there were on average 2640 female invasive breast cancers 
diagnosed each year in the region. Over this period 91 male invasive breast cancers were 
diagnosed, an average of 18 per year. In addition to female invasive cancers, a total of 
134 female in situ cancers were diagnosed over this period, an average of 27 per year. 
The number of female in situ cancers diagnosed each year was thus little over 1% of the 
female invasive total, demonstrating the low incidence of symptomatic in situ disease 
prior to the introduction of screening. The risk of breast cancer rose with age, 
demonstrated by the age specific incidence rates in Figure 4.1. 
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catchment areas before screening began, In Figure 4.3 each catchment area is labelled 
with the unit code allocated by the Department of Health. Incidence rates varied from 
173.7/100,000 in North Birmingham (MBD), an area with a largely inner city 
population, to 196.1/100,000 in South Birmingham (MBS), an area encompassing both 
deprived and affluent districts. Thus the catchment area of the North Birmingham 
screening service had a pre-screening incidence amongst women aged 50-64 years 7.2% 
below the regional average of 186.2/100,000, whereas that of the South Birmingham 
service was 5.1% above the regional rate. Differences in the baseline incidence rates are 
important because after the introduction of screening such variations could influence the 
cancer detection rates achieved by different screening units, with those in a low 
incidence areas likely to achieve lower detection rates than those in high baseline 
incidence areas. Differentiating between this effect and the influence of screening 
sensitivity, which also affects detection rates, is difficult. 
Figure 4.4 shows SIRs for breast cancer in the West Midlands according to level of 
material deprivation. The clear trend in incidence, with higher SIRs in more affluent 
areas, reflects the increasing incidence of breast cancer with increasing affluence 
reported elsewhere (Leon, 1988). 
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from 36% in Worcester (M04) to 17% in Warwickshire (M28). A drop of 36% would 
be impractical to achieve in the time available, while a drop of over 16% should be 
possible in Warwickshire. A more feasible approach to achieving the HoN target is being 
taken by the West Midlands NHS Executive. The 25% reduction is being applied 
regionally, so that each DHA must achieve a 25% reduction, including those with 
relatively low baseline mortality (Baker, personal communication). Unlike incidence, 
mortality showed no clear trend according to level of deprivation, shown in the S M R s  in 
Figure 4.7. This lack of association suggests that, although affluent women were more 
likely to develop the disease, this group had better survival than deprived women, 
resulting in the similar mortality across deprivation levels. 
Figure 4.8 demonstrates a general fall in mortality from 1983 to 1994. From 1983-87 
mortality fell, particularly in 55-59 year olds, although mortality in 50-54 year olds rose 
slightly. From 1990 onwards a downward trend in mortality for women aged 55-69 can 
be seen. The 55-69 year age group is considered suitable for monitoring changes in 
mortality in relation to the NHSBSP since it is in this group that any effect would be 
expected to be apparent (Quinn and Allen, 1995). From 1983-87, prior to the 
introduction of screening, mortality in this group fell by 4.9%. A further drop of 8.9% 
was identified between 1988, which marked the start of a staggered introduction of 
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Five year survival rates varied from 63% in Yorkshire to 69% in the South East, with 
the West Midlands taking a middle position at 65.5%. These rates are not adjusted for 
age, and thus differences could reflect variations in age distribution. 
Figure 4.9 shows five year relative survival rates for women in the West Midlands 
diagnosed with invasive breast cancer between 1984 and 1988 according to age at 
diagnosis. The overall pattern indicates worsening survival with increasing age. The 
highest survival rate of 72% was observed amongst 45 - 49 year olds, although younger 
women fared worse than this. Amongst women aged 50 and 74 years survival showed 
little change with age, with survival rates worsening after age 74 years. 
Figure 4.10 shows five year relative survival rates for women diagnosed with breast 
cancer in the West Midlands between 1984 and 1988. Survival rates varied from 61.4% 
in North Staffordshire (M07) to 71.9% in Coventry (M17). North Staffordshire and 
Sandwell (M19) displayed survival rates significantly lower than the regional rate of 
65.5%, while Coventry, North Worcestershire (M26) and Hereford (M02) displayed 
showed rates significantly higher than the regional average. These inequalities in survival 
are likely to reflect variation in factors including stage, the biological characteristics of 
tumours, treatment factors, and characteristics such as diet and lifestyle. Stage is a 
reflection of the earliness of diagnosis, which may differ across the region, as knowledge 
and understanding of breast cancer, and availability of diagnostic facilities differ. 
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4.3 THE CHARACTERISTICS OF BREAST CANCER IN THE 
WEST MIDLANDS 
Prior to analysis 2.7% of the 251 1 cases diagnosed in 1983, and 8.4% of the 2907 cases 
diagnosed in 1987 were excluded, leaving 2444 and 2663 cases respectively for analysis 
from the two years. Tables detailing the characteristic of these cases are presented in full 
in Tables A7.1 to A7.11 in Appendix Seven. 
4.3.1 
Tables A7.1, A7.2 and A7.3 in Appendix Seven present the distribution of cases by age, 
by DHA, and by both age and DHA respectively. In the overall study population, age at 
diagnosis ranged from 18 to 104 years, with a mean of 62.4 years. Overall 1129 (22.2%) 
of cases were aged less than 50 years, 2194 (43.2%) 50-69 years, and 1754 (34.5%) 70 
years or more. There was no significant difference in age between years (Chi square 3.4 
df 2 p=0.18). Age varied significantly between DHAs for the years combined (Chi 
square 61.9 df 28 p=0.0002), but although variation was significant in 1983 (Chi square 
46.4 df 28 p=0. 16) it was insignificant in 1987 (Chi square 36.9 df 28 p=0. 12). 
4.3.2 Stage at diagnosis 
Tables A7.4 and A7.5 in Appendix Seven present the distribution of cases by stage, and 
by stage and age respectively. The staging algorithm described in Chapter Three 
allocated stage to 2841 cases (56.0%) overall. Stage was allocated to significantly more 
cases diagnosed in 1983 than in 1987 (63.9% vs. 48.6%, Chi square 121.0 df 1 
p<0.0001). The lower proportion staged in 1987 reflected lack of local node data, 
caused partly by methods used to abstract data on the PDP11 database prior to transfer 
onto GRACE. Lack of stage was most common in the youngest cases of which 50.8% 
were unstaged, with the lowest unstaged proportion in those aged 50-69 years (39.0%). 
The distribution of cases by stage is shown in Figure 4.11. In the total study population 
27 cases (0.5%) were stage 'O,  494 (9.7%) stage ‘1', 678 (13.4%) stage '2a', 456 (9.0%) 
stage '2b', 788 (15.5%) stage '3' and 398 (7.8%) stage '4’, with 2236 remaining unstaged. 
Age at diagnosis and DHA of residence 
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4.3.3 Tumour grade 
Tables A7.6 and A7.7 in Appendix Seven present the distribution of cases by grade, and 
by grade and age respectively. Overall only 1723 cases (33.9%) had grade recorded, 
with a significantly higher proportion graded in 1987 than in 1983 (30.5% vs. 37.1% Chi 
square 25.1 df 1 p<0.0001). Of graded cases, a higher proportion were recorded with a 
"good" grade (grade I or 11) in 1987 (39.1%) than in 1983 (23.8%). "Good" grade 
cases were older than "poor" grade (Chi square 8.12 df 2 p=0.017), with 31.1% of the 
559 "good" grade cases being over 70 years old compared to 25.3% of the 1164 "poor" 
grade cases. Whether these variations with age and year reflected genuine trends, 
changes in the selection of cases undergoing pathological investigations, or selective 
reporting of data to the WMCIU was not investigated. 
4.3.4 Deprivation level 
Tables A7.8, A7.9 and A7.10 in Appendix Seven present the distribution of cases by 
deprivation level, by deprivation level and age, and by deprivation level and stage 
respectively. Significantly more cases diagnosed in 1987 fell into the more affluent 
categories (Mantel Haenzel Chi square 11.6 df 1 p=0.0007) compared to those 
diagnosed in 1983. The proportion of younger women rose with increasing affluence 
(Chi square 63.4 df 8 p<0.0001). Of the 2052 women in the most affluent or affluent 
areas, 548 (26.7%) were aged less than 50 years, whereas of the 1896 women in 
deprived or very deprived areas, only 348 (18.4%) were in this age group (Chi square 
39.2, df 1 p<0.0001). 
Stage distribution worsened with increasing deprivation, shown in Figure 4.13. Of the 
1153 staged cases in affluent or very affluent women, only 141 cancers (12.2%) were 
stage '4, compared to 179 of the 1088 cancers in deprived or very deprived women (Chi 
square 8.2, df 1 p=0.004). The reverse was true of early stage cancers, with, of the 1153 
staged cases in affluent or very affluent women, 223 cancers (19.3%) being stage ‘1’, 
compared to only 165 (15.2%) of the 1088 cancers in deprived or very deprived women 
(Chi square 6.8, df 1 p=0.009). 
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4.3.5 Histological group 
The distribution of cases by histological group is shown in Figure 4.14 and is also 
described in Table A7.11 of Appendix Seven. 
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Significane more of the 5077 cases studied had no recorded histological confirmation 
recorded at the WMCIU in 1983 than 1987, with 362 cases without histology in 1983 
compared to 126 cases in 1987 (14.8% vs 4.8%, Chi square 146.7 df 1 p<0.0001). This 
fall suggests an improvement in histological investigation or reporting to the WMCIU 
over this period. The proportions of cases without histology by age and deprivation level 
in he study group are described in Tables A7.12 and A7.13 in Appendix Seven. The 
proportion without histology rose with age (Chi square 271.0 df 2 p<0.0001), with 
18.8% of the oldest and 2.2% of cancers in women under 50 years having no histology. 
Lack of histological confirmation rose with deprivation (Mantel Haenzel Chi square 36.0 
df 1 p<0.0001), with 11.4% of the most deprived and 7.1% in the most affluent being 
without recorded histology. The overall level of histological investigation was good with 
85.2% of breast cancers diagnosed in 1983 and 95.2% of cases diagnosed in 1987 
having histological type recorded on the WMCIU database. 
Of cases with histological confirmation a total of 86 in situ cancers and 9 sarcomas were 
recorded. Of the 4503 invasive carcinomas, 3841 (85.3%) were ductal carcinomas of no 
special type (NST), 358 (8.0%) lobular carcinoma and 295 (6.6%) special type 
carcinomas, with similar distributions between years (Chi square 4.3 df 2 p=0.16). 
4.4 PROGNOSTIC CHARACTERISTICS OF CANCERS 
ACCORDING TO SCREENING HISTORY 
A total of 755 breast cancers arising post-screening and 788 pre-screening controls 
diagnosed in 1987 were examined. The post-screening cancers were divided into 
prevalent and incident screen detected cancers, cancers in non-attenders, and interval 
cancers. The interval cancers examined were the "core" set identified by the method 
described in section 2.4.2 of Chapter Two. Of the cancers examined, 693 of the 
post-screening cancers and 695 of the pre-screening controls had confirmed invasive 
histology. The prognostic characteristics of these cases were examined. The relative 
incompleteness of data for cancers in non-attenders and pre-screening controls, which 
may have contributed to the apparent differences found, was discussed in Chapter Three. 
96 
4.4.1 Invasive status 
The invasive status of the cancers analysed is shown in Table 4.2. 
Only 2.2% of the pre-screening control group were in situ. The in situ proportion in 
non-attenders was similar at 2.3% (Chi square 0.08 p=0.8). Interval cancers had a higher 
in situ proportion than controls (Chi square 3.7 p=0.06), but this difference was not 
significant. 6.9% of prevalent screen detected cancers were in situ, significantly more 
than controls (Chi square 11.9 p=0.0006). 14.1% of incident screen detected cancers 
were in situ, significantly higher than controls (Chi square 37.5 p<0.0001). 
4.4.2 Prognostic characteristics 
The histological type, size, nodal status and grade of cases is shown in Table 4.3. 
4.4.2.1 Histological type 
Although rates of lobular cancer varied from 6.0% in prevalent screen detected cancers 
to 11.7% in interval cancers, no post-screening group had a proportions of lobular 
carcinoma significantly different from pre-screening controls (all Chi square tests with 
Yates correction p>0.05). The proportion of special type cancers varied between 
post-screening groups. The rate amongst interval cancers (4.7%) was similar to the 
control group (4.8%), (Chi square 0.01 p=0.91) but prevalent and incident screen 
detected cancers had significantly more special type cancers, with rates of 12.6% (Chi 
square 17.7 p<0.0001) and 14.3% (Chi square 15.7 p<0.0001) respectively. Only 1.3% 
of cancers in non-attenders were special type, but this was not significantly less than the 
control group (Fisher's exact test 2.5 p=0.24). These variations could reflect difference 
in pathological expertise or data quality rather than real differences in histology. 
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4.4.2.2 Tumour size 
The distribution of cases by size and screening history is shown in Figure 4.15. Only 
27.4% of the pre-screening control cancers were <20mm, compared to 69.1% of 
prevalent screen detected cancers and 69.4% of incident screen detected cancers. 38.7% 
of interval cancers were <20mm, and only 27.7% of cancers in non-attenders fell into 
this category. Compared with pre-screening controls, prevalent and incident screen 
detected cancers were smaller (Mantel Haenzel (MH) Chi square 144.3 p<0.0001, and 
94.1 p<0.0001 respectively). Interval cancers were also significantly smaller (MH Chi 
98 
square 13.8 p<0.0001). Cancers in non attenders had a similar size distribution to the 
control group (MH Chi square 0.3 p=0.60). 
4.4.2.3 Nodal and metastatic status 
The distribution of cases by nodal and metastatic status is shown in Figure 4.16. 
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Chi square 33.98 p<0.01), with incident screen detected cancers also having a more 
favourable distribution (MH Chi square 50.9 p<0.01). The distribution of interval 
cancers was significantly more favourable than the control group (MH Chi square 4.8 
p=0.03). Cancers in non-attenders displayed a similar stage distribution to the control 
group (MH Chi square 0.3 p=0.56). The prognosis of all the incident cancers grouped 
together was also more favourable than the control group, (MH Chi square 25.8 
p<0.0001), suggesting a general shift towards earlier stage which should lead to 
improved survival. 
4.4.2.5 Tumour grade 
The distribution of cases according to grade and screening history is shown in Figure 
4.18. Over 57% of control group cancers were of poor grade. Prevalent and incident 
screen detected cancers had significantly lower proportions of poor grade cancers, with 
18.7% and 23.0% being poor grade respectively. Although more interval cancers were 
poor grade (4 1.1%) than screen detected cancers, this proportion was significantly lower 
than the control group. 53.5% of cancers in non-attenders were of poor grade, similar to 
the control group. 
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variation in baseline incidence rates between districts could influence the apparent 
cancer detection rates achieved by screening units, with those in low baseline 
incidence areas likely to achieve lower detection rates than those in high baseline 
incidence areas independently of the quality of screening 
incidence rates in the screening age group were rising before the introduction of 
screening, with rates in 50-64 years olds rising by 3.6% per year from 1983-87 
a pre-screening trend in falling mortality in 55-69 year olds continued after 
screening began in 1988 but is unlikely to be due to screening 
pre-screening variations in mortality and survival suggest differences in prognostic 
characteristics and/or treatment across the region 
although affluent women display higher rates of the disease, mortality patterns 
indicate that these women experience better survival than more deprived groups 
Detailed examination of the 5077 cases diagnosed in 1983 and 1987 revealed that 
56% were staged by the staging algorithm, with lack of local nodal status being 
responsible for most of those remaining unstaged 
85.2% of cases in 1983 and 95.2% in 1987 had histological type recorded. 
Significantly more cases had no recorded histology in 1983 than 1987, suggesting 
an improvement in histological investigation or reporting over this period 
only 1.6% of cancers were in situ, and of invasive carcinomas, 85.5% were ductal 
carcinomas of no special type, 8.0% were lobular carcinomas and 6.6% 
carcinomas of "special type" 
22.2% of women were aged <50 years, 43.2% 50-69 years, and 34.5% 70 years or 
more, with a higher proportion of cancers in affluent women occurring below the 
age of 50 years 
there were significant associations between increasing age, increasing deprivation 
and poorer stage 
Analysis of the characteristics of breast cancers diagnosed after the introduction of 
screening revealed differences in prognosis according to screening his tory. 
only 2% of pre-screening cancers were in situ compared with 6.9% of prevalent 
and 14.1% of incident screen detected cancers, indicating possible overdiagnosis 
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27.4% of pre-screening cancers were <20mm, compared to 69.1% of prevalent 
and 69.4% of incident screen detected cancers, 38.7% of interval cancers and 
27.7% of cancer amongst non-attenders 
34.1% of pre-screening cancers had involved local nodes or metastases, compared 
to 15.3% of prevalent and 20.3% of incident screen detected cancers, 26.3% of 
interval cancers and 38.4% of cancers in non-attenders 
57% of pre-screening cancers were of poor (high) grade, compared to 18.7% of 
prevalent and 23.0% of incident screen detected cancers, 41.1% of interval 
cancers and 53.5% of cancers in non-attenders 
screen detected cancers had the most favourable prognosis, and cancers in 
non-attenders the poorest. The prognosis of interval cancers was poorer than for 
screen detected cancers but more favourable than that of pre-screening cancers 
These results suggest that women with screen detected cancer should display better 
survival than those with breast cancer diagnosed outside the NHSBSP, although lead 
time bias must be accounted for in any analysis of survival. There is some evidence that 
overdiagnosis and/or length bias may be occurring in the NHSBSP due to detection of 
relatively high proportions of in situ and special type cancers. The poor prognosis of 
cancers in non-attenders suggests that women who do not access the NHSBSP are a 
particularly high risk group. 
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CHAPTER FIVE 
RESULTS: TREATMENT OF AND SURVIVAL FROM BREAST CANCER IN 
THE WEST MIDLANDS 
5.1 INTRODUCTION 
In this chapter the findings from an examination of treatment data recorded at the 
WMCIU are presented. Data recorded for breast cancers diagnosed in 1983 and 1987 
were examined, with treatment restricted to that given within six months of diagnosis. 
The data were examined in relation to two issues. Firstly the reliability of routinely 
recorded treatment data was considered. Treatment patterns were then compared with 
the King's Fund guidelines (King's Fund, 1986) to identify changes which may have been 
implemented following the publication of the guidelines. 
5.2 
Treatment data are provided in full in Tables A8.1 to A8. 10 in Appendix Eight. 
THE NATURE AND VARIATION OF RECORDED TREATMENT 
5.2.1 Recorded surgical treatment 
Tables A8.1 and A8.2 in Appendix Eight provide the distributions of recorded treatment 
by year and age. The frequency of recorded treatment is shown in Figure 5.1. 
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Of the 5077 cases studied only 381 (7.5%) had no treatment data recorded, 841 (16.6%) 
had non-surgical oncology data only, 1520 (29.9%) had conservative surgery, and 2335 
(46.0%) had a mastectomy recorded. No treatment data were recorded for 172 cases 
(7.0%) in 1983 and 209 cases (7.9%) in 1987. Reasons for lack of treatment were 
known for 84.3% of the cases in 1983 and 38.8% in 1987. They included poor physical 
condition, refusal, and presentation with disease too advanced to treat. In the remainder 
of the cases it was unknown whether treatment had been absent or the data were 
incomplete. Overall the oldest women were more likely to have no treatment recorded, 
with 23 of the 1129 aged <50 years (2.0%), and 25 1 of the 1754 women aged 70 years 
or more (14.3%) having no treatment recorded. 
Use of non-surgical oncology in the absence of surgery changed little over this period, 
being recorded for 413 cases in 1983 (16.9%) and for 428 cases in 1987 (16.3%), and 
was recorded most often for elderly women, with 61.8% of the 841 cases in this 
treatment group aged 70 years or more. Table A8.4 in Appendix Eight details recorded 
non-surgical oncology for patients without recorded surgery. For this group of 841 
cases, hormone therapy was recorded for 758 (90.1%), and radiotherapy for 302 
(35.9%), with chemotherapy recorded for only 52 cases (3.7%). 
The frequency with which each type of surgery was recorded showed highly significant 
changes between 1983 and 1987. Mastectomy was recorded for 1353 cases in 1983 
(55.4%), but for only 982 cases in 1987 (37.3%) (Chi square 165.8 df 1 p<0.0001). 
Conservative surgery rates showed a simultaneous rise, being recorded for 506 cases in 
1983 (20.7%) and for 1014 cases in 1987 (38.5%) (Chi square 190.8 df 1 p<0.0001). 
These changes are in line with the King's Fund recommendation to use conservative 
surgery where appropriate. However, other possible reasons for differences in the rates 
must be considered. To estimate whether recording of surgical treatment was reasonably 
complete, overall surgical (mastectomy plus conservative surgery) rates across the 15 
DHAs were compared. Although variations in the use of mastectomy versus 
conservative surgery might be expected, partly as a result of clinical preference, large 
differences in the overall surgical rate could signify areas with poor data completeness. 
Figure 5.2 shows overall surgical rates in 1983. 
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Overall surgical rates varied significantly (Chi square 4 1.7, df 14 p<0.001). However, 
when the DHA with the lowest rate, North Staffordshire (M07), is excluded, the 
variation ceases to be significant. North Staffordshire had the highest proportion of 
metastatic cases (14%) compared to the regional average of 1 1%, which although failing 
to achieve significance, suggests that the apparent lack of surgery in North Staffordshire 
reflects, at least to some extent, clinically advanced disease which would not be 
appropriately treated by surgery. Similar observations were made using 1987 data, 
suggesting that recording of surgery was reasonably complete. 
In both years the frequency of recorded surgical treatment varied with age. Figure 5.3 
shows that younger women were more likely to have conservative surgery than older 
groups in both years. In 1983, 144 of the 526 women aged under 50 years (27.4%) had 
conservation surgery recorded, falling to 202 of the 1088 50-69 year olds (18.6%) and 
160 of the 830 women aged 70 or more (19.3%) (Mantel Haenzel Chi square 10.2 df 1 
p=0.001). In 1987 the trend with age was more marked, with conservation surgery 
recorded for 3 14 of the 603 women aged less than 50 (52. l%), 436 of the 1106 50-69 
year olds (39.4%) and 264 of the 924 women in the oldest group (28.6%) (Chi square 
85.5 df 1 p<0.0001). 
107 

inter-district differences were significant in both years. In 1983 mastectomy was 
recorded for only 44.3% in South Birmingham (M25)  rising to 68.9% in 
Wolverhampton (M22), with significant variation across DHAs (Chi square 58.9 df 14 
p<0.0001). In 1987 rates ranged from 25.3% in South Staffordshire (M27) to 60.2% in 
Walsall (M21) (Chi square 89.9 df 14 p<0.0001). Hereford (M02) and Walsall 
maintained consistently high mastectomy rates relative to other districts throughout the 
period studied, while rates in North Worcestershire (M26) dropped dramatically in 1987 
compared with 1983. Large changes in practice were also apparent in Coventry (M17), 
Dudley (M18), Wolverhampton (M22) and South Staffordshire (M27). 
An increase in conservative surgery was seen across the region, shown in Figure 5.5, 
with the regional average rate rising from 20.7% to 38.5%. Inter-district variation in 
conservative surgery rates was significant, ranging from 7.7% in Hereford (M02) to 
26.4% in South Staffordshire (M27) in 1983 (Chi square 54.9 df 14 p<0.0001) and from 
24.2% in Walsall (M21) to 50.6% in South Staffordshire in 1987 (Chi square 59.9 df 14 
p<0.0001). In general, districts with high rates in 1983 also had high rates in 1987, but 
the marked increases in the conservative surgery rate in 1987 in Wolverhampton (M22) 
and North Worcestershire (M26) may reflect significant changes in practice. 
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5.2.2 Non-surgical oncology 
Table A8.2 in Appendix Eight describes the non-surgical recorded for cases in the study 
group. Recorded non-surgical oncology is also shown in Figure 5.6. For the years 
combined, 1859 of the 5077 cases studied (36.6%) had recorded radiotherapy, 2038 
(23.5%) hormone therapy, and 196 (3.9%) chemotherapy. 
5.2.2.1 Radiotherapy 
The completeness of non-surgical treatment data is related to the means by which data 
are notified to the WMCIU. Radiotherapy data are usually submitted directly by the five 
radiotherapy departments in the West Midlands, and the active communication links that 
exist between these departments and the WMCIU mean that completeness of 
radiotherapy data is believed to be reasonably high. Recorded radiotherapy rates rose 
from 33.9% in 1983 to 39.1% in 1987 (Chi square 14.5 df 1 p<0.0001). Use of adjuvant 
radiotherapy with conservative surgery was recommended by the King’s Fund guidelines 
to reduce the risk of recurrence. Table A8.5 in Appendix Eight provides the treatment 
data for cases undergoing conservative surgery. Figure 5.7 shows that, of 1520 cases 
with recorded conservative surgery, 51.0% of 506 cases also received radiotherapy in 
1983, rising to 59.1% of 1014 cases in 1987 (Chi square 17.4 df 1 p<0.0001). This rise 
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together with the associated increase in conservative surgery in 1987 compared with 
1983 (20.7% to 38.5%) suggests that the King's Fund recommendations did have an 
effect on practice in the West Midlands region. Of similar significance is the increase in 
hormone therapy in combination with radiotherapy for women undergoing conservative 
surgery. This change is again completely in line with the King's Fund recommendations. 
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Recorded radiotherapy rates varied across the region, shown in Figure 5.8, with the 
regional average rising from 33.9% in 1983 to 39.1% in 1987. In 1983 rates ranged 
from 19.0% in North Staffordshire (M07) to 56.5% in Coventry (M17) (Chi square 92.7 
df 14 p<0.0001). Rates in 1987 ranged from 24.2% in Walsall (M21) to 48.1% in 
Hereford (M02) (Chi square 33.3 df 14 p=0.003). 
5.2.2.2 Hormone therapy 
Hormone therapy is often prescribed within, and recorded by radiotherapy departments, 
and if this is the case hormone therapy is notified to the WMCIU at the same time as 
radiotherapy. Hormone therapy may also be prescribed in other clinical settings 
including out-patient appointments and primary care, from which it is known that 
notification of data to the WMCIU is incomplete. It is thus likely that recorded hormone 
therapy data are incomplete, and variation in recorded rates between DHAs, which are 
not presented, is likely to reflect differences in data completeness. 
Despite this under-recording, it is probable that some of the changes in recorded 
hormone therapy over the period studied are due to genuine changes in clinical practice. 
Hormone therapy was recorded for 658 of 2444 cases in 1983 (26.9%), rising to 1380 
of 2633 in 1987 (52.4%) (Chi square 329.2 df 1 p<0.0001), suggesting that the King's 
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Fund guidelines were acted upon. Older women were more likely to have recorded 
hormone therapy, shown in Figure 5.9, in line with the guidelines. In 1983 hormone 
therapy was recorded for 14.5% of the youngest women, rising to 40.5% in the oldest 
(Mantel Haenzel Chi square 145.9 df 1 p<0.0001). In 1987 rates rose from 38.3% in the 
youngest to 58.0% in the oldest group (Mantel Haenzel Chi square 59.4 df 1 p<0.0001). 
5.2.2.3 Chemotherapy 
Chemotherapy may be prescribed within radiotherapy departments, but may also be 
prescribed in other in-patient and out-patient settings, from which notification of data to 
the WMCIU is again known to be less complete. In this analysis, of the 196 cases with 
recorded chemotherapy, 106 (54.1%) had this treatment notified to the WMCIU by a 
radiotherapy department. Despite the King's Fund guidelines recommending 
chemotherapy, recorded rates fell significantly in the West Midlands, being recorded for 
118 women in 1983 (4.8%) and 78 women in 1987 (3.0%) (Chi square 11.4 df 1 
p=0.0007). These observations must be viewed with great caution as the completeness 
of out-patient chemotherapy data is known to be poor. 
113 
Some differences in usage between groups were, however, apparent. Figure 5.10 shows 
that, in line with the guidelines, in both years younger women were significantly more 
likely to have recorded chemotherapy. In 1983 chemotherapy rates fell from 9.5% in the 
youngest to 1.1% in the oldest group (Mantel Haenzel Chi square 51.2 df 1 p<0.0001) 
and in 1987 from 5.6% in the youngest to 1.1% in the oldest women (Mantel Haenzel 
Chi square 26.2 df 1 p<0.0001). 
5.2.3 
The King's Fund guidelines recommended that stage and age should be considered when 
allocating appropriate treatment. Recorded data suggest that age was taken into 
account, for example, older women were more likely to have hormone therapy recorded 
and less likely to undergo conservative surgery in both years. To examine whether 
treatment differed with stage, treatment recorded for early (stage ' O ,  '1' and '2a'), and 
locally advanced (stage '2b' or '3') invasive breast cancers was examined. To reduce 
possible confounding by age the analysis was restricted to the 1139 early and locally 
advanced stage cancers dagnosed in 50-69 year olds. 
Treatment combinations are presented in Figure 5.11. Each cell represents a 
combination of surgery, radiotherapy (RT), chemotherapy (CT) and hormone therapy 
(HT). The percentage of cases with each combination is shown, with darker shading 
indicating a larger contribution to the total. The likely incompleteness of hormone 
therapy and chemotherapy data should be considered when interpreting the grids. 
In 1983 recorded treatment differed significantly with stage, with 291 of the 296 early 
cancers (98.3%) having surgery compared to 266 of the 315 advanced cancers (84.3%) 
(Chi square 34.7 df 1 p<0.0001). Conservative surgery was recorded for 65 early stage 
(22.0%), but only 24 (7.6%) advanced cancers (Chi square 24.1 df 1 p<0.0001). 
Hormone therapy was recorded for only 37 early cancers, but for 87 advanced cancers 
(12.6% vs. 27.6% Chi square 20.6 df 1 p<0.0001), and radiotherapy was also more 
often recorded for advanced disease (29.2% vs. 53.9% Chi square 37.9 df 1 p<0.0001). 
Chemotherapy was recorded for only 18 early cancers, and for 13 advanced cancers 
(6.2% vs 4.1% Chi square 0.8 df 1 p=0.36). 
Treatment variation according to stage 
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5.2.4 Surgical caseload 
Tables A8.7 to A8.10 describe treatment recorded for the study group according to 
surgical caseload. The annual caseload of surgeons treating cases diagnosed in 1983 and 
1987 is shown in Figure 5.12. Caseload was available for 1800 of the 1859 cases 
diagnosed in 1983 with surgery recorded (96.6%), and for 1850 of the 1996 surgically 
treated cases in 1987 (92.7%). Caseload could not be ascertained for cases where the 
treating surgeon was unidentified. Of cases diagnosed in 1983 for which surgical 
caseload was available, 320 (1 7.8%) received treatment from a high caseload surgeon 
(treating >30 cases/year) compared to 507 (27.4%) of cases diagnosed and treated in 
1987 (Chi square 48.2 df 1 p<0.0001). However, even in 1987, almost 75% of cases 
were treated by surgeons with an annual caseload of <=30 new cases per year. 
Stage distributions amongst the 1480 cases treated by a low caseload (<=30 cases/year) 
surgeon and the 320 treated by a high (>30 case/year) caseload surgeon in 1983, and for 
the 1343 and 570 cases treated by low and high caseload surgeons respectively in 1987 
are shown in Figure 5.13. In 1983 there was little difference in stage distribution 
according to caseload, with an average of 36.1% of cases (35.5% low caseload, 36.3% 
high caseload) remaining unstaged after using the staging algorithm. Only 4.4% of cases 
in each caseload group were metastatic at diagnosis, a low proportion which reflects the 
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Amongst cases with conservative surgery the rise in recorded radiotherapy from 1983 to 
1987 was apparent for both low and high caseload surgeons. However, there was no 
difference in the frequency of recorded radiotherapy according to caseload in either year. 
Radiotherapy was recorded for 50.5% and 54.0% of cases diagnosed in 1983 receiving 
surgery from low and high caseload surgeons respectively (p=0.59), and, for 1987 cases, 
60.1% and 59.3% respectively (p=0.89). The rise in recorded hormone therapy for this 
group from 1983 to 1987 was also apparent in both caseload groups, but once again, 
there was no difference in the frequency of recording according to caseload. 
5.3 SURVIVAL OF BREAST CANCERS DIAGNOSED IN 1983 AND 1987 
5.3.1 Findings from univariate analysis 
The five year relative survival rates in this section are presented in Tables A8.11 to 
A8.21 in Appendix Eight. The 33 cases registered from a death certificate only and 16 
cases registered from a post mortem report only in 1983 (2%) were excluded, as were 
the 14 and 9 cases respectively diagnosed in 1987 (0.9%), leaving 2395 and 2610 cases 
diagnosed in 1983 and 1987 respectively eligible for analysis. The five year relative 
survival rate for all breast cancers diagnosed in 1983 was 62.7% [95% CI 60.4 - 65.0], 
rising significantly to 66.4% [64.2 - 68.6] for those diagnosed in 1987 (Chi square 4.4, 
df 1, p= 0.04). Five year survival rates for invasive breast cancers (excluding sarcomas) 
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rose from 62.3% [60.0 - 64.7] in 1983 to 66.0% [63.3 - 67.9] in 1987, although this rise 
just failed to achieve significance (Chi square 3.5 df 1 p=0.06). 
5.3.1.1 Survival by stage 
Survival by stage is shown in Figure 5.15. Survival rates rose from 10.4% [95% CI 6.1 - 
14.7] for stage '4' cancers to 88.4% [84.4 - 92.4] for stage '1'. For stage 'O' cancers, 
which were in situ and had negative nodes, there were 2 breast cancer deaths amongst 
1983 cases, suggesting incomplete removal of the tumour and progression to invasive 
cancer, or that the diagnosis of in situ cancer was incorrect. There were no deaths 
amongst in situ cases diagnosed in 1987 leading to relative survival in excess of 100%. 
Survival rates for stage '1' and stage '2a' cases were slightly higher in 1987 than in 1983, 
and that of stage '4' cancers worsened slightly from 1983 to 1984, although none of 
these differences was significant. For stage '2b' cases, five year relative survival rates 
dropped from 64.6% in 1983 to 53.5% in 1987 (p<0.05). Stage '2b' is made up of both 
larger node negative cases (>=50mm), and smaller node positive cases (>=20mm and 
<50mm). The proportion of node positive stage '2b' cases was similar in each year (8.5% 
1983, 8.6% 1987). The average size of tumours in this stage group were also similar 
between years both for node negative and node positive cases. It was thus unlikely that 
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the observed survival difference between years for stage '2b cases reflected a genuine 
difference in the size or nodal status of cancers making up this stage group. However, 
poorer completeness of nodal recording in 1987 may have resulted in exclusion of some 
node negative cases from this stage group. 
Stage '3' cases from 1983 fared better than those from 1987 (48.0% 1983, 40.6% 1987, 
p<0.05). In this study stage '3' included stage '3a' and '3b' cancers. There was little 
difference in the contribution made by stage '3b' in both years (90.9% 1983, 87.7% 
1987). It is possible that the results for stage '2b' and stage '3' cancers reflect improved 
recording of staging information in 1987, perhaps due to an increase in the use of 
detailed investigations. Such an increase might lead to 'stage migration', as apparently 
localised cancers, which would previously be allocated an early stage are, as a result of 
more rigorous investigation, found to be more widespread and allocated a higher stage 
(Barr et al., 1992). This migration would result in fewer cases being incorrectly 
allocated an early stage, so that survival would appear to improve for early stages 
(stages '1' and '2a' in this study), but worsen for higher stages (stages '2b, '3', and '4). It 
is also possible that these difference in survival by stage reflect changes in other factors 
which influence survival such as treatment regimen or patient-related factors. 
5.3.1.2 Survival by histological group 
The five year relative survival rates according to histology are shown in Figure 5.16, 
from which sarcomas were omitted as there were less than 10 cases in either year. In 
both years survival varied significantly between histological groups. For 1983 cases of 
unknown histology, survival was only 22.8%, but of 1987 cases in this group survival 
was better at 47.2%, possibly reflecting increased use of non-surgical therapy for women 
not undergoing surgery. In situ cancers, allocated stage ' O  if nodes were recorded as 
negative, displayed very high survival rates. Survival for lobular carcinomas was high at 
73.2%, and survival for special type carcinomas was as expected even higher at 84.5% 
overall. Invasive ductal carcinomas of no special type, which made up the majority of 
cancers, had an overall survival of 64.2%. 
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5.3.1.3 Survival by grade 
Five year survival rates by grade are shown in Figure 5.17. Cases allocated a "good" 
grade had a five year survival rate of 79.9% [75.6 - 84.2] overall, whereas ''poor'' grade 
cancers had a survival rate of only 61.7% [58.5 - 64.9]. The majority of cases (66.1% 
overall) did not have grade recorded and displayed a survival rate of 63.0% overall, 
similar to the poor grade cancers. 
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5.3.1.4 Survival by DHA 
TO examine whether the high survival rate for in situ cancers could have been 
responsible for inter-district variation in survival, rates were calculated for all breast 
cancers, and again for invasive carcinomas only. In the second analysis, in situ cancers 
and sarcomas were excluded, but cases without histology were included. The decision to 
include those without histology was based on the poor survival observed in this group 
which suggested that most of these cancers were invasive. There was a high degree of 
correlation in both years between the rank order by survival for each DHA for all 
cancers compared to that for invasive carcinomas (1983 cases Spearman rank 
correlation coefficient 0.95 p<0.0001, 1987 cases 0.97 p<0.0001). Since inter-district 
variation remained after removal in situ cancers and sarcomas, these cases were 
excluded from all survival analyses thereafter. Survival rates for invasive breast cancers 
in each DHA are shown in Figure 5.18. 
For cases diagnosed in 1983 survival for invasive carcinomas ranged from 55.9% in 
Hereford (M02) to 70.5% in South Staffordshire (M27). None of the DHAs were 
significantly different from the regional rate, partly due to the small numbers in each 
DHA. For cases diagnosed in 1987 rates ranged from 57.5% in South Birmingham 
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( M 2 5 )  to 77.9% in Hereford (M02), both of which again failed to differ significantly 
from the regional rate. 
5.3.1.5 Survival by age 
The highest survival rates were observed in women aged <50 years (67.8% [65.0 - 
70.7], with the two older groups displaying lower rates of 62.4% [60.2 - 64.6] for 50 - 
69 year olds and 63.3% [59.7 - 66.8] for the oldest women. Variation in survival 
between age groups was significant (Pearson Chi square 13.8 df 2 p=0.001). Within age 
groups, however, the year groups studied did not differ significantly from each other. 
5.3.1.6 Survival by deprivation level 
Five year survival rates according to the Townsend group are shown in Figure 5.19. For 
1983 cases the variation in survival with deprivation level was significant, with a clear 
trend in survival with the more deprived groups displaying poorer survival rates. The 
trend was less clear for 1987 cases, and although more deprived groups fared worse 
than the more affluent groups, the variation across deprivation levels just failed to 
achieve significance (Pearson Chi square 9.5 df 4 p=0.05). 
5.3.1.7 Survival by treatment type 
Survival rates according to treatment type are shown in Figure 5.20. 
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The highest survival rates were observed in cases undergoing conservative surgery, with 
survival rates of 77.2% for 1983 and 80.8% for 1987. Cases undergoing mastectomy 
displayed lower survival rates of 68.1% for 1983 and 65.5% for 1987. Amongst cases 
with only non-surgical treatment or with no treatment data recorded survival was poor. 
Figure 5.21 shows survival rates for cases with recorded conservative surgery according 
to the type of adjuvant therapy. For 1983, cases with recorded hormone therapy alone 
fared the best, followed by those without adjuvant therapy and those with radiotherapy 
only recorded. For 1987 cases the highest survival was observed in those without 
recorded adjuvant therapy, with those with recorded hormone therapy faring almost as 
well. Those with radiotherapy recorded alone or with hormone therapy displayed slightly 
lower survival rates. In both years cases with chemotherapy recorded fared poorly. 
Figure 5.22 shows survival for mastectomy cases according to non-surgical therapy. 
Variation in survival between adjuvant therapy options was significant in both years. The 
best survival was observed in those with no adjuvant therapy recorded. For 1983 cases 
survival rates in those with recorded adjuvant therapy ranged from 60.1% for those with 
hormone therapy only recorded to 5 1.6% for those with both radiotherapy and hormone 
therapy recorded. For 1987 cases where adjuvant therapy was recorded the best survival 
was seen in those with hormone recorded only, with those with recorded chemotherapy 
displaying poor survival. Survival for patients with recorded chemotherapy in 1987 was 
poorer than seen for this group for cases diagnosed in 1983. 
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5.3.1.8 Survival by surgical caseload 
Survival rates according to surgical caseload are shown in Figure 5.23, Survival 
variation according to caseload failed to achieved significance in either year. There was 
no clear trend in survival with increasing caseload, although of cases diagnosed in 1987, 
those treated by the lowest caseload surgeons displayed the poorest survival. 
5.3.2 Findings from multivariate analysis 
Multivariate analyses were carried out on cases for which all the factors examined in 
univariate analyses were recorded. This restricted the study population to 1041 cases, 
20.8% of the original group of 5005 eligible for survival analysis. Of the 1041 cases 
there were almost equal numbers in terms of year of diagnosis, with 5 19 cases diagnosed 
in 1983 (49.9%), and 522 in 1987 (50.1%), with no significant difference in the 
likelihood of cases in either year being selected (Chi square 1.46 df 1 p=0.23). Selected 
cases were significantly younger than those unselected, with 271 of the 1041 selected 
(26.0%), and 1483 of the 3964 unselected cases (37.4%) being aged 70 years or more 
(Chi square 46.4 df 1 p<0.0001). Furthermore, the selected group did not represent each 
DHA equally, with the proportion of cases from each DHA included varying from 
11.2% for Walsall to 34.5% for Warwickshire (Chi square 13.7 df 14 p=0.008). 
Selected cases were less deprived than unselected cases, with 189 (16.2%) of selected, 
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and 748 of the 3944 unselected cases for which deprivation level was available (19.0%) 
being in the most deprived group (Chi square 4.09 df 1 p=0.04). These observations 
reflect the differing data quality across the region described in Chapter Four, with data 
quality being poorest for the oldest and most deprived women. All DHAs were 
represented in the selected study group, however, and 26.0% of selected cases were 
aged 70 years or more. 
The poorer survival identified in the univariate analysis for older and more deprived 
women suggested that selected cases could be biased towards better survivors. Amongst 
the 4910 invasive cancers, five year survival rates for the 1041 selected cases was 63.4% 
compared to 64.2% for the 3869 unselected cases (Pearson Chi square 0.36 df 1 
p=0.55). In addition, a Cox model was created for the 5005 cases into which selection 
for the multivariate analysis was entered as a categorical variable, but failed to achieve 
significance (Wald 1.09 df 1 p=0.30). Thus despite the biases identified, selection for 
multivariate analysis was not associated with better survival, and thus performing 
multivariate analysis on the selected cases was considered to be valid. 
Table 5.1 describes models in which stage, grade, age, histology, deprivation level, 
treatment, DHA and year were entered singly into Cox models. 
When entered alone, stage was the most significant factor, followed by treatment. Grade 
was also highly significant. Deprivation level was significant (p=0.01), but age, 
histology, DHA and year failed to achieved significance. When the process was repeated 
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using a baseline model including stage, treatment remained highly significant while the 
significance of grade and deprivation level was reduced. Histology, age and year 
remained non-significant. DHA became significant after adjustment for stage, although 
non-significant alone, indicating. that, stage for stage, survival covaried significantly 
with DHA. 
Table 5.2 shows statistics for the overall model. Stage, treatment group, DHA, grade 
and deprivation band were selected for inclusion in the model. Stage was the most 
significant factor, followed by treatment group. DHA was selected as the next factor for 
entry, followed by grade and finally deprivation level. The significance of the model 
based on the overall change in the log likelihood was high (p<0.0001). 
Table 5.3 also describes the overall model. Relative risks for each risk factor are given in 
comparison to reference categories of stage '1' cancers, treated with surgery alone, of 
good grade, in the most affluent area. To aid interpretation of calculated relative risks, 
the reference category selected for each covariate was the category likely to have the 
best prognosis. The DHA selected as the reference category, Hereford (M02), was 
chosen simply because it is numerically the first DHA listed. Interpreting relative risks 
for individual DHAs in comparison to this reference DHA is of limited use, and for this 
reason relative risks for every individual DHA are not provided in Table 5.3. 
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Compared to stage ‘1', stage '2a' cases were at a non-significant elevated risk, but the 
risk to other stages was increased significantly with advancing stage. Poor grade cancers 
were at significantly higher risk than good grade (RR 1.37 [1.1 - 1.721). Deprivation 
groups other than middle range were at non-significant elevated risk compared to the 
most affluent, whereas those in the middle range were at a non-significantly reduced 
risk. Results for treatment were, at first glance, surprising. As expected, those without 
surgery were at elevated risk compared to those with surgery alone (RR 2.17 [1.51 - 
3.131). However, all the surgical groups with recorded adjuvant treatment were also at 
elevated risk, with only the surgery + hormone therapy group displaying a 
non-significant elevation (RR 1.16 [0.86 - 1.571). This is at variance with the weight of 
evidence in support of the benefits of adjuvant therapy for breast cancer. This result 
probably reflects incompleteness in the recording of chemotherapy and hormone therapy 
data, particularly for women who received these treatments in out-patient or primary 
care settings in the absence of radiotherapy. It is likely that such women had a better 
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prognosis than those requiring treatment at radiotherapy centres, and thus that 
chemotherapy and hormone therapy data recording was biased towards women with 
poorer health. Lack of chemotherapy and hormone therapy data is probably associated 
with a better prognosis, giving rise to the observed results. Relative risks for each DHA 
were calculated in comparison to M02 as an arbitrary reference category, and are not 
shown. Only M07 displayed a significantly elevated risk (RR 2.03 [1.08 - 3.841). 
Separate stage-specific models were produced using forward stepwise selection to 
assess the influence of other covariates within stage. The stage-specific models are 
described in Table 5.4. 
For stage '1' and '2b', none of the other covariates influenced survival. For stage '2a' 
cases treatment group was significant. For stage '3' cases, age, grade, and treatment 
group were significant, and for stage '4' cases, only histological group was significant. 
Table 5.5 shows relative risks from the overall stage-specific model for stage '2a' cases. 
Those without surgery were at significantly elevated risk compared to those with 
surgery alone recorded. Surgical groups for which adjuvant treatment were recorded 
were at elevated risk, with all groups being at significantly higher risk except for the 
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surgery + hormone therapy group (RR 1.02 95% CI 0.53 - 1.99). Table 5.6 shows the 
relative risks from the stage-specific model for stage '3' cases. 
Although age was significant, neither of the two older age groups displayed a relative 
risk significantly different from women aged < 50 years. Poor grade cancers were at 
elevated risk compared to good grade cancers (RR 2.04 95% CI 1.33 - 3.12). The 
results for treatment group were similar to those found in other models, with the surgery 
+ hormone therapy group being the only category with a relative risk not significantly 
elevated compared to the reference category of surgery alone. Table 5.7 shows relative 
risks from the overall stage-specific model for stage '4' cases. 
The reduced risk for lobular carcinoma was non-significant. The significantly elevated 
risk found for special type carcinomas, commonly associated with a good prognosis, 
probably reflected the fact that there were only 3 special type carcinomas out of 75 
cases. Where models are based on so few data their clinical relevance must be viewed 
with caution. 
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To further assess the influence of surgical type (conservative surgery or mastectomy) 
and surgical caseload on survival, the 933 cases with recorded surgery, and for which 
caseload and all other data items were available, were selected. Stage, surgical type, 
adjuvant therapy type, annual surgical caseload, age, grade, histological type, 
deprivation level, DHA, and year of diagnosis were entered singly as a categorical 
covariates, resulting in the models described in Table 5.8. 
Surgical caseload was non-significant (p=0.90), and surgical type also failed to achieve 
significance (p=0.06). Only stage, adjuvant therapy group, grade and deprivation level 
were significant and were selected for inclusion in an overall model using forward 
stepwise selection. The relative risks for this model were similar to those identified in the 
model for all cases (Table 5.2), with risk increasing with worsening stage and grade 
cancers, and relative risks being of similar magnitude to those presented in Table 5.3. 
Once again, the elevated relative risks for women with recorded adjuvant therapy 
suggest incompleteness in adjuvant therapy data recording. Although deprivation level 
was significant in the model, no individual deprivation sub-category achieved 
significance in comparison to the most affluent women. 
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5.4 SUMMARY 
Examination of treatment recorded at the WMCIU for breast cancers diagnosed in 1983 
and 1987 revealed changes in recorded treatment over this period which were in 
agreement with the King's Fund recommendations 
mastectomy rates fell from 55.4% to 37.3% with a simultaneous rise in recorded 
conservative surgery rates from 20.7% to 38.5%. In both years younger women 
were more likely to have conservative surgery than older women 
despite probable incompleteness of data, a rise in recorded hormone therapy from 
26.9% to 52.4% was identified, with older women more likely to have recorded 
hormone therapy in both years 
recorded radiotherapy rates rose from 33.9% to 39.1%. This was most apparent 
amongst women receiving conservative surgery, in whom rates of adjuvant 
radiotherapy rose from 5 1 .O% to 59.1% 
incompleteness of chemotherapy data meant that little could be concluded 
regarding use of adjuvant chemotherapy. Very low rates were identified in both 
years, being recorded most often for the youngest women 
in both years both age and stage were determining factors in allocating treatment 
the proportion of patients treated by high caseload surgeons (defined as those 
treating >30 cases/year) rose from 17.8% to 27.4%, but even in 1987 nearly 75% 
received surgery from surgeons with lower caseloads, with 15% treated by 
surgeons with a caseload of <10 cases/year 
although high caseload surgeons used conservative surgery less often for early 
stage disease in 1987 than low caseload surgeons, there was little difference in 
recorded adjuvant radiotherapy for conservative surgery cases according to 
surgical caseload, suggesting that use of adjuvant therapy did not differ markedly 
In addition, in both years rates of recorded mastectomy, conservative surgery and 
radiotherapy varied significantly across D H A .  Although incompleteness in staging data 
prevented examination of this variation more closely, is likely that this variation reflects, 
at least in part, variation in clinical practice. 
Univariate survival analysis identified the following associations between the suspected 
prognostic factors entered into analyses and five year relative survival 
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five year survival rates for all breast cancers rose significantly from 62.7% to 
66.4%, with the rise for invasive cancers from 62.3% to 66.0% just failing to 
achieve significance 
stage was a highly significant factor, with five year relative survival rates rising 
from 10.4% for stage '4' cases to 88.4% for stage '1' cases 
special type and lobular carcinomas displayed more favourable survival than ductal 
carcinomas of no special type which made up the majority of cancers. As 
expected, in situ cancers displayed high survival rates, and tumours of good grade 
displayed better survival than poor grade tumours 
relative survival varied significantly across DHAs, with poorer survival rates 
identified for older compared to younger women, and for women living in 
deprived areas of the region compared to more affluent districts 
women without recorded surgery displayed poor survival compared to those with 
mastectomy or conservative surgery. However, amongst those receiving surgery, 
recorded adjuvant therapy of any type appeared to confer a survival disadvantage 
no trend in survival according to surgical caseload was identified 
Multivariate analyses were performed, restricting the study population to 1041 of the 
5005 cases eligible for survival analysis (20.8%) by excluding those cases which did not 
have all the data items entered into univariate analysis were recorded. 
all DHAs, ages and deprivation levels were represented in the 1041 cases selected, 
but these cases were significantly younger and less deprived than unselected cases, 
with unequal representation for each DHA in the selected group 
this biasing effect reflected poorer data quality amongst older and more deprived 
women, and differing data quality across the region 
despite this bias towards younger and less deprived women in the selected group, 
selection for the multivariate analysis was not associated with better survival 
The following factors were identified as being significant in determining survival in the 
multivariate analysis 
stage was highly significant after adjustment for all other factors, with the risk of 
death for stage '4' cases being over 8 times greater than that of stage '1' cases 
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grade was significant in the overall model, although less significant than stage. 
Poor grade cancers were at a 37% higher risk than good grade cancers 
although survival differences according to tumour histology and age were revealed 
in univariate analyses, these factors were not significant in the overall model 
deprivation level was the least significant factor in the overall model, with the 
most deprived women having a 21% higher risk compared to the most affluent. 
DHA was not significant when entered alone but was retained in the overall model 
treatment type was highly significant, with those with no recorded surgery being at 
higher risk than of those with surgery alone 
the apparent survival disadvantage conferred by recorded adjuvant therapy 
confiimed the results of the univariate analyses. This finding may reflect 
incompleteness of hormone therapy and chemotherapy data for some women with 
a good prognosis who contaminated the "no adjuvant therapy" group which was 
used as the comparison group in the multivariate analysis 
in a model constructed for cases with recorded surgery, neither surgical type 
(mastectomy or conservative surgery) nor surgical caseload achieved significance, 
a result in accordance with the univariate analysis 
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CHAPTER SIX 
RESULTS: AN EVALUATION OF THE NHSBSP 
6.1 INTRODUCTION 
In this Chapter outcome measures used to evaluate the NHSBSP are described using 
data from the West Midlands, and suggestions made on how their calculation and use 
might be improved. To assess the impact of screening in the West Midlands a 
retrospective technique was used to allocate screening histories to breast cancers arising 
in women eligible for screening. Cases identified as possible interval cancers in this 
process were then used in an examination of the definition, classification and 
implications of interval breast cancers, including the effects of operational factors on 
interval rates and the predicted impact of a shorter, two year screening round. 
6.2 A CRITICAL ASSESSMENT OF OUTCOME MEASURES 
USED TO EVALUATE THE NHSBSP 
6.2.1 Uptake rate 
The current minimum target uptake rate is 70% (NHSBSP, 1993b), a quality standard 
which has remained unchanged since the introduction of screening (NHSBSP, 1988). 
However, if satisfactory cumulative uptake over several rounds is to be achieved the 
70% minimum target may be inadequate. If 70% uptake is applied to a hypothetical 
group of 1000 women entering the programme at age 50 years, and continued through 
the five screening rounds for which this group normally would be eligible, the predicted 
pattern of attendance that would result is presented in detail in Figure 6.1 and 
summarised in Figure 6.2. After five rounds, based on 70% attendance, only 16.8% of 
eligible women would have attended all five screens, and only 36.0% a total of four 
screens. Of those attending a total of four times, 60% would have included a lapsed 
attendance, so that two or more screens would be at least six years apart. The length of 
time between screens is critical to the success of screening and the occurrence of such 
lapsed attendance reduces the potential mortality reduction achieved. Of those attending 
three times, 60% would have included a lapsed attendance, and 16.7% of these women 
would not have attended any two consecutive screens. 
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Figure 6.2 also demonstrates the impact of applying a 75% and 80% uptake rate to 
cumulative attendance rates. If a target uptake rate of 75% is applied, which was set as an 
achievable quality standard in 1993 (NHSBSP, 1993b), but has since been withdrawn 
(Radiological Big '18', personal communication), over five rounds, nearly 25% of women 
would attend all five screens, and assuming 80% uptake, over 30% would attend in all 
rounds. To achieve an overall 70% uptake after 5 rounds, with attendance at all 5 rounds, 
an uptake rate of 93.2% at each round would be required. This simplistic model assumes 
that the probability of attending remains static regardless of previous screening history. 
The real situation, however, is more complex, as demonstrated by the achieved uptake 
rates according to screening history for a single West Midlands screening unit shown in 
Figure 6.3. For women who attended in the previous round an uptake rate of 92.9% was 
achieved and uptake for first time invitees (76.0%) was also high. Uptake for previous 
attenders who defaulted in the previous round was lower at 68.7%, but for women who, 
despite being invited, had never attended previously, uptake was low at 37.9%. The 
current standard for uptake rates set by the NHSBSP does not take previous screening 
history into account, being set as a single standard. The simplistic model based on 70% 
uptake shows that, in order to achieve the high cumulative attendance needed to produce 
the desired impact on mortality, a much stricter target which more closely reflects the real 
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situation needs to be set for re-attendance rates. In addition, the current KC62 report only 
allows attendance at the previous invitation to be ascertained. Monitoring cumulative 
attendance over three or more rounds will thus inevitably involve complex evaluation 
techniques unless the KC62 report can be modified to allow screening history to be 
described in more detail. 
6.2.2 
Essential to the effectiveness of screening is the detection of sufficient invasive cancers. 
Up until 1996 non-invasive (DCIS) and micro-invasive breast cancers were included in the 
calculation of cancer detection rates for 50-64 year olds (NHSBSP, 1993b). The inclusion 
of non-invasive and micro-invasive cancers in the total artificially inflated the rates 
achieved, since it is the only detection of potentially fatal invasive cancers that can lead to 
the mortality reduction desired. 
Cancer detection rates and the Standardised Detection Ratio 
Detection rates are currently calculated separately for prevalent and incident screens with 
quality standards set to reflect the higher rates expected at prevalent screens. However, 
invasive cancer detection rates (ICDRs) should be higher for older age groups as the 
underlying incidence of cancer increases with age. 50-64 year old or all ages ICDRs must 
be interpreted in relation to the age structure of the population from which they are 
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calculated to avoid misinterpretation of the achieved rate. The 1996 standards 
(Radiological Big '1 8', personal communication) assume that first time invitees are 
50-52.9 years old, and that the incident population is aged 53-64.9 years now that most 
units are past their prevalent round. Data on 50-52.9 year olds are not available from a 
KC62 report but data for 50-54 year olds shown in Figure 6.4 demonstrate that although 
such assumptions may be reasonable for some units, e.g. unit A, for others such as unit F 
the prevalent screening population is clearly not predominantly aged 50-54 years old. 
Similarly, the all ages incident ICDR may not only represent the 53-64.9 year age group. 
The currently recommended method of calculating ICDRs is to include cancers detected 
in the 50-54 year age band for prevalent screens, but to use the 50-64 year value for 
incident screens. There are several problems associated with this approach. The format of 
a KC62 report version 2.8 is shown in Appendix Two. The data required to produce a 
50-54 year ICDR are unavailable from the KC62 version 2.8, and must be estimated. This 
is because the number of invasive cancers is not stratified by age for each Table in the 
KC62. The currently recommended method of estimating the number of 50-54 years 
invasive cancers is to assume that the overall proportion of invasive cancers in 50-54 years 
olds provided in Table G is representative of the invasive proportion in this age group in 
Table A (prevalent screens). The validity of this adjustment is questionable when the total 
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number of cancers detected by a Unit may be small, and the KC62 report needs to be 
altered to give rates for 50-52.9 year olds directly so that such adjustment becomes 
unnecessary. In addition, cancers detected at prevalent screens in women not aged 50-54 
years are currently excluded from the calculation of the ICDR, and cannot therefore 
contribute to this measurement of screening performance at all. 
An alternative measure to the ICDR has been developed using cancer detection rates 
achieved by the Swedish Two Counties Study to estimate expected rates according to 5 
year age band (Blanks et al., 1996a). Standardised Detection Ratios (SDRs) can then be 
calculated to adjust for the influence of differing age distributions in the screened 
population. An SDR of 1.0 indicates parity with the Swedish Two Counties Study and 
thus would suggest that the mortality reduction achieved in the Swedish Two Counties 
Study should be achievable in the NHSBSP. The advantages of using an SDR over the 
ICDR are illustrated by the data in Figure 6.5. 
In Figure 6.5 the achieved outcome measure is presented as a percentage of the minimum 
standard, which for the SDR is 0.75. At Unit D, the 50-64 years cancer detection rate 
calculated from the KC62 report is less than 40% of the minimum quality standard, but 
the SDR, which adjusts for the large number of younger women in the screening 
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population of unit D, is much closer to the minimum target, although still not achieving it. 
At unit E, on the other hand, the equivalent all ages ICDR gives the impression of a very 
effective screening unit, but the SDR, which takes into account the older population, falls 
short of the minimum. The 50-54 year ICDRs are, in each case, close to the equivalent 
SDRs in terms of the minimum standard, and it is questionable whether any additional 
information is gained by calculating both the 50-54 ICDR and the SDR particularly when 
the 50-54 year ICDR relies on an estimated correction factor of questionable reliability. 
The effect of background geographical variation in incidence on SDRs has been examined 
nationally, and the correction factor needed to adjust for background variation estimated 
at a maximum of 15% (Blanks et al., 1996b). Although the influence of variation in 
background incidence on invasive cancer detection rates and SDRs is recognised by the 
NHSBSP as a problem, use of individual correction factors by Units is currently 
considered too complicated to be of value (Blanks, personal communication). However, 
with the variation in background incidence rates across the screening catchment areas of 
the West Midlands (illustrated in Chapter Four) ranging from 173.7/100,000 to 
196.1/100,000 in 50-64 year olds, a maximum variation of 13%, the importance of such 
correction factors should not be under-estimated. 
SDRs for incident screens are not currently calculated by the NHSBSP due to the impact 
of under-detection in previous rounds. For example, a Unit producing few false negative 
results in the first round might achieve a high prevalent SDR compared to a Unit with a 
higher false negative rate. At the next incident screen, however, the situation might be 
reversed, as the Unit with a low false negative rate will detect only genuine incident 
cancers, while the second Unit might achieve a higher SDR by also detecting cancers that 
were missed at the previous screen. The need for incident SDRs is increasing since the 
majority of the women currently being screened are incident, but until a method is devised 
that allows for this "overspill" effect, incident SDRs may be misleading, and the 
development of the incident SDR is ongoing (Blanks, personal communication). 
6.2.3 
The prognostic characteristics of screen detected cancers can be used as surrogate end 
points to indicate whether screening is likely to be successful. Results of the Swedish Two 
The small cancer detection rate and non-invasive cancer (DCIS) rate 
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Counties Study showed a correlation between increasing size and increased nodal 
involvement, with size being the most important prognostic factor (Tabar et al., 1992). 
Other factors such as grade are useful, but inter-observer variation in allocation of grade 
(Duffy et al., 1991; Sloane et al., 1994) may make comparison of absolute rates of 
tumours by grade misleading. 
Definition of the small cancer detection rate has undergone several revisions since this 
measure was first introduced (NHSBSP, 1988). DCIS and micro-invasive cancers were 
included in the invasive cancer total until 1993 (NHSBSP, 1993b), but the 1996 QA 
Standards (Radiological Big ' 18', personal communication) exclude micro-invasives from 
totals for invasive cancers and include them with in situ cancers. The 1989 and 1993 
standards defined "small" as <=10mm, but the 1996 standards define small as <10mm and 
4 5 m m  in line with European mainland practice. In addition the 1996 standards for small 
cancer rates are divided into prevalent and incident, and minimum and expected values. 
The number of changes in this outcome measure have led to problems. Unless pre-1995 
data are reproduced using KC62 version 2.8 no trends can be identified as previous 
version of the KC62 report used <=10mm to define small cancers rather than <10mm. 
Furthermore, calculated measures provided by the KC62 version 2.8 for small cancer 
detection rates are now incorrect as they include micro-invasives in the small cancer 
detection rates. The "new" measures will thus appear poorer than the previous KC62 
version 2.8 measures if a unit has detected a significant proportion of micro-invasive 
cancers. Figure 6.6 demonstrates the effect of excluding micro-invasive cancers from the 
small cancer detection rate. At Units B, C, D, H, I and J, no micro-invasives were 
diagnosed and the change in definition makes no difference. At Unit A the detection rate 
of cancers <15mm when calculated with micro-invasives included exceeds the minimum 
standard, but fails to achieve it when micro-invasives are removed. 
In addition to the absolute rate of small cancers detected, the proportion of small cancers 
is important (Day et al., 1988). The proportion of small invasive cancers (<10mm and 
<15mm) detected in 1994/95 are shown in Figure 6.7. One Unit (unit D) achieved the 
recommended 30% target for cancers <10mm, and four units, units A, C, E and F met the 
50% target for cancers <15mm. 
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Although not currently routinely calculated as an outcome measure by the NHSBSP, the 
small cancer proportion is simple to calculate and provides additional information about 
the likely success of screening. To be successful, not only should large numbers of small 
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cancers be detected by screening, but large, more advanced cancers should be rarely 
found. Like the invasive cancer detection rate, the small cancer detection rate is dependent 
on the age structure of the screening population. A small cancer SDR has recently been 
developed and may replace the small cancer detection rate (Blanks et al., 1995c). 
The detection of non-invasive cancers is assessed by the DCIS rate, which is misleadingly 
named as it in fact includes all in situ breast cancers including the lobular variant (LCIS). 
The DCIS rate is not calculated by KC62 version 2.8. Recently the definition of the DCIS 
rate has been changed to include micro-invasive cancers. The 1996 QA standards stipulate 
a lower (>10%) and upper (<20%) limit for screen detected in situ disease. The upper 
limit is significant as a high DCIS rate may indicate over-diagnosis or misclassification of 
invasive disease. Figure 6.8 shows calculated DCIS rates for the West Midlands. 
When micro-invasive cancers are included in DCIS rates units A, E, and G produce rates 
exceeding the maximum standard whereas the achieved rates excluding micro-invasives 
were within the recommended limits. Unit H detected less than the minimum rate of 
DCIS, and units B, F and J exceeded the maximum standard, regardless of the calculation 
method. A further difficulty stemming from the change in interpretation of micro-invasive 
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cancers is that cancer registries include micro-invasive cancers with invasive cancers, 
making comparison of data in relation to this outcome measure from the NHSBSP and 
cancer registries difficult. A possible solution to this difficulty that is being proposed for 
national use is the use of a separate behaviour code for micro-invasive tumours as 
specified by the SNOMED classification system (American College of Pathologists, 1980) 
by pathologists thus allowing their identification. 
6.2.4 
Measures using open biopsy data are calculated by QASS reports (described in Appendix 
Two) as well as from the KC62 version 2.8. An obstacle to the use of open biopsy data is 
that the KC62 version 2.8 does not distinguish between open surgical biopsies and other 
histological diagnostic procedures such as trucut or wide bore needle biopsy. Thus open 
biopsy data cannot be separated from pre-operative histology. Confusion has been created 
by the provision of conflicting standards for open biopsy rates and benign open biopsy 
rates in a variety of publications, as demonstrated in Table 6.1. 
Outcome measures for surgical procedures 
Not only has the misuse of the term "rounds" persisted in the 1995 "Good Office Practice" 
definitions, but the maximum target for benign open biopsies is greater than the maximum 
allowed total open biopsies rate. The updated QA Guidelines for Surgeons (NHSBSP, 
1996a) has replaced the incorrect usage of "rounds" with the correct "screens", but omits 
to give a target for the open biopsy rate. The total open biopsy rate is not calculated by 
the KC62 version 2.8, cannot be derived from it, and is not included in the 1996 QA 
standards. Inconsistencies such as these highlight the need for clear and comprehensive 
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guidelines on the definition and use of outcome measures and targets, and especially those 
measures used by different professional groups within the NHSBSP. 
Until 1996 the malignant:benign open biopsy ratio (M:B ratio) was used as an outcome 
measure, reflecting the need to minimise the use of benign biopsy, particularly for women 
without breast cancer. The M:B ratio is Calculated by the QASS report, is provided by the 
KC62 version 2.8 report and it is also possible to derive a M:B ratio for open biopsies 
from the QASS report. The updated version of the Surgical Guidelines (NHSBSP, 1996a) 
has withdrawn the use of this measure. The main reason for withdrawal is the difficulty of 
allowing for small numbers when assessing a calculated M:B ratio. An apparently poorer 
result may be produced for units which strives to minimise the total open biopsies 
performed, but produces an apparently better result for units undertaking a larger total of 
open biopsies, but for which the proportion of benign biopsies is lower. Furthermore, the 
M:B ratio is calculated by the QASS report using a different method that that used to 
produce the same measure by the KC62 report. It is dangerous to have two standard 
reports available, each of which calculates apparently the same outcome measure for the 
same time period, but which in fact use different definitions and produce different results. 
The positive predictive value (PPV) of open biopsy was also used in the past as an 
outcome measure but has also been withdrawn due to the effect of small numbers. 
The avoidance of over-treatment is an objective of the NHSBSP. Surgical outcome 
measures relating to treatment can only be calculated from QASS reports. The 1992 QA 
Guidelines for Surgeons set a standard of >50% of cancers of <=15mm to be treated with 
conservative surgery, but the updated version published in 1996 omitted this outcome 
measure. Unfortunately the QASS was not designed to provide the data for this outcome 
measure, as treatment data for tumours <=15mm cannot be identified. 
6.2.5 Early recall rate 
The standard set for early recall rates attempts to ensure that use of this procedure is 
minimised. It is calculated as an overall rate, not split into prevalent and incident screens. 
The current target of 1% of those screened was achieved all units in the West Midlands in 
1994/95. This standard was revised from an earlier standard of 0.25% which was 
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suggested in 1995 (Radiological 'Big 18’, personal communication). In 1994/95 some 
West Midlands units produced early recall rates of more than 3 times this lower standard. 
Placing women on early recall direct from screening should not occur, and instances of 
this procedure are monitored by the regional QA Committee. The early recall from 
screening rate is calculated by the KC62 version 2.8, but as all outcome measures are 
presented to one place of decimals, if a value of <0.04 is produced, the outcome measure 
is incorrectly presented as 0.0. In addition, the current definition of this measure exclude 
women appearing in Table D, who are invited to screening as a result of early recall. 
Although such women should not be placed on early recall again, this procedure has been 
recorded in the West Midlands. Excluding women appearing in Table D of the KC62 
version 2.8, who arrive at screening on early recall, from calculations masks this 
occurrence, which should be identified rapidly and investigated to minimise the likely 
distress caused by repeated invitations to early re-screen. 
6.2.6 
A target of >70% for pre-operative diagnosis by cytology or FNAC was included in the 
quality standards suggested by the Radiological 'Big 18' in 1996. In addition a minimum 
standard for the rate of pre-operative diagnosis of impalpable lesions by cytology and 
needle histology was set at >30%. However, the KC62 version 2.8 does not provide data 
describing whether lesions are palpable or impalpable, and does not provide the results of 
needle histology separately from those resulting from open biopsy. The only measure 
which can currently be calculated for the KC62 version 2.8 is the rate of pre-operative 
diagnosis by cytology for all cancers. The updated QA Guidelines for Surgeons (NHSBSP 
1996a) set a standard for pre-operative cytological diagnosis of >60% for palpable and 
impalpable lesions. No unit achieved the lower standard of >60% in 1994/95, with some 
units demonstrating very low rates. It could be that such units use needle histology instead 
of fine needle aspiration cytology, making it difficult to draw conclusions on the basis of 
this outcome measure until a relevant standard is provided. However, it is unlikely that 
large differences can be accounted for in terms of needle histology as this procedure was 
known to be not extensively used in the West Midlands in 1994/95. To address this issue a 
national audit of pre-operative diagnosis of screen detected cancers has recently been 
undertaken by the Radiological 'Big 18'. 
Rate of pre-operative diagnosis by cytology 
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52 cancers arose in women who were not registered at the unit or at neighbouring units, 
suggesting inaccuracy or incompleteness of the FHSA population register. 13 cancers 
arose in women who were excluded from screening by their GP. Over 22% were 
diagnosed before the first screening invitation. Arrangements for screening in the 
prevalent round were unusual in that women aged 50 to 64 years were all invited for the 
first time, whereas in subsequent rounds those invited for the first time are largely aged 
50-52.9 years. The increasing risk of breast cancer with age might therefore have been 
expected to result in higher incidence amongst older women awaiting screening compared 
to younger women. However rates of cancers diagnosed before screening were 
30.9/10,000 in 50-54 year olds, 30.5/10,000 in 55-59 year olds, and 25.9/10,000 in 60-64 
year olds. Thus the unusually high proportion of older women invited in the first round did 
not explain the relatively high number of cancers detected before the women could be 
screened. Incidence of "before screening" cancers rose over the first round from 
17.9/10,000 in 1990, to 25.8/10,000 in 1991 and 33.8/10,000 in 1992. This might reflect 
increasing awareness of breast cancer over this period due to the NHSBSP and media 
interest causing women to present symptomatically before being called for screening. 
A total of 307 cancers (31.55% of the total eligible) were screen detected, of which 
94.1% were found at routine screens, 8 at early recall, and 10 cancers were found at 
screens resulting from a self or GP referral in women eligible for routine screening. There 
were a total of 278 interval cancers including 236 arising at <36 months from the last 
screen, and a further 42 "late invitation" intervals arising at >36 months from the last 
screen in women too old to be re-invited, or who, although eligible for re-invitation, did 
not receive anther appointment prior to diagnosis. 
Of the 102 cancers diagnosed in non-attenders, 86 arose within 36 months of the last 
invitation, and a further 16 cancers were diagnosed at 36-59.9 months from the last 
invitation. Of the 86 non-attenders diagnosed <36 months, 13 (15%) were diagnosed 
within 3 months of invitation. Although the NHSBSP predicts the occurrence of 
"programme provoked" cancers (NHSBSP, 1993a), no definition of these cancers is 
currently available. Given the short interval between the invitation and diagnosis it is 
possible that, in at least some of this 15% of cancers, the invitation precipitated 
presentation into the symptomatic breast service. 
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6.4 AN EXAMINATION OF THE DEFINITION AND CHARACTERISTICS 
OF INTERVAL CANCERS 
6.4.1 The effect of exclusion criteria on interval cancer rates 
Figure 6.10 shows the means by which, of 278 possible interval cancers, 213 were 
identified as "core" intervals. 86% of "core" intervals were known to the unit; the 
additional 30 being identified after cross-reference with records at the WMCIU. Table 6.3 
gives further details of the 65 cancers excluded from the core set and the 11 '*core" 
intervals detected in "high risk" women. 
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Four cases were due to lack of histological confirmation, or because the lump was not a 
breast cancer. Twelve non-invasive cancers were excluded, including 1 case that arose at 
36 months or more. Of 41 cancers excluded on the grounds of an interval of 36 months or 
more, 10 had been identified as intervals by the Unit and none had been re-invited prior to 
diagnosis. A further 8 cases were excluded on the grounds of age at screening. 
The effect of exclusion criteria on calculated interval cancer rates is shown in Figure 6.1 1. 
If no exclusions are applied, the rate of interval cancers arising from the first round was 
47.1/10,000 women. Exclusion of cancers without histological confirmation, those found 
not to be breast cancers, non-invasive cancers and cancers in those not aged 50-64 years 
each produced small reductions in the interval rate. The largest drop, from 43.1/10,000 to 
36.1/10,000 was produced by restricting interval cancers to those diagnosed at <36 
months from the last screen. The rate produced using the most restrictive criteria 
(34.1/10,000) was 27.6% lower than the highest rate from these data. To ensure 
consistency it is vital that everyone calculates interval cancer rates using the same set of 
criteria. It is also important that the exclusion criteria used do not artificially reduce the 
apparent rate of interval cancers as is currently the case where only histologically verified 
cancers diagnosed within 36 months are included in most studies (Woodman et al., 1995; 
Day et al., 1995; Asbury et al., 1996). 
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screening (Radiological Big ' 18', personal communication). This second standard assumes 
that screening units are universally operating a 36 month screening round. It is clear from 
Figure 6.12 that not only are core interval rates in excess of the standards, but if 
"non-core" intervals are included, the observed interval cancer rate occurring after 24 
months is over twice the current standard in the unit examined in this study. 
6.4.2 Variation in core interval cancer rates with time after screening and age 
The overall core interval cancer rate was 36.1 per 10,000 women screened. Taking only 
these core interval cancers into consideration, Table 6.4 shows that, as in other studies, 
interval rates increased with the t h e  from the last screen (Tabar et al., 1987; Peeters et 
al., 1989; Woodman et al., 1995). 
Incidence in 50-64 year olds in the resident population rose by 1% per year from 1980-87, 
a smaller rise than the 2% per year seen nationally (Quinn and Allen, 1995). The 
underlying incidence rate in 1992 in the catchment area of the unit studied was estimated 
at 21.5/10,000. As a proportion of the underlying incidence, core interval cancer rates 
were 27.6% at 0-11 months, 56.7% at 12-23 months, and 82.5% at 24-35 months from 
the last screen, similar to the North West (Woodman et al., 1995) and East Anglia (Day et 
al., 1995). Rates of core interval cancers by age at screening are shown in Figure 6.13. 
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Interval cancer rates varied little with age in the first two periods, but in the 23-35 month 
period, rose from 14.1/10,000 in 50-54 year olds and 17.4/10,000 in 55-59 year olds to 
22.7/10,000 in 60-64 year olds, although the differences were not statistically significant. 
6.4.3 
Table 6.5 describes the radiological classification of "core" interval cancers. 
Radiological classification of core interval cancers 

Assuming that this total rate of true interval cancers remained constant with time, an 
estimated 79 cancers might have detectable at two years from the last screen. Thus the 
proportion of core interval cancers that could have been detected at two years was 
estimated at 37.3%. Operating a two year screening round might thus bring about a 
37.3% reduction in the interval cancer rate based on the data used in this investigation. 
6.4.4 
Any improvement in screening sensitivity relative to underlying incidence will reduce the 
interval cancer rate. This includes true intervals, since the classification "true" does not 
mean that the cancer was necessarily undetectable at the last screen, but that it was not 
detected by the method used. Techniques which improve sensitivity, such as two view 
screening which is already used for prevalent screens and which has been shown to 
increase the detection of small cancers (Blanks et al., 1996c), may allow such cancers to 
be detected by screening and thus not arise as interval cancers. 
Other factors influencing core interval cancer rates 
Figure 6.15 shows SDRs for first round prevalent screens, and for prevalent and incident 
second round screens (1 April 1992 - 31 March 1995) at the Warwickshire, Solihull and 
Coventry Breast Screening Unit. 
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Prevalent SDRs rose from an average of 0.74 in the first round when single-view 
mammography was used, to 1.48 in the third year following the introduction of two-view 
mammography in April 1992. Although a proportion of this increase is undoubtedly due 
to the use of two-view mammography, from 1992 the parallel but smaller rise in incident 
SDRs is consistent with an underlying, general improvement in screening sensitivity as the 
programme matured. Fewer interval cancers would thus be expected following screens in 
the second round from this unit without any changes to the round length. 
Figure 6.16 describes the time between screening invitations for 155 women with incident 
second round screen-detected cancers. A quality standard suggested by the NHSBSP is 
that >95% of women should be re-invited within 2 months of the tri-ennial anniversary 
(Radiological Big '1 8', personal communication). The average screening round for the unit 
was 35.8 months, but only 83 (51.9%) were re-invited within the 2 month target zone. Of 
the 155 women, 72.5% were re-invited within 36 months of the last screen, with 27.5% 
re-invited at 36 months or more, and 17.3% re-invited at >39 months. 
Re-screening at regular intervals is critical to success of any screening programme aimed 
at detecting diseases of insidious onset (Wilson and Jungner, 1968). The Forrest 
Committee decided that a three year screening round was appropriate, but stressed that 
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more research was required in this area (HMSO, 1986). Running a population based 
screening programme so that all women are invited and re-invited at three-year intervals 
is, however, extremely difficult. Even if the average round length for a unit is 36 months, 
the round length for individual women may vary substantially, so that some women 
experience much longer or shorter screening rounds. Furthermore, data with which to 
evaluate round lengths for individual women are not easily available. 
6.5 SUMMARY 
The NHSBSP QA Service has developed a number of outcome measures to act as 
performance indicators and early indicators of success for the NHSBSP. Many are 
calculated by the "KC62" report software used to collate screening activity data for the 
Department of Health. This investigation identified a number of problems associated with 
these outcome measures which reduce their usefulness. 
some measures calculated by the KC62 reports are inconsistent with the methods 
recommended by the NHSBSP, for example small cancer detection rates are 
currently calculated excluding micro-invasive cancers, but these cancers are 
included in the small cancer detection rates calculated by KC62 reports 
some measures that could be Calculated from the raw data provided by a KC62 
report are not calculated, for example the DCIS rate 
some calculated measures cannot be reproduced from raw data on KC62 reports, 
for example the benign open biopsy rate 
some measures used by the NHSBSP are not calculated by, and cannot be derived 
from KC62 reports, for example the open biopsy rate 
some measures which are no longer recommended by the NHSBSP are provided by 
KC62 reports, for example the malignant:benign open biopsy ratio 
changes in the recommended definitions used to calculate outcome measures have 
been a source of confusion, in particular in relation to the invasive cancer detection 
rate. Current recommendations are to calculate the prevalent invasive cancer 
detection rate for women aged 50-54 years only even though a significant 
proportion of women at attending some units are not in this age group. In addition, 
it is assumed that most of the women in the 50-54 year age group are 50-52.9 years 
old, although the validity of this assumption cannot be assessed from a KC62 report, 
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and in order to perform the calculation, the number of invasive cancers detected in 
women aged 50-54 must be estimated since it is not supplied by the KC62 report 
the SDR attempts to adjust invasive cancer detection rates for the age distribution 
of the screened population. However, the SDR is currently only calculated for 
prevalent women, who now make up a small proportion (around 20%) of those 
screened at many units 
as well as changes to the definitions of outcome measures, some of the quality 
standards set for these measures have undergone repeated revisions as the NHSBSP 
has progressed, leading to more confusion, for example in the case of cancer 
detection rates. In addition, for some measures such as the benign open biopsy rate, 
inconsistency exists in the quality standards set by different professional groups 
within the NHSBSP 
some quality standards have remained unchanged although needing revision, for 
example the uptake rate which has remained unchanged since 1988 at 70%. When 
70% uptake is applied to a hypothetical screening population over five rounds, only 
16.8% of women attend all five screens, and only 36% a total of four screens. To 
improve the utility of this outcome measure and help to ensure high cumulative 
uptake, a higher quality standard for re-uptake rates is required and it must be made 
possible to identify which screening round women were last invited and/or screened 
To assess the impact of the NHSBSP on a selected West Midlands population a 
retrospective technique was devised to identify a cohort of women with cancers eligible 
for screen detection in the prevalent round and to allocate screening histories to the 973 
cancers in this group. 
only 31.6% of cancers were screen detected. 94.1% of these were found at routine 
screens, 3.2% as a result of self or GP referral and 2.6% at an early recall screen ' 
22.9% were diagnosed before the screening invitation. Incidence rates in this group 
were similar according to age at invitation, but rates rose over the screening round 
28.6% of cancers arose as interval cancers after a negative screen, of which 84.9% 
arose at <36 months from the last screen, and 15.1% were diagnosed at >=36 and 
<60 months from the last screen, in women either ineligible for re-invitation due to 
age, or in women who, although eligible, failed to receive a re-invitation prior to 
diagnosis 
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10.5% arose in non-attenders of which 15% were diagnosed within 3 months of the 
invitation date and which could be "programme provoked" cancers 
5.3% arose in women never invited for screening, indicating that the accuracy and 
completeness of the population register needs to be improved 
An examination of the definition and interpretation of the interval cancers identified that 
the definition of interval cancers needs classification. In this investigation 
using the most inclusive criteria, the rate of interval cancers arising from the 
prevalent screening round was 47.1/10,000 women screened 
of the 278 interval cancers identified, 10.8% were unknown to the screening unit 
and were only identified after cross-matching data from the WMCIU and the 
screening unit 
by excluding cancers without histological confirmation, non-invasive cancers, 
cancers arising in women not aged 50-64 years at screening, and cancers arising at 
>=36 months from the last screen, the rate fell by 23% to 36.1/10,000. The largest 
contribution to this drop came from exclusion of cancers arising at >=36 months 
from the last screen 
interval cancers fulfilling these criteria were termed "core'' intervals 
rates of core interval cancer rose from 5.9/10,000 at 0-11 months, to 12.2/10,000 at 
12-23 months and 18.0/10,000 at 23-35 months from the last screen 
expressed as proportions of the expected underlying incidence, estimated as 
21.5/10,000, the incidence of core intervals rose from 27.6% at 0-11 months, to 
56.7% at 12-23 months and 82.5% at 23-35 months from the last screen 
in the third year after screening the highest rate of core intervals was identified in 
women aged 60-64 years at screening 
radiological classification of core intervals identified 44.1% true intervals, 22.5% 
false negative and 9.9% occult. Lack of diagnostic mammograms meant that 15.5% 
could only be classified as "not false negative" and a further 8.0% were 
unclassifiable 
from this investigation it was estimated that moving to a two year round would lead 
to a 37.3% drop in interval cancers 
Although a shorter screening round would reduce the rate of interval cancers, 
improvement in screening sensitivity would also lead to reduced interval rates including 
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rates of true interval cancers. SDRs have risen for the unit studied from 1989 to 1995, 
suggesting improvements in sensitivity including that brought about by the introduction of 
two-view screening in 1992. In addition, although the NHSBSP assumes that a three year 
round is currently in operation, this is often not the case. In this investigation, despite an 
average round length for the unit of 35.8 months, only 51.9% of women were re-invited 
to screening within two months of the triennial anniversary, with 27.5% re-invited at 36 
months or more from the last screen. High interval cancer rates may not indicate that a 
three year round is insufficient, but that the three year round is not being maintained, and 
although a two year round would reduce interval cancers rates, there are a number of 
alternative solutions to high interval cancer rates might be more effective and less costly 
than shortening the screening round and which should be explored before implementing a 
two year screening round. 
162 
CHAPTER SEVEN 
DISCUSSION AND CONCLUSIONS 
7.1 IMPROVING THE AVAILABILITY AND VALIDITY OF ROUTINELY 
COLLECTED PROGNOSTIC DATA 
7.1.1 The availability and validity of prognostic data recorded at the WMCIU 
The WMCIU is ideally placed to undertake population-based studies of breast cancer in 
the West Midlands since it is unique in recording detailed data for all breast cancers 
diagnosed in the region. For evaluations to be valid, the availability of data must be high 
and data recorded at the WMCIU must be complete and accurate. This study 
demonstrated that it was broadly possible to undertake examine the main issues relating 
to breast cancer using routinely collected data. A number of problems associated with 
routinely recorded data were identified, and a range of solutions were identified which 
not only improved the usefulness of data available for this study, but will result in 
improvements in the quality of data recorded at the WMCIU in the future. 
The completeness and accuracy of recording tumour characteristics at the WMCIU was 
found to be generally high. A high proportion of histologically verified cases, and a low 
proportion of death certificate registrations are indicators of high data validity (Parkin et 
al., 1994). It was thus encouraging to find that, of the 5077 breast cancers examined, 
only 9.6% had no histological confirmation, and only 1.4% of cases were registered 
from a death certificate or post mortem report only. This compares with the South East 
where, even in 1991, 17% of breast cancers had no histological verification and 13% 
were diagnosed from death certificates only (Thames Cancer Registry, 1994). With the 
improvements in data coding and storage introduced at the WMCIU as a result of this 
study, the data recorded at the WMCIU were considered to be of sufficiently high 
quality for analytical purposes despite the limitations imposed by missing data. 
An audit of staging data recorded at the WMCIU revealed that less than 5% of breast 
cancers diagnosed in 1983 had stage recorded on the WMCIU's old computer database. 
This, however, was only a reflection of the similarly small proportion of cases with stage 
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recorded in the case notes. Although the completeness of the recording of stage at the 
WMCIU was poorer than for other types of prognostic data, the accuracy with which 
staging data were recorded was very high at 96.3%. The main reason for absence of 
recorded stage at the WMCIU was the failure of Trusts to send staging data to the 
WMCIU. Lack of recorded stage at cancer registries is a well recognised problem. Only 
0.89% of breast cancers diagnosed in 1982-86 in the South West region were staged, 
and 0.28% in the Wessex region (Bristol Cancer Epidemiology Unit, 1995). In the South 
East only 24% of 334 breast cancers diagnosed in 1990 had stage recorded (Chouillet et 
ai., 1994). In addition, a study at the Thames Cancer Registry (TCR) comparing data 
recorded for bladder cancers at the TCR with data from hospital notes concluded that, 
although data recorded by the TCR were generally reliable, stage was largely unreliable 
due to missing data in the hospital notes and misclassification of recorded stage at the 
TCR (Gulliford et al., 1993). The problem of missing and unreliable staging data is thus 
not restricted to the WMCIU or to breast cancer. 
The methods used to classify and store prognostic data can have a large impact on the 
utility of the data recorded. A significant problem identified in the recording of tumour 
characteristic data on the old WMCIU database was misuse of the codes for local node 
status. This meant that cases for which no information about the local nodes was 
available in the notes were recorded as "nodes negative", resulting in cases with 
unknown nodal status being indistinguishable from those for which the nodes were 
recorded in the notes as negative. The poorer survival for cases with unknown nodal 
status compared to those for which nodes were known to be negative suggests that at 
least some of these cases had positive nodes, and demonstrates that the grouping of 
cases in this way limited the usefulness of prognostic data recorded on the old WMCIU 
database. The development of the new WMCIU database GRACE during the course of 
this project provided the opportunity for improvements in coding rules and to the 
database structure identified as a result of this study to be implemented. 
Of the 2444 breast cancers diagnosed in 1983 in this study, 34.9% had no size and 
28.6% had no nodal status recorded in the case notes. These proportions are similar to 
those reported in Scotland, where of 3786 breast cancers diagnosed in 1980-88, 28.6% 
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had no size, and 33.1% no nodal data recorded (Gillis and Hole, 1996). In the present 
study, 69.5% of cases had no grade recorded. This lack of grading has also been 
reported in Yorkshire, where, of 12,861 breast cancers diagnosed between 1979 and 
1988, grade was not recorded for 47% (Sainsbury et al., 1995b). The lack of these 
prognostic data in the present investigation reflects lack of data in the notes since, in 745 
of 1387 cases (53.7%) without a pathological size, and 476 of 1322 cases (36.0%) 
without pathological node status recorded, the pathology report sent to the WMCIU did 
not record these prognostic data. The lack of data in the West Midlands was therefore 
seen to stem partly from a lack of pathological investigation and/or data recording by 
Trusts as well as failure to supply data to the WMCIU. While improvements to coding 
rules and database design have enhanced the utility of data recorded by the WMCIU, the 
potential of data recorded is restricted by the proportion of missing data. 
Various methods of increasing the staged proportion have been used by cancer 
registries. Manual combination of recorded tumour characteristic data to retrospectively 
allocate stage has been undertaken in the South East, where the staged proportion 
amongst 338 breast cancers diagnosed in 1990 rose from 24% to 47.4% (Choiullet et 
al., 1994). In the Wessex region, peripatetic data collection officers have been employed 
since 1987 to visit hospitals and collect data with which to allocate stage to breast 
cancers using a defined protocol (Wessex Cancer Intelligence Unit, 1992). This process 
has led to a rise in the staged proportion from 0.28% for 1982-86 to 62.5% in 1987-91 
(Bristol Cancer Epidemiology Unit, 1995). The high completeness and accuracy of 
tumour characteristic data identified in the present study allowed the development of a 
staging algorithm combining tumour characteristics to allocate stage to breast cancers at 
the WMCIU. This resulted in 63.9% of the 2444 cases diagnosed in 1983 being staged, 
a 13-fold increase in the staged proportion. The algorithm provided a means of routinely 
allocating a stage for breast cancers recorded at the WMCIU and was able to produce a 
significant rise in the staged proportion. The algorithm needs to be tested in other 
populations, and its utility was restricted by the completeness of data sent to the 
WMCIU, in particular with regard to local node status and tumour size, necessitating the 
incorporation of a number of assumptions which may not always be justified. However, 
the availability of the staging algorithm at the WMCIU, in conjunction with improved 
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coding and data storage on GRACE, allows large series of breast cancers to be staged 
quickly and consistently. The same methodology is to be introduced for other cancers, 
based on the pilot carried out is this study of breast cancer. 
The ideal solution to lack of staging data at cancer registries would be for stage to be 
ascertained and recorded for all breast cancers by a clinician at diagnosis, and for these 
data to be transferred to the WMCIU. However, until this is the case, strategies to 
allocate stage, such as the staging algorithm, have an important role to play. There are 
two barriers to recording prognostic data at the WMCIU - failure to ascertain and/or 
record prognostic data at diagnosis, and failure to supply data to the WMCIU. In order 
to meet the requirements of the Minimum Data Set for Cancer Registration (MDSCR), 
not only must data supply to cancer registries be efficient, but Trusts must collect and 
store complete staging data in an accessible form. In response to the Calman-Hine report 
(HMSO, 1995), a Regional Cancer Implementation Team was set up in 1995 to visit 
those Trusts in the West Midlands applying for Cancer Unit and Cancer Centre status. 
The Cancer Implementation Team considered the availability and quality of information 
collection systems as a key quality criterion. The importance of data collection has been 
further recognised in the Clinical Outcome Group (COG) guidelines for breast cancer 
(NHS Executive, 1996a) produced in response to the Calman-Hine report. These 
guidelines recommended that purchasers of breast cancer services should monitor 
patient outcomes, stipulating that staging data were desirable, and pointing out both the 
importance of cancer registries and the need to improve information collection systems. 
The use of peripatetic data collectors in Wessex to improve the availability of data, 
including stage, for breast and colorectal cancers is unfeasible in the West Midlands due 
to the large geographical size and population density of the region. Furthermore, in 
Wessex, even with access to the hospital notes, 37.5% of breast cancers remained 
unstaged because staging data were not recorded by clinicians (Bristol Cancer 
Epidemiology Unit, 1995). A different approach is being applied in the West Midlands 
as part of the Calman-Hine implementation process. A region-wide oncology 
information system is currently being set up to allow direct supply of clinical, 
pathological and treatment data from Trusts to the WMCIU. In addition, several 
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projects are currently being undertaken aimed at improving the availability of 
pathological data. The WMCIU is planning to ask pathology laboratories to send special 
reports detailing additional nodal procedures to the WMCIU in an attempt to improve 
the completeness of nodal data recording. An audit of pathology reports sent to the 
WMCIU is being carried out to assess the completeness and quality of a range of 
prognostic data including size, nodal status and grade in relation to guidelines provided 
by the NHSBSP (NHSBSP, 1996a) and BASO (BASO, 1995). With the introduction of 
a region-wide oncology information collection system the timeliness, accuracy and 
completeness of data should be improved particularly in clinical data fields. However, 
region-wide audit will be required to monitor the quality of data provided and to ensure 
the comparability coding systems and the consistency of their utilisation. This new data 
collection system, in combination with the improvements in data coding and storage 
introduced with the new database GRACE, and the availability of the staging algorithm, 
should mean that the reliability of data recorded at the WMCIU will continue to improve 
and allow more detailed evaluation of breast cancer in the West Midlands in the future. 
7.1.2 
Analysis of prognostic data collated on HQA reports supplied by West Midlands 
screening units revealed similar problems to those seen with pathological data at the 
WMCIU. In 1994/95 three of the nine screening units supplying data had no size 
recorded for >5% of cancers, failing the quality standard of 5% set by the Radiological 
'Big 18' (Radiological 'Big 18', personal communication), with rates varying across the 
region from 0% to 6.3%. This lack of data is not isolated to the West Midlands, with the 
national proportion of screen-detected cancers with size missing reported as 12% for 
1990-93 (Moss et al., 1995). In the present study five units had no grade specified for 
>5% of cases, with rates varying from 0% to 14.7%. On average 42.1% of cancers had 
no local node data recorded, with rates varying from 10.3% to 75.0% across the region. 
Whether lack of data reflected reluctance to sample nodes, or failure to supply pathology 
data to screening units was not investigated in the present study but will be followed up. 
However, in the West Midlands programme, completeness of prognostic data increased 
from 1992 to 1995, indicating that improvements in the ascertainment of the data or 
their reporting to screening units occurred over this period. 
The availability of prognostic data recorded by the NHSBSP 
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The availability of prognostic data according to screening history revealed marked 
differences. Histological confmation, size and grade were available more often for 
screen detected cancers compared to those detected symptomatically as interval cancers, 
cancers in non-attenders or cancers diagnosed prior to the start of screening. The 
availability of local node status, however, was particularly poor amongst prevalent 
screen detected cancers, although incident screen detected cancers had more complete 
local node data. Lack of nodal data probably reflects failure of pathology laboratories to 
supply follow-up pathology reports to screening units as well as to the WMCIU. This 
lack of prognostic data is a barrier to the evaluation of the impact of screening. Any 
examination of survival for breast cancers according to screening history must not only 
incorporate complex adjustments to allow for lead time bias, but is also dependent on 
the availability of complete, high quality prognostic data. For example, in a study of 
survival for breast cancer patients in the UK Trial of Early Detection of Breast Cancer, 
high levels of data incompleteness were identified which limited the ability of the study 
to assess the impact of the trial. Of the 2995 cancers studied, although the authors did 
not report exact numbers of cancers with missing data, from the graphs provided it can 
be estimated that approximately 5% had no size recorded, and nodal status was absent 
for 30%, with data incompleteness being more marked for cancers presenting 
symptomaticaily (Moss et al., 1994). 
Screening aims to reduce mortality in the population invited, an aim reflected in the 
Health of the Nation (HoN) target for breast cancer of a 25% reduction in mortality 
between 1990 and the year 2000 in women aged 50 - 69 years (HMSO, 1992). In the 
West Midlands, crude mortality rates in women aged 55-69 years, the group used by the 
NHSBSP to monitor mortality, fell by 4.9% between 1983 and 1987, and by 8.9% 
between 1988 and 1994. It unlikely that screening, which was not fully implemented in 
the region until 1991, is responsible for much of this reduction, which is more likely to 
reflect an increase in the use of adjuvant therapy. The situation in the West Midlands 
mirrors a national trend in falling mortality prior to the introduction of screening in 1988 
(Quinn and Allen, 1995; ONS, 1996). Although welcome, this background mortality 
drop complicates the evaluation of screening, since not only is there an inevitable delay 
before any mortality reduction due to screening can be expected, adjustments will be 
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necessary to account for the underlying mortality reduction when assessing the impact of 
screening. In addition to monitoring mortality, surrogate endpoints such as a shift 
towards early stage breast cancers in the invited population can be used as early 
indicators of success for the NHSBSP (Bull et al., 1991), and evidence of such a stage 
shift has been identified in Wessex (Wight et al., 1993). Detecting a stage shift requires 
the combined efforts of the NHSBSP and cancer registries in identifying breast cancers 
in the invited population, and is hampered if prognostic data are incomplete. Data 
completeness indicators are now included in the KC62 reports submitted annually by 
each unit to the Department of Health, and it is the responsibility of the regional Quality 
Assurance Reference Centre (QARC) to liaise with units in order to minimise data 
incompleteness. The NHSBSP QA service in the West Midlands also includes 
assessments of data completeness in annual QA visits to each unit, and recommendations 
to improve data completeness and quality are made as a result. Further improvements to 
data quality have resulted from siting the QARC within the WMCIU allowing ready 
combination of cancer registration and breast screening data. 
7.2 REDUCING THE IMPACT OF BREAST CANCER IN THE WEST 
MIDLANDS 
7.2.1 
Before examination of treatment recorded at the WMCIU was undertaken, the reliability 
of recorded treatment data was assessed. While treatment data describing surgery and 
radiotherapy were considered to be reasonably complete and accurate, those describing 
hormone therapy and chemotherapy were less robust. Until the completeness of adjuvant 
treatment data supplied to the WMCIU is improved, which is an aim of the region-wide 
oncology information collection system currently being developed, recorded rates of 
hormone therapy and chemotherapy at the WMCIU need to be viewed with caution. The 
problem with incompleteness of adjuvant chemotherapy and hormone therapy data at the 
WMCIU is largely a reflection of the failure to collect routine outpatient adjuvant 
therapy data within Trusts. Unless out-patient chemotherapy and hormone therapy data 
are included in day case minimum data sets (as is the case in a small minority of West 
Midlands hospitals) the only record of the patient's treatment will be a hand-written 
Treatment patterns for breast cancers in the West Midlands 
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entry into the patient's detailed medical records. As part of the Calman-Hine 
implementation programme in the West Midlands, all Trusts applying for Cancer Centre 
or Cancer Unit status are being advised to install an adjuvant therapy prescribing 
database on which all chemotherapy episodes or hormone treatments (in, out and day 
case) will be recorded. Direct downloading of data to the WMCIU will then ensure high 
completeness for all Trus t-based chemotherapy and hormone procedures in the future. 
Tracking hormone therapy prescribed by GPs will, however, still remain a problem. 
The changes in recorded treatment identified in this study were in agreement with the 
King's Fund guidelines on the management of breast cancer (King's Fund, 1986) 
suggesting that these guidelines may have had a significant impact on clinical practice in 
the West Midlands. A decrease in recorded mastectomy rates over this period from 
55.4% to 37.3% was mirrored by a simultaneous increase in conservative surgery rates 
from 20.7% to 38.5%. Reports from elsewhere in the UK indicate that this fall in the 
mastectomy rate was not isolated to the West Midlands (Morris et al., 1992), with rates 
in Yorkshire falling from 70% to 44% in the period 1978-92 (Sainsbury et al., 1995a). 
In the West Midlands older women were less likely to undergo conservative surgery in 
both years, a result also reported by the Yorkshire region (Yorkshire Cancer 
Organisation, 1995). Despite the incompleteness of adjuvant chemotherapy and hormone 
therapy data in the present study, a rise in recorded hormone therapy was seen, 
particularly in older women, and recorded radiotherapy rates also increased. In line with 
the King's Fund guidelines, women receiving conservative surgery were more likely to 
have recorded adjuvant radiotherapy in 1987 than 1983, with 46.3% of cases having 
recorded radiotherapy in 1983 compared to 57.9% in 1987. 
In the West Midlands chemotherapy was recorded most often for women aged less than 
50 years, a situation also reported in Yorkshire, suggesting that chemotherapy may have 
been directed more at pre-menopausal women, in line with the King's Fund guidelines. 
However, because of the known problems with notification of out-patient chemotherapy 
data, little could be concluded regarding the use or changes in the use of adjuvant 
chemotherapy, although the very low rates of recorded chemotherapy in the West 
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Midlandsmirror those reported from the South East (Chouillet et al., 1994) and 
Yorkshire (Yorkshire Cancer Organisation, 1995). 
In addition to the clear changes in treatment between 1983 and 1987, in both years there 
were differences in recorded treatment for early stage and advanced cancers, and for 
older and younger women, suggesting that stage and age were determining factors in 
allocating treatment. In the West Midlands, the release of the King's Fund guidelines 
co-incided with a shift in clinical practice towards the recommendations. The extent to 
which these changes can be directly attributed to the guidelines is unknown, but 
nonetheless, the ability to detect significant changes after a relatively short time is 
encouraging. However, despite clear improvements in treatment in the West Midlands 
over this period, clinical practice still differed from the King's Fund guidelines in some 
respects, for example, even in 1987 over 42% of women undergoing conservative 
surgery had no adjuvant radiotherapy recorded. This type of divergence from the King's 
Fund guidelines has been reported elsewhere in the UK (McCarthy et al., 1991; 
Choiullet et al., 1994). An additional cause for concern is the significant variation in the 
use of conservative surgery, mastectomy and radiotherapy across the West Midlands 
both in 1983 and 1987, suggesting inconsistency in clinical preference. Variations in 
treatment have also been reported by other UK regions (Choiullet et al., 1994; 
Sainsbury et al., 1995a) and a recent survey of Trusts revealed differences in access to a 
variety of treatments (Cancer Relief Macmillan Fund, 1996), indicating that the problem 
of inconsistency in clinical practice is a national one which still needs to be addressed. 
7.2.2 
Cancer care in the UK is being reorganised with breast cancer care concentrated into 
multi-disciplinary specialist teams (HMSO, 1995; NHS Executive, 1996a). To monitor 
improvements following these changes valid markers of multi-disciplinary specialist care 
are needed. Surgical caseload is currently being used as a marker for specialist care in 
the COG recommendation that all breast referrals should be to specialist breast teams 
with a throughput of at least 100 cases/year (NHS Executive, 1996a). 
Evidence that treatment from specialist teams leads to improved survival was provided 
by a recent Scottish study, with five year survival rates for breast cancer patients treated 
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Surgical caseload, treatment and survival 
by specialist surgeons being 9% higher than for those treated by non-specialists (Gillis 
and Hole, 1996). Gillis and Hole identified specialists based not on surgical caseload, but 
by the fulfilment of a number of criteria, including involvement in dedicated breast 
clinics, associations with pathologists and oncologists, and maintenance of patient 
records. Although treatment data were not investigated, Gillis and Hole suggest that the 
improved outcomes may reflect use of adjuvant therapies. 
Associations between patient throughput and patient outcomes have been reported for a 
number of cancers including breast cancer (Stiller et al., 1994). A report from Yorkshire 
estimated that, of the 12,861 breast cancer patients diagnosed between 1979 and 1988, 
those treated by surgeons with a caseload of more than 30 cases a year had a 15% 
reduction in the risk of death compared to those treated by surgeons with lower 
caseloads (Sainsbury et al., 1995b). In the present study no association between survival 
and surgical caseload was identified in both a univariate analysis and in a multivariate 
model which adjusted for other factors including stage. Sainsbury and colleagues 
suggest that the survival advantage that they identified resulted, at least in part, from 
increased use of adjuvant therapy in this group (Sainsbury et al., 1995b). In the present 
study high caseload surgeons were less likely to use conservative surgery for early 
disease in 1987, suggesting that clinical practice was altered in line with the King's Fund 
guidelines more rapidly by surgeons treating fewer cases. However, no difference in 
recorded radiotherapy or hormone therapy rates was apparent amongst conservative 
surgery cases according to caseload. Thus the present study provides no evidence of 
differences in adjuvant treatment according to caseload, and indeed suggests that such 
high caseload surgeons were slower in changing clinical practice in line with the King's 
Fund guidelines than their lower caseload colleagues. 
The King's Fund guidelines also recommended that breast cancer care should be 
delivered by multi-disciplinary specialist teams (King's Fund, 1986). In the present study 
it was not possible to identify specialist surgeons or multi-disciplinary working, but an 
increase in surgical caseload was identified, with the proportion of cases treated by 
"high" caseload surgeons (treating >30 cases/year) rising from 17.8% in 1983 to 27.4% 
in 1987. Despite this rise, nearly three quarters of women diagnosed in 1987 were 
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treated by low caseload surgeons. With the introduction of the NHSBSP, and the site 
specialisation demanded by the Calman-Hine report and BASO it might be expected that 
this trend in increasing surgical caseload has continued since 1987. However, a recent 
survey of breast surgeons in the UK found that, although the average annual caseload 
was high at 66, one third of surgeons saw 25 or fewer new cases per year. Furthermore, 
half of the 425 responders estimated that they spent less than 20% of their time on breast 
surgery, with 90% declaring another specialist interest in addition to breast surgery 
(Harries et al., 1997). Thus the shift towards site specialisation demanded by the 
Calman-Hine report must be encouraged if all breast cancer patients in the UK are to 
receive treatment from a surgeon with a dedicated specialist interest in breast cancer. 
The improved care supplied by specialist teams is unlikely to reflect caseload alone, 
more probably being the result of a multi-disciplinary approach, with increased clinical 
expertise, specialist interest, and effective communication between professional groups 
involved in patient care (Dixon, 1996). Although an association between high caseload 
and specialisation was identified in one study (Sainsbury et al., 1995a), it seems that 
caseload alone may be invalid when used as the sole marker of high quality, 
multi-disciplinary care (Baum, 1996; Sikora, 1996). Monitoring improvements in breast 
cancer care is vital if the recommendations made by the Calman-Hine report are to have 
their intended impact. If caseload is to be used as a proxy for specialist care, the 
limitations of such a simplistic approach must be recognised. Surgical caseload would be 
better used in conjunction with other indicators of quality such as those used in a recent 
national survey (Harries et al., 1997). Routine monitoring of improvements in care must 
be undertaken on a regular basis and will require detailed and up to date knowledge of 
working practices within Trusts. This process will require close co-operation between 
those undertaking the monitoring function, such as cancer registries, and Trusts 
undertaking the care of breast cancer patients. 
7.2.3 
To implement effective strategies to reduce the impact of breast cancer in the West 
Midlands, and to achieve maximum impact with scarce NHS resources, patterns of 
disease in the region must be recognised so that actions taken to reduce the impact of 
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the disease can be targeted effectively. Incidence rates of invasive breast cancer varied 
significantly across the West Midlands prior to the introduction of screening in 1988. 
Similar variation has been reported elsewhere in the UK, for example in Yorkshire 
(Yorkshire Cancer Organisation, 1995). Differing incidence rates suggest variation in the 
prevalence of risk factors for the disease, but as no preventative measures are currently 
available, efforts to reduce the impact of the disease and eliminate inequalities take the 
form of early diagnosis and improvements in treatment. In the UK, breast cancer 
screening is offered to women aged 50-64 years by the NHSBSP, and, for those outside 
this age range, through access to a variety of diagnostic facilities. 
Re-screening variation in mortality and survival across the West Midlands suggests 
variation in prognostic characteristics and/or treatment across the region which need to 
be taken into account when implementing strategies to enable the HoN target for breast 
cancer to be met (HMSO, 1992). In the present study the small but significant rise in the 
five year survival rate from 62.7% in 1983 to 66.3% in 1987 suggests a trend in 
improving survival in the region. However, year of diagnosis was not retained in a Cox 
model when entered alone or in combination with other prognostic factors. This is likely 
to reflect differences between the two survival analysis techniques. Only five years of 
follow up were included in the univariate analysis, whereas up to a maximum of twelve 
years of follow up were included in the multivariate analysis. Thus although five year 
relative survival rates improved significantly between 1983 and 1987, longer term cause 
specific survival did not improve. This is likely to reflect the tendency of apparently 
localised breast cancer to metastasise even after a prolonged disease-free period. 
Survival analysis incorporating more than five years of follow up may thus be more 
useful than five year survival rates in assessing the outcome for breast cancer patients. 
Absence of prognostic data reduced the proportion of cases for which survival analysis 
could be performed. Selection for multivariate analysis, for which all the data items 
included in univariate analyses were required, restricted the study group to only 20.8% 
of the 5005 cases eligible for univariate survival analysis. Absence of grade and stage 
were mainly responsible for this restriction, which potentially reduced the degree to 
which the findings from Cox models produced could be generalised. Although selected 
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cases were significantly younger and less deprived than unselected cases, there was no 
difference in five year relative survival rate for the unselected and selected groups. In 
addition, a Cox model into which selection for the multivariate analysis was entered as 
the only variable provided no evidence that selection was associated with better survival. 
Therefore, despite this restriction of the sample size imposed by absence of data, the 
Cox models produced for the 1041 cases were considered to be reasonably generalisable 
to the total study group. However, that this restriction was necessary clearly 
demonstrates the need for improved routine recording of prognostic data. 
In this study the significance of a number of established prognostic factors was assessed 
for a West Midlands population. A clear trend in five year relative survival rates was 
seen according to stage, with survival rates rising from 10.4% for stage '4' cases to 
88.4% for stage '1' cases. In the univariate analysis stage '3' cases from 1983 fared better 
than those from 1987 (48.0% 1983, 40.6% 1987, p<0.05). It is possible that this result 
reflected improved recording of prognostic data in 1987, perhaps due to an increase in 
the use of detailed investigations. Such an increase might lead to 'stage migration', as 
apparently localised cancers, which would previously be allocated an early stage are, 
following more rigorous investigation, found to be more widespread and allocated a 
higher stage (Barr et al., 1992). This migration would result in fewer cases being 
incorrectly allocated an early stage, so that survival would appear to improve for early 
stages (stages '1' and '2a' in this study), but worsen for higher stages (stages '2b, '3', and 
'4'). It is also possible that these difference in survival by stage reflect changes in other 
prognostic factors such as treatment type or patient-related factors. Stage was the 
strongest predictor of survival in the overall Cox model, suggesting that early diagnosis 
is the key to improved outcome for breast cancer patients in the West Midlands. 
The well established significance of tumour grade (Elston et al., 1991) was also 
confirmed in this study group in both univariate and multivariate analysis. In the present 
study screen detected cancers were both smaller and of lower grade than symptomatic 
cancers. There is some support for the theory that tumours become metastatic as they 
get larger, a process termed phenotypic progression (Ponten et al., 1990) and thus that 
by arresting tumour development when tumours are small, progression to aggressive 
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disease may be avoided. Thus, in addition to detecting cancers at an earlier stage, it is 
possible that early diagnosis may also improve survival by reducing the proportion of 
high grade tumours. Whether phenotypic progression occurs in breast cancer is the 
subject of continuing debate. A recent Finnish study assessed the aggressiveness of 739 
breast cancers according to screening history (Hakama et al., 1995). The identification 
of similar levels of aggressiveness amongst the pre-screening control group compared to 
incident screen-detected cancers was interpreted as evidence that the aggressiveness of 
tumours did not worsen during the pre-clinical detectable phase, and was put forward by 
the authors as evidence against phenotypic progression. However, concerns over the 
interpretation of the study findings have been raised (Day et al., 1995; Paci, 1995; 
Alexander et al., 1995), focusing on the relatively low sensitivity of the Finnish 
screening programme. Further research into the possible occurrence of phenotypic 
progression will be required if this issue is to be resolved. 
The previously reported significance of histological type (Ellis et al., 1992) was 
confirmed in the present study, with invasive carcinomas of "special type" and lobular 
carcinomas displaying high five year survival rates. However, only 6.6% of the invasive 
carcinomas examined were of "special type", with a further 8% being lobular 
carcinomas, and thus the favourable survival of these histological types has little impact 
on the overall population survival. These proportions are similar to those reported 
elsewhere (Merseyside and Cheshire Cancer Registry, 1994). 
Survival varied across the West Midlands, an observation similar to variations reported 
elsewhere in the UK (Yorkshire Cancer Organisation, 1995), with poorer survival 
identified in women aged >50 years compared to younger women. In the 5077 cases 
analysed, 46.7% arose in women aged 65 years or more, with an association between 
increasing age and poorer stage. Screening alone cannot reduce breast cancer mortality 
throughout the population, as currently screening is restricted to 50-64 year olds. 
Women aged 65 years or more are not currently invited for screening, although such 
women are able to request screening if they wish. Screening women aged 65 years or 
more has been shown to be effective in reducing mortality in Sweden (Chen, 1995). 
Following calls from the charity Age Concern, the NHSBSP is considering extending the 
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age range for routine screening up to 69 years. Demonstration projects assessing the 
efficacy of screening women aged 65-69 were initiated in 1996 at two pilot sites to run 
for three years, with first results expected by the year 2000. In the meantime, women 
aged 65 or more are being encouraged to request screening (NHSBSP and Age 
Concern, 1996). Recommendations have been issued by the NHSBSP that written 
information sent by the NHSBSP to women should include information on accessing the 
service for those about to become ineligible for routine invitation. The rising risk of 
breast cancer with age, and the decreasing density of breast tissue which makes 
mammography more effective, means that breast cancer is more easily detected by 
screening in this age group than in younger women. Widening the age range to include 
65-69 year olds would provide a means of significantly reducing breast cancer mortality 
in a greater proportion of the population than is currently eligible for routine screening. 
In the study group, the most deprived women displayed the poorest survival, a trend 
established by a number of other studies (Vernon et al., 1985; Karjalainen et al., 1990; 
Kogevinas et al., 1991; Shrijvers et al., 1995). However, within the population there 
was not only a significant association between increasing age and more advanced stage, 
but also between more advanced stage and increasing deprivation. Poorer prognosis 
amongst deprived women has been identified elsewhere (Richardson, 1992), although 
not in all studies (Carnon et al., 1994). Although the poorer survival amongst deprived 
groups is likely to reflect poorer prognostic characteristics in these women, in the 
present study, deprivation was retained in the multivariate Cox model after adjustment 
for stage, grade, and treatment type. This finding suggests that the influence of 
deprivation cannot be entirely attributed to variation in other prognostic characteristics 
entered into the model. In the present study it was not possible to adjust for 
Co-morbidity, and it is thus possible that underlying ill health could be responsible to 
some extent for the observed trend. Actions aimed at reducing breast cancer mortality 
must take account of associations between deprivation and survival. Lower screening 
uptake amongst deprived women (Hoare et al., 1993) suggests that screening is likely to 
have less impact amongst deprived women. Efforts to increase screening uptake are 
encompassed in health promotion activities undertaken by the NHSBSP (NHSBSP, 
1995f) and should be particularly targeted at women living in deprived areas. Promoting 
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early diagnosis for those outside the screening age range is also vital. Projects targeting 
areas of low uptake in the West Midlands are underway in collaboration with the 
Geographical Information System (GIS) project team at the WMCIU. 
In the present study cases without recorded surgery fared worse than those surgically 
treated. Although women with recorded conservative surgery fared slightly better than 
mastectomy patients in the univariate analysis, there was no difference between these 
groups after adjustment for other factors in the multivariate model, an observation in line 
with other studies (EBCTCG, 1994, Fisher et al., 1995; Riley et al., 1995). However, 
the apparent lack of survival advantage conferred by all types of adjuvant therapy in the 
present study was unexpected given the weight of evidence supporting the benefits of 
these therapies (EBCTCG, 1992). This outcome is likely to reflect incompleteness of 
adjuvant chemotherapy and hormone therapy data, as well as possible selection of 
patients with a generally poor outlook for adjuvant therapy. This survival disadvantage 
was present even for surgical cases with recorded radiotherapy, who displayed a 44% 
elevation in risk compared to those with surgery alone after adjustment for other 
prognostic factors. This result was particularly unexpected given that the completeness 
of radiotherapy data is considered to be high at the WMCIU due to the strong links with 
the five radiotherapy centres in the West Midlands. It is possible that this finding came 
about because the group for which no adjuvant therapy was recorded was contaminated 
with cases which, despite receiving adjuvant hormone and/or chemotherapy, did not 
have this reported to the WMCIU, possibly reflecting that they did not require any 
treatment at a radiotherapy department. If this was the case the favourable survival for 
such cases would elevate the overall survival of the "no adjuvant therapy" group, which 
was used as the reference group against which the survival for those with recorded 
adjuvant therapy was assessed. Thus identification of apparent survival disadvantages for 
cases with recorded adjuvant therapy in comparison to the "no adjuvant therapy" group 
may reflect this contamination rather than a genuine survival disadvantage. No 
association between survival and surgical caseload was identified in either univariate or 
multivariate analysis in contrast to results from elsewhere (Yorkshire Cancer 
Organisation, 1995; Sainsbury et al., 1995a; Gillis and Hole, 1996). 
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The completeness of treatment data should, in addition to prognostic data, be improved 
with the introduction of a region-wide oncology information collection system. 
Monitoring treatment and prognostic data will play a crucial role not only in identifying 
improvements in care, but in evaluating whether such changes have an impact on patient 
outcome. With the current activities aimed at improving the quality of both prognostic 
and treatment data supplied to the WMCIU, the WMCIU is ideally placed to undertake 
this monitoring and evaluating function and thus to contribute to the improvement of 
outcomes for breast cancers patients in the West Midlands. 
7.3 MAXIMISING THE IMPACT OF THE NHSBSP IN THE WEST 
MIDLANDS 
7.3.1 
Monitoring the performance of the NHSBSP is a vital function of the QA service and, 
from the outset of screening in the UK, the need to calculate performance indicators 
which could be compared with quality standards was recognised. In addition, as 
previously discussed, measures which act as early indicators of success in terms of likely 
mortality reduction are essential so that the impact of the programme can be assessed. A 
number of outcome measures are currently calculated by the "KC62" software used by 
the programme to compile reports of screening activity for the Department of Health, 
and, in addition, further outcome measures not included in the KC62 report are 
recommended by the NHSBSP (Radiology 'Big 18', personal communication). 
For outcome measures to be useful and valid the data with which outcome measures are 
calculated must be complete and accurate, and the method of calculation must be valid 
and consistently applied. Targets set in relation to each outcome measure should reflect 
both the need to readily identify unacceptably poor performance (the minimum 
standard), and to allow prediction of whether the programme is likely to bring about the 
mortality reduction desired (the expected standard). This study identified a number of 
problems associated with the use of currently available outcome measures. 
Some difficulties arise due to the lag time between the introduction of changes in the 
definition of outcome measures, and incorporation of changes into the KC62 software. 
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Improving the usefulness of outcome measures 
For example, whereas micro-invasive cancers were previously included in small cancer 
detection rates (NHSBSP, 1993b), current definitions exclude them (Radiological 'Big 
18', personal communication). However, the small invasive cancer detection rates 
calculated by KC62 reports extant in 1996/97 still include micro-invasive cancers. This 
inconsistency causes confusion and can give the appearance that acceptable small cancer 
detection rates are being achieved when this is not the case. If KC62 reports are to 
continue to calculate outcome measures then all the measures which can be calculated 
from the raw data presented in these reports, which are also currently recommended by 
the NHSBSP, should be provided. Currently the DCIS rate is not calculated by a KC62 
report, although it can be calculated from the raw data provided. It is also currently 
impossible to calculate an overall open benign biopsy rate because needle biopsies are 
included with open biopsies in the raw data. Furthermore the overall open biopsy rate is 
quoted in national performance reports (Moss et al., 1995; NHSBSP, 1995d), but is not 
provided by, and cannot be calculated from KC62 reports. Different publications 
produced by the NHSBSP provide different quality standards for the same outcome 
measures, for example those for benign open biopsies (NHSBSP, 1992; 1993b; 1995b; 
1996). Further inconsistency in the use of outcome measures by different professional 
groups within the NHSBSP is demonstrated by the fact that the malignant:benign open 
biopsy ratio is still calculated by the KC62 report despite the recommendation by the 
Radiological 'Big 18' that this measure be withdrawn as a performance indicator due to 
biasing effect of small numbers. However, the malignant:benign biopsy ratio was 
retained in the 1996 update of the Surgical QA Guidelines (NHSBSP, 1996b). 
The outcome measures calculated by KC62 reports are intended to provide a ready 
source of QA data for the NHSBSP. However, until the problems described are 
rectified, outcome measures calculated by KC62 reports must be treated with caution. A 
review of the KC62 software is ongoing, and it is hoped that changes to the software 
which eliminate these difficulties will be made as soon as possible. In addition, when new 
KC62 software is released, previous years of data should be reproduced using the new 
version of the software. This would allow identification of trends in outcome measures 
to evaluate progress. Of particular importance for smaller screening units is the 
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aggregation - of data across years to counteract the effect of small numbers, which is not 
possible unless data for several years are produced using consistent methods. 
Of critical importance to the success of screening is the achievement of adequate 
compliance rates. The quality standard for this measure has remained unchanged at a 
minimum of 70% since screening was introduced (NHSBSP, 1988). However, when this 
70% rate is applied to a hypothetical screening population over five screening rounds, 
the resultant cumulative attendance rates reveal that this quality standard needs to be 
raised and split into prevalent and incident standards. The simple model used predicted 
that, if the 70% standard was met in all rounds, only 16.8% of women would attend in 
all five rounds, and 36% in four rounds. In particular, a stricter standard for the 
reattendance rate is required if this outcome measure is to be useful in improving 
screening performance. Given that reattendance rates across the West Midlands in 
1994/95 ranged from 85% to 96%, a minimum standard of 85% for the reattendance 
rate, with an expected standard of 90% would not be unreasonable. Measuring 
cumulative uptake in the NHSBSP over four or more rounds will be difficult. A recent 
study from the Njimegen screening programme calculated cumulative attendance over 
17 years of two-yearly screening, and identified that, although compliance in the first 
round was high at 88%, cumulative uptake after 8 and 9 rounds fell to 39% and 24% 
respectively (Scaf-Klomp et al., 1995). Lower uptake rates have been achieved in the 
NHSBSP, with overall uptake rates for all screens in 1993/94 reported as 72% 
(NHSBSP, 1995e) rising slightly to 76.7% in 1994/95 (NHSBSP, 1996b) and it is likely 
that achieved cumulative uptake in the UK will be lower than that in Njimegen. 
However, the current format of the KC62 report only provides information about 
attendance in the current round and at the previous two invitations. Calculations of 
cumulative uptake over more than three rounds will require complex analysis of data 
describing screening histories recorded by screening units, and is likely to be lengthy 
process. These issues needs to be addressed by the NHSBSP so that a routine method of 
calculating cumulative uptake over several rounds can be made available. 
The calculation and interpretation of measures assessing whether sufficient cancers are 
being detected has undergone many changes. In the past, all breast cancers detected by 
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screening,-both invasive and in situ, were included in the cancer detection rate 
(NHSBSP, 1988). As it is invasive cancers which are potentially fatal, in situ cancers are 
now excluded from calculations which are, in addition, split for prevalent and incident 
screens (Radiological 'Big 18', personal communication). The effect of the age of the 
screened population on the achieved detection rates has resulted in further changes to 
the recommended calculation method. The NHSBSP currently recommends the 
calculation of invasive cancer detection rates for prevalent women restricted to those 
aged 50-54 years only (Radiological 'Big 18', personal communication). While the 
assumption that most women attending for the first time are aged 50-52.9 years is 
reasonable for well established units, is not always valid. In addition, it is currently 
necessary to estimate the number of invasive cancers in this age group as it is not 
supplied by the KC62 report. This restriction also excludes cancers detected in prevalent 
women aged 55-64 years, which although a minority, are nevertheless part of the 
programme. In contrast, the NHSBSP currently recommends that incident invasive 
cancer detection rates are calculated for 50-64 year olds, whereas if this were consistent 
with the calculation of prevalent invasive cancer detection rates, women aged 55-64 
years only would be included. 
The Standardised Detection Ratio (SDR) has recently been introduced as an outcome 
measure by the NHSBSP in an effort to adjust observed cancer detection rates according 
to the age distribution of the invited population. The SDR utilises expected cancer 
incidence rates obtained from the Swedish Two Counties Trial on the assumption that, 
given that the UK programme achieves comparable cancer detection, mortality reduction 
similar to the Swedish trial should be realised (Blanks et al., 1996). More recently this 
method has been extended to the detection of small cancers, with the development of 
SDRs for small (<15mm) and larger (>=15mm) cancers (Blanks et al., 1995~). 
Maintaining a high quality screening programme is essential if breast cancer mortality is 
to be reduced, and the detection of sufficient cancers is both a crucial performance 
indicator, and a marker of likely mortality reduction for the programme. Hence, differing 
baseline incidence rates between districts have implications for the evaluation of the 
NHSBSP, as they could influence both the apparent cancer detection rates achieved by 
different screening units and rates of interval cancers. 
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Those units situated in low baseline incidence areas might be likely to achieve lower 
detection rates than those in high baseline incidence areas independently of the quality of 
screening. In a recent study background correction factors relative to the national 
average were calculated for a sample of NHSBSP catchment areas to allow for variation 
in baseline incidence when interpreting observed cancer detection rates or SDRs (Blanks 
et al., 1996b), with the largest correction factor bringing about a 15% change. The 
average correction factor for West Midlands programmes was estimated at only 3%, 
ranging from -5% to 6% across the region. These correction factors were calculated 
using geographical information obtained for women aged 45 years or more in 1968-85 
(Swerdlow et al., 1993), and, as Blanks and his colleagues point out, calculation of 
correction factors is more accurate if based on detailed geographical information relating 
to women in the screening age group. In the present study, correction factors for 50-64 
years olds relative to the West Midlands average incidence rate in 1983-87 varied 
between catchment areas from -7.2% to 5.1%. Further work examining baseline 
incidence is being undertaken in collaboration with the GIS project team at the WMCIU. 
Currently the NHSBSP recommends that SDRs are only calculated for prevalent 
screens. Incident SDRs are complicated by the impact of the detection of cancers at the 
incident screen which were missed at the prevalent screen (termed "overspill" cancers). 
Thus a screening unit with poor sensitivity might achieve a low SDR in the prevalent 
round, but, in the subsequent round, achieve a higher SDR for incident women as 
cancers missed at the last screen are detected. Such a unit would also be expected to 
display a high interval cancer rate due to the symptomatic presentation of false negative 
cancers. A study of data from the Dutch screening programme analysed the previous 
screening mammograms of 44 women with incident screen detected cancer, and 
concluded that in 9% the cancer was apparent on the previous mammogram, and that in 
a further 48% "minimal signs" which could have indicated cancer were present (van 
Dijck et al., 1993). Although based on a small sample, these findings suggest that this 
overspill effect may be considerable. Development of the incident SDR is ongoing and it 
is likely that a method for calculating this measure will be available for routine use in the 
near future, although the impact of any overspill effect must be taken into account when 
assessing achieved SDRs (Blanks, personal communication). As around 80% of women 
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screened at many units currently attend incident screens the prevalent SDR provides 
insight into screening performance for a minority of women screened. An incident SDR 
must become a routine QA measure as soon as possible. A simple method of assessing 
the overspill effect would be to present incident SDRs along with the prevalent SDR 
relating to the screening year three years earlier. For example, overspill would be a likely 
explanation for a unit achieving a low prevalent SDR in 1990 and a high incident SDR 
for the same women returning for their re-screen in 1993, which also displayed a high 
interval cancer rate arising from the prevalent screens in 1990. Such calculations require 
the identification of the screening round in which women were invited to attend. Now 
that many units are in their third screening round, separating women invited in the 
second and third rounds is difficult, requiring complex manipulation of data from the 
screening office computer. A means of readily identifying the screening round, according 
to both the screening unit and the woman, in which women are invited will become more 
important as the programme matures. This need must be addressed at a national level. 
The rising incidence in the screening age group prior to the introduction of screening in 
the West Midlands has been seen nationally (Quinn and Allen, 1995), and also has 
implications for the NHSBSP. When setting cancer detection targets it is necessary to 
estimate the expected incidence of cancer in the absence of screening. This estimation 
was undertaken in this study and elsewhere (Woodman et al., 1995, Blanks et al., 
1996a), with the incidence of interval cancers arising in each 12 month period following 
a negative screen presented as the proportion of the expected underlying incidence. In a 
recent study the rate of expected increase was greatest for the oldest women (Prior et 
al., 1996), suggesting that expected rates should be calculated separately for each age 
band rather than for the age group 50-64 years. In the present study the expected 
incidence rate used in calculations was for the 50-64 year age group, an approach also 
used elsewhere (Woodman et al., 1995). It is important that the increasing complexity 
surrounding the assessment of cancer detection rates, SDRs and interval cancers should 
not reduce the usefulness and accessibility of QA data calculated for the NHSBSP. 
Since being introduced in 1987, the NHSBSP has continuously developed the methods 
used to evaluate progress. The NHSBSP recognised at the outset that further research 
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was needed into some aspects of the programme, and has incorporated changes to 
evaluation methods based both on the results of research, and in the light of experience 
gained by screening units since 1987. For example, the quality standard for the early 
recall rate, set at a maximum of 0.25%, was subsequently raised to 1% as nationally 
achieved early recall rates revealed the earlier target to be too low (Radiological Big '18', 
personal communication). In addition, the format and content of KC62 reports has been 
developed since the start of screening, although the version current in 1997 still requires 
considerable amendment. While the readiness to incorporate new ideas into the methods 
used to evaluate the programme is a strength of the NHSBSP, it also has the potential to 
cause confusion for those working in the programme. To avoid this: 
clear and up to date definitions of recommended outcome measures and the 
relevant quality standards should be circulated to all those involved in the 
evaluation of the NHSBSP 
changes from previous definitions must be identified, and advice supplied as to the 
date from which new definitions apply 
when new quality standards are set these must be circulated rapidly to all those 
involved in evaluation of the NHSBSP, with clear information on how these differ 
from the previously used standards, and from what date the new standards apply 
where measures are being used to assess the programme, the sources of the data 
and the definitions used to calculate them must be clearly stated 
where assumptions are made in the calculation of outcome measures these must be 
validated, and if found to be invalid remedial action must be taken 
finally, guidance on the interpretation of outcome measures should be provided for 
those who may want to be informed of the progress of their local screening service 
but who are unfamiliar with the definitions used, such as purchasers 
7.3.2 
Evaluation of a population based screening programme is more difficult that that of a 
randomised controlled trial of screening due to the lack of a defined control population. 
However, where population based screening has been introduced in a staggered fashion 
it is sometimes possible to construct a control group from women not invited in the early 
years of the programme. For example, a recent study of the Finnish programme 
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identifieda-control group of women not selected for invitation in the introductory phase 
of the programme (Hakama et al., 1997). Comparison of death rates amongst women 
invited and uninvited for screening revealed a significant reduction in risk for those 
invited. However, as the Finnish programme has matured women in this retrospectively 
constructed control group have been invited for screening and thus identifying a control 
population for assessment of more recent screening performance will not be possible. 
Other means of assessing the impact of population based screening, are thus required. 
In the present study a retrospective technique was designed to identify a cohort of 
women with breast cancer for whom the cancer could potentially have been detected by 
screening in the prevalent screening round. Although the catchment area of only one 
screening unit was considered, this unit is the largest in the West Midlands, accounting 
for nearly 20% of women aged 50-64 years in the region. Women in the cohort were 
followed up until diagnosis and the screening history classified. Of the 973 breast 
cancers studied, only 31.6% were screen detected, and 22.9% arose in women known to 
the screening unit but diagnosed before the screening invitation. Despite the increasing 
risk of breast cancer with age, incidence rates in this group did not rise with age at 
invitation. It is possible that, for some of these women, the arrival of a screening 
invitation precipitated presentation into the symptomatic service, and thus that some of 
this group of cancers were "programme provoked', although the extent of such an effect 
could not be assessed in this study. This investigation focused on the prevalent round, 
and the proportion of women diagnosed while eligible for screening but prior to 
invitation is expected to have fallen now that the programme has completed the 
prevalent round across the West Midlands. Whether this has occurred can only be 
ascertained by performing similar analyses for later years. 
In the sample investigated 278 cancers (28.6%) arose after a negative screen. The 
majority of these (84.9%) were interval cancers arising at <36 months from the last 
screen. Also included in the 28.6% were breast cancers arising at 36-59 months in 
women no longer eligible for routine invitation due to age, and in women re-invited to 
screening at more than 36 months, at which time the cancer was already diagnosed. A 
further 10.5% arose in non-attenders, of which 15% were diagnosed within three 
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months of the invitation. It is possible that, for these women, although the screening 
invitation was not taken up, it provided the impetus for seeking medical attention. Thus 
these 15% could, in addition to some of those diagnosed prior to the invitation date, 
include some of the programme provoked cancers, although once again it was not 
possible to explore this issue further in this study. In addition, 5.3% of breast cancers 
arose in women not known to the screening programme, indicating inaccuracy in the 
population register used to identify eligible women. 
A study of the South East Thames screening programme examined data from the 
prevalent round (Garvican et al., 1996). No established protocol is available for 
undertaking this type of study and methodological differences exist between the scheme 
used to identify the eligible population and allocate screening histories in South East 
Thames and in the present study. In the present study a cohort of women eligible for 
having their breast cancer detected in the prevalent round was identified retrospectively 
and followed up. In South East Thames a cross-sectional analysis of cancers arising 
between 1988 and 1993 was used, although the study focused on the screening histories 
of cancers presenting in 1991 and 1992. The likely impact of this difference in 
methodology is demonstrated by the example of a women invited for screening during 
the prevalent round in 1991, and diagnosed with an interval cancer in 1993 after the 
prevalent round had finished. In the present study this cancer would be included in the 
study cohort. However, had this study been cross-sectional, and included only cancers 
diagnosed within the prevalent round, this cancer would have been excluded. A cross 
sectional methodology thus excludes cancers arising after the period of screening has 
ended and may provide an over-optimistic view of the impact of screening. 
Of 4202 breast cancers diagnosed in 1991-92 in South East Thames, 47.9% were screen 
detected, 10% were interval cancers, 6.6% arose in non-attenders, 17.4% were 
diagnosed prior to invitation, 7.4% were unknown to the screening service, and, at the 
time of publication, the screening histories of 10.7% had yet to be checked (Garvican et 
al., 1996). Both the South Thames East programme, and the Warwickshire, Solihull and 
Coventry Screening Service (WSCSS) achieved most QA standards for the prevalent 
screening round. Invasive cancer detection rates in both studies exceed the minimum 
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standard, being 5.1/1000 in the South East and the slightly lower rate of 4.1/1000 at the 
WSCSS, although differences in the age structure of the eligible populations could 
account for this difference. The SDR for the WSCSS for the prevalent round was 0.73, 
just under the target of 0.75, although SDRs have risen since then, being, for example, 
1.48 in 1994/95. As the data presented by South East Thames were not stratified by age, 
and as no prevalent round SDR was provided, it was not possible to assess the influence 
of age differences on the difference in achieved cancer detection rates for South East 
Thames and the WSCSS. It is possible that lower sensitivity in the WSCSS could 
account for the lower screen detected proportion seen. However, the difference in study 
methodology is likely to account to some extent for the higher proportion of screen 
detected cancers reported by South East Thames (47.9%) compared to 36.1% identified 
in this study, and the lower proportions of interval cancers in South East Thames. 
Despite the methodological differences, both studies reveal that, although programmes 
may meet the quality standards set by the NHSBSP, the proportion of screen detected 
cancers is low, indicating low programme sensitivity (Garvican et al., 1996). This low 
sensitivity has serious implications for the likely impact of the programme on the 
population. Authors from the South East estimated that, as only 40% of breast cancers 
arose in women in the age range eligible for screening, and just under 50% of breast 
cancers in eligible women were screen detected, only 20% of women could have an early 
diagnosis due to screening (Garvican et al., 1996). In the present study only 36.1% of 
cancers in eligible women were screen detected in the present study, and 3 1% of cancers 
diagnosed pre-screening arose in 50-64 year olds. Thus, from these figures, only 10% of 
breast cancer patients potentially benefit from early diagnosis by screening. Even if the 
25% HoN mortality reduction were to be achieved in this 10%, only a 2.5% 
population-wide mortality drop would be achieved. If the NHSBSP can only achieve 
such a small mortality reduction the cost effectiveness of the programme must be 
reviewed. Further work examining the proportions of cancers according to screening 
history in the West Midlands will be carried out. 
Also of concern is that, like the West Midlands, South East Thames identified a 
significant proportion of cancers in women not known to the screening service, making 
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up 7.4% of cases in South East Thames and 5.3% of cases in the present study. Women 
are omitted from the Prior Notification Lists (PNLs) utilised by the NHSBSP if they are 
not registered with a GP. In addition, if the details on the PNL are incorrect, for 
example, if addresses or ages are incorrect, invitations will not be received by women. 
Although it is difficult to increase the proportion of women registered with GPs, it may 
be possible to increase the proportion of such women who self refer for screening by 
means of health promotion initiatives. In addition, improving the accuracy of population 
registers is vital (Bowling, 1989; Bickler, 1993). The establishment of computerised 
links between health authorities and the screening service in some parts of the country, 
for example in Coventry, has improved the quality of the population register in these 
areas considerably (Wheaton, personal communication). 
To assess the impact of screening it is not only necessary to establish the proportions of 
breast cancers according to screening history in the eligible population, but also to 
examine the prognosis of these cancers. In this study pre-screening rates of non-invasive 
cancer (DCIS) were low, making up only 2% of the pre-screening control group. 
Amongst screen detected cancers, however, 6.9% of prevalent and 14.1% of incident 
breast cancers were DCIS. The proportion of screen detected DCIS has been reported 
nationally as 18% for 1990-93 (Moss et al., 1995), with 20.5% of screen detected 
cancers in South East Thames in 1988-93 being DCIS or micro-invasive cancer 
(Garvican et al., 1996). Although these rates are within or near to the current quality 
standard range of 10%-20% (Radiological 'Big 18', personal communication), the high 
DCIS proportion amongst screen detected cancers may be a cause for concern. The 
proportion of DCIS that progress to invasive disease has been estimated at 2550% 
(Page, 1995). Thus, a significant proportion of screen detected DCIS may not progress 
to invasive cancer if left untreated, raising doubts as to the benefits of screening for 
these women. A study of the outcome for women with screen detected DCIS is being 
designed in the West Midlands NHSBSP. 
In the present study, as elsewhere, screen detected cancers had a generally more 
favourable prognosis in terms of size, nodal status and grade than cancers diagnosed 
pre-screening (Duffy et al., 1991; Tabar et al., 1992; Crisp et al., 1993; Wight et al., 
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1993; Moss et al., 1994). The prognostic characteristics of cancers in non-attenders 
were particularly poor. Although the prognosis of interval cancers were more favourable 
than those of pre-screening cancers they were poorer than for the screen detected group. 
This suggests that cancers detected after the introduction of screening, with the 
exception of cancers in non-attenders, should display better survival than cancers 
detected pre-screening. However, detection by screening of high proportions of special 
type cancers may indicate length bias, in which screening preferentially detects those 
types of cancer which have lowest aggressive potential. If this is the case aggressive 
tumour types are more likely to be diagnosed symptomatically than by screening, and are 
also more likely to present at a later stage, as both this study and others have identified 
poorer prognostic characteris tics amongst cancers diagnosed symptomatically compared 
to screen detected cancers (Duffy et al., 1991; Tabar et al., 1992; Crisp et al., 1993; 
Wight et al., 1993, Moss et al., 1994). The occurrence of length bias would reduce the 
ability of the NHSBSP to bring about a fall mortality in eligible women. However, the 
identification of high proportions of special type tumours in the NHSBSP may reflect an 
increase in specialist knowledge amongst pathologists increasingly involved in the 
NHSBSP compared to those working only in the symptomatic service. 
In this study, although screen detected cancers were of favourable prognosis, cancers 
arising outside the programme were of poorer prognosis. The favourable prognosis of 
interval cancers in comparison to pre-screening controls suggests an increase in breast 
awareness in women who have been screened. However, interval cancers had a poorer 
prognosis than screen detected cancers. Unless screen detected cancers make up the 
bulk of breast cancers in the eligible population, screening is likely to have less impact 
on survival and mortality in the population than expected. In addition, there is some 
evidence that overdiagnosis and length bias may be occurring in the programme, both of 
which reduce the potential benefit resulting from the programme. The NHSBSP has put 
much effort into developing internal quality assurance and improvements to the 
management of the service are ongoing (NHSBSP, 1995d). However, although attention 
is being focused on interval breast cancers, the occurrence of other breast cancers 
outside the NHSBSP in the eligible population has received less scrutiny. Unless the 
NHSBSP can increase the proportion of breast cancers detected by screening it is 
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unlikely to achieve it's aims. Analyses similar to those undertaken here will be critical in 
assessing whether, since the prevalent round, the situation has become more favourable. 
Before further investigations are performed, however, it is important that a consistent 
investigative technique is identified so that studies conducted in different parts of the UK 
will be comparable. 
7.3.3 
Although the significance of interval breast cancers has always been recognised by the 
NHSBSP (Day et al., 1989) there still remains ambiguity in the definition of interval 
breast cancers. In this investigation the impact of changing the definition was explored 
using the 278 interval cancers identified. When restricted to histologically confirmed, 
invasive breast cancers, occurring in women aged 50-64 years at screening, and arising 
at <36 months from the last negative screen, the total fell to 213 (termed "core" 
intervals). These restrictions led to a drop in the overall interval cancer rate arising from 
the prevalent round from a maximum of 47.1/10,000 women screened to 36.1/10,000. 
The largest change in the calculated interval cancer rate was brought about by the 
exclusion of cancers arising at >36 months from the last screen. This has serious 
implications since, although the NHSBSP assumes that a three year round is currently 
operating for all women, this is not always the case. In the sample analysed 27.5% of 
women were re-invited at 36 months or more from the last screen, with 17.3% waiting 
over 39 months for a re-invitation. Where a woman, although eligible for re-invitation, 
was not offered another appointment prior to the diagnosis of a cancer symptomatically 
at >36 months from her last screen, it is arguable whether this should be excluded from 
interval cancer rates. Occurrence of such cancers represents a failure of the NHSBSP 
and to exclude such cases from the figures may mask a significant problem. 
From this investigation it is clear that changing the definition of interval cancers can have 
a significant impact on calculated rates. In addition, of the 278 interval cancers, 30 were 
unknown the screening unit and were only identified by cross-checking information 
between the screening unit and the WMCIU, highlighting the need for effective 
information exchange. To assist future assessments the definition of an interval cancer 
must be made clear and applied in a standardised fashion throughout the NHSBSP. To 
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facilitate identification of interval cancers, and all breast cancers arising in women 
eligible for screening, the exchange of information between the cancer registries and the 
NHSBSP is vital. A modem link based in the WMCIU allowing access to the NHSBSP 
computer system by staff at the QAFC is currently being introduced and will allow ready 
comparison of NHSBSP and cancer registration data. 
This investigation identified high interval cancer rates which rose as the time from the 
last screen increased, giving an overall rate of 36.1/10,000 women screened for core 
interval cancers arising from the prevalent round. This high rate supports findings other 
studies (Woodman et al., 1995; Day et al. 1995a). In the present study interval cancer 
rates, expressed as proportions of the estimated underlying incidence, rose from 27.6% 
at 0-11 months from screening, to 56.7% at 12-23 months and 82.5% at 24-35 months. 
These rates are similar to the findings reported for East Anglia (Day et al., 1995a), and 
for the North West (Woodman et al., 1995). The West Midlands, East Anglia and the 
North West all display proportionate interval rates roughly double those of 17%, 30% 
and 56% respectively reported by the Swedish Two Counties trial (Day et al., 1995a). 
Authors in East Anglia predicted a 18% mortality fall based on comparison of the 
proportionate interval and compliance rates achieved and those reported by the Swedish 
Two Counties study (Day et al., 1995a). Given the similar proportionate incidence and 
compliance rates in the West Midlands a comparable mortality drop might also be 
expected in this region, less than the 25% HoN target (HMSO, 1992). 
Although there is no doubt that rates of interval cancers in the UK are too high, how this 
situation should be addressed is the subject of much debate. Radiological classification 
of interval cancers which provides information about whether or not the cancer could 
have been detected at the previous screen is vital in the assessment of interval cancers, 
and should be performed using a standardised set of criteria. Radiological classification 
relies on comparison of the screening film with a mammogram taken at diagnosis. In the 
absence of diagnostic mammography, interval cancers remain unclassifiable, unless an 
estimated radiological classification system such as that used in this study is employed. 
For example, in a recent study of interval cancers in the North West, only the 53% of 
cancers with a diagnostic mammogram were included in the study (Asbury et al., 1996). 
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In the present investigation, cancers without diagnostic mammograms were classified by 
examination of the screening mammogram alone using a scheme devised by Simpson and 
his colleagues (Simpson et al., 1995). Using this method a radiological classification was 
available for 92% of the 213 core interval cancers. 
Of the core intervals in the study, 44.1% were true intervals, 22.5% were false negative 
(present on the previous mammogram) and 9.9% were occult. Lack of diagnostic 
mammograms meant that 15.5% could only be classified as "not false negative", and 
were made up of a mixture of true and occult interval cancers. Only 8% of core interval 
cancers were radiologically unclassifiable. These proportions are similar to those 
reported by Simpson and colleagues for a series of 167 interval cancers of 46% true 
intervals, 26% false negative, 11% occult and 16% unclassifiable (Simpson et al., 1995). 
Interval cancers arising in the third year represented 49% of interval cancers in this study 
and in a series reported by the North West (Woodman et al., 1995). Authors in the 
North West reported that 80% of interval cancers arising in the third year were true 
intervals (Asbury et al., 1996) compared to an estimated 68% in the present study. The 
high proportion of true interval cancers identified in the third year has prompted calls to 
shorten the screening round to two years (Woodman et al., 1995; Asbury et al., 1996). 
However, the present study estimated that a possible 37.3% of interval cancers might be 
avoided by detecting them at screening using a shorter two year round. 
There are two means of reducing interval cancer rates. Improving screening sensitivity, 
leading to the detection of more cancers relative to the underlying incidence rate, should 
reduce the incidence of false negative interval cancers. The second strategy, that of 
implementing a shorter screening round, is based on the assumption that the current 3 
year round is too long in relation to the sojourn time of many breast cancers. Where the 
sojourn time is less than the round length, it is possible for breast cancers to arise and 
become symptomatic in the time between one negative screen and before the next screen 
is due. Screening at a shorter interval should detect some of these cancers and thus 
reduce the rate of interval cancers. In the present study there was little difference in 
interval cancer rates according to age at diagnosis for cancers arising in the first 24 
months from screening, but in the 24 - 35 month period interval cancer rates were 
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highest in-the 60-64 year age group. This is in contrast to a report from the North West 
which identified a lower risk of interval cancers in older women compared to those aged 
50-54 years (Threlfall et al., 1997). This difference might be explained by the use of 
separate expected incidence rates for each age group in the North West compared to the 
single figure used in the present study. Threlfall and colleagues suggest that the higher 
risk of interval cancers in younger women might be addressed by introduction of a 
shorter screening round this age group. However, any shortening of the screening round 
would be difficult and costly, and if different round lengths were used for different age 
groups, the organisational complexity would be considerable. Until larger series of 
interval cancers are available from which proportionate incidence rates for each age 
group can be calculated, it seems unlikely that such drastic changes to the organisation 
of the screening programme are justified on the basis of the current research findings. 
Crucial to the current debate over whether a shorter round is required is the presence of 
some confusion over the meaning of the radiological classification "true" interval cancer. 
True interval cancers are those which were not detectable on the previous screening film 
which was taken using the screening method current at the time. However, this does not 
necessarily mean that the tumour was absent at the time of the previous screen. With 
improved sensitivity, for example, using a cranio-caudal X-ray view in addition to the 
oblique view, some cancers which would be missed by an oblique view alone may be 
visible. Had the original screening been an oblique view only, on which the cancer was 
not shown, this cancer would be classified as a true interval. Thus adding an additional 
view may lower the rate of true and false negative interval cancers. The improved 
sensitivity of two view screening is borne out by a study of prevalent screening activity 
for 1994/95, which identified that screening units using two view screening for prevalent 
women achieved a small cancer SDR (<15mm) 42% greater than those units using one 
view screening (Blanks et al, 199%). The difference in SDRs for non-invasive and 
micro-invasive cancers was only 3%, and for larger invasive cancers (>=15mm) was only 
7%. Thus, use of two view screening improves sensitivity such that, in particular, more 
small cancers are detected. As it is the detection and treatment of these cancers which 
has the potential to bring about a mortality reduction, introduction of two view 
screening for incident screens in addition to prevalent screens seems desirable. The 
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findings reported by Blanks and colleagues confirm earlier work comparing the effect of 
one and two view screening, which identified higher cancer detection rates for two view 
screening, and in addition, identified a reduction in the referral rate, so that by using two 
view screening, specificity as well as sensitivity is improved (Moss et al., 1995). 
Interpreting interval cancers is a retrospective process and changes that will cause a fall 
in interval cancer rates may already be in place, although this reduction is not yet 
detectable. There is evidence that sensitivity in the West Midlands programme has risen, 
with SDRs increasing since 1992. Improvements in sensitivity are expected with the 
introduction of two view screening for all prevalent screens since August 1995 (Wald et 
al., 1995). Thus the NHSBSP may already be detecting more cancers and potentially 
reducing future interval cancer rates. The extension of two-view screening to incident 
screens would be likely to improve sensitivity throughout the programme and should be 
considered, especially as incident women currently make up the majority of women 
screened. In addition, double reading of films has been shown to increase sensitivity 
without a large increase in cost (Brown et al., 1996; Seradour et al., 1996). Double 
reading counteracts inter-observer variation in the interpretation of mammograms and, in 
a recent study, resulted in 12% more cancers being detected than would have been 
diagnosed by a single reader (Parham et al., 1996). Lack of radiologist time makes 
routine double reading difficult, and although a number of screening services have 
trained members of radiography staff to act as first-line readers, many screening services 
in the UK do not undertake any double reading. 
Although the NHSBSP is currently based on a 3 year screening round, many women 
experience a longer round length. Thus, interval cancer rates may not indicate that a 
three year round is insufficient, but that the three year round is not being maintained. 
The NHSBSP is currently under pressure to extend the age for routine invitation to 
include women aged 65-69 years. The NHSBSP represents a large commitment of 
scarce NHS resources. Although a two year round would undoubtedly reduce interval 
cancers rates, there are a number of alternative solutions to high interval cancer rates, 
such as improvements in sensitivity which are already in place, which may be more 
effective and less costly than shortening the screening round. 
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7.4 CONCLUSIONS 
High incidence and mortality from breast cancer make it a major health problem in the 
West Midlands and in the UK as a whole. As no method of preventing the disease is yet 
available, actions to reduce its impact focus on reducing mortality and improving 
survival. Stage at diagnosis, the type of treatment received, and a number of biological 
factors including tumour grade have been identified as important factors in determining 
survival from breast cancer. 
Any actions taken to reduce mortality and improve survival must be monitored and 
evaluated to ensure effectiveness. The true impact of such actions cannot be ascertained 
from randomised clinical trials or small studies, but require population based studies. 
Currently cancer registries are the only source of population based data for such studies 
in the UK, and, furthermore, cancer is the only disease for which such population based 
registers exist. To be useful, population based data must be of high quality. In this study, 
few cases had stage recorded on the WMCIU database but this reflected the small 
number for which stage had been sent to the WMCIU. However, where data were 
supplied to the WMCIU, the accuracy and completeness with which tumour 
characteristics were recorded at the WMCIU were very high. This allowed the 
development of a staging algorithm combining tumour characteristic data to allocate 
TNM stage to breast cancers. This staging algorithm requires testing against other 
populations, and incorporates a number of assumptions which may not always be 
justified. Nonetheless the staging algorithm is a useful tool allowing a TNM stage to be 
allocated at the WMCIU for breast cancers thus increasing the utility of the data for 
analytical purposes. Similar staging algorithms are soon to be developed for other 
cancers. Furthermore, improvements to the coding rules and database structure made as 
a result of this study will improve data quality for all cancers. 
This study demonstrated that it was broadly possible to undertake evaluation of the main 
issues relating to breast cancer using routinely collected data. The limitations of cancer 
registry data identified in this study are mostly imposed by inadequacies in the supply of 
data from Trusts, and the extent to which such important prognostic data are stored in a 
readily accessible form within Trusts. This is apparent not only for prognostic data but 
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for adjuvant chemotherapy and hormone therapy which are recognised as being key to 
improved patient outcome. The Calman-Hine Report identified the need to monitor the 
effects of restructuring cancer services on outcome. High quality data detailing all stages 
of patient care, from diagnosis to initial treatment and follow up, are required for this 
process which necessitates multi-disciplinary data collection. These data should be 
collected by Trusts so that they can monitor the management of their own patients. 
Transmission to the cancer registry then becomes a routine component of the Trust's 
data collection processes. When this process is in place, the type of quality assurance 
developed in this study will become an integral part of the WMCIU's data collection, 
evaluation and audit role of the cancer care available in the West Midlands. 
The evaluation of the impact of the NHSBSP is hampered by the lack of a control 
population, and survival analysis comparing screen-detected cancers with symptomatic 
cases will always be complicated by lead time bias. However, comparison of screening 
data with cancer registry data allows indicators of the likely-effect of screening to be 
derived. In the sample of pre-screening cancers examined stage was confirmed as the 
most significant prognostic factor, with treatment type, tumour grade, and level of 
deprivation also identified as important. The NHSBSP aims to reduce mortality by 
detecting breast cancers early. In the sample examined, only 31.6% of cancers in eligible 
women aged 50-64 years were screen detected. In combination with the observation 
that, in the pre-screening population, only 31% of cancer patients were aged 50-64 
years, this means that only 10% of breast cancer patients directly benefit from early 
diagnosis by screening. Even if the 25% HoN target mortality reduction was achieved 
for screen-detected cancers, this would translate into a 2.5% population-wide reduction. 
Thus, although the prognostic characteristics of screen detected cancers were clearly 
better than those of breast cancers diagnosed outside the screening programme, the 
impact of this on breast cancer mortality in the entire population is likely to be smaller 
than expected. The favourable prognosis of interval breast cancers compared to cancers 
diagnosed pre-screening could reflect an increased breast awareness in women who have 
been screened, and thus could, in this respect, represent a beneficial effect of the 
programme. However, with increased sensitivity, at least some of these cancers might 
have been detected at the previous screen when at an earlier stage. The negative 
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psychological impact of the diagnosis of an interval cancer should not be ignored 
although little research has been carried out in this area. The NHSBSP represents a 
massive input of scarce NHS resources, and efforts to increase the potential population 
benefit must be made. Further assessment of the proportions of cancers detected by 
screening using the method developed in this study will now be carried out to evaluate 
whether improvements since the prevalent screening round have been made. 
The NHSBSP represents the first model in the NHS of a structured multi-disciplinary 
service in which quality assurance is a core activity. The existence of the NHSBSP has 
undoubtedly had a beneficial knock-on effect on the symptomatic breast service and in 
the development of services provided for other cancers. However, the NHSBSP QA 
system stills needs refining. The current KC62 statistical report does not provide all the 
data needed for the calculation of the range of outcome measures used by the NHSBSP. 
The definition and layout of the KC62 report is currently under review, and the problems 
identified in this study have been fed back to the NHSBSP to facilitate this review 
process. This study identified a number of problems associated with the definition of 
outcome measures and their associated quality standards. For example, the minimum 
standard for the uptake rate is set at 70% for all screens. Cumulative uptake over several 
rounds must be high if the desired mortality reduction is to be achieved, and should be 
considered when setting the standard. This study demonstrated that, after five rounds, 
70% of women would attend all five screens only if an uptake rate of 93.2% were to be 
achieved in each round, and thus the 70% standard currently applied to each year and 
round of screening is inadequate and must be raised. It is important that an iterative 
process is established between those calculating and using outcome measures, and those 
setting quality standards. Auditing a service against inappropriate standards or using 
invalid outcome measures can be counterproductive and may provide misleading 
information. As a result of this study, problems identified with outcome measures and 
quality standards have been fed back to the NHSBSP via the West Midlands QA 
Committee members. 
Much attention is currently being focused on interval breast cancers as a QA measure for 
the NHSBSP. This study identified a need for clarification of definition of interval 
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cancers. The current definition excludes cancers arising at 36 months or more from the 
last screen. These cancers themselves signify an important problem, reflecting variation 
in the round length operated by the NHSBSP, which is assumed in the current definition 
of an interval cancer to be a uniform 3 years. Excluding these cancers in this study 
reduced the observed interval cancer rate from 43.1/100,000 to 36.1/100,000. Thus, for 
meaningful interpretation of interval cancer data, factors that influence interval cancer 
rates must be considered in the collation of national data. 
Finally, improving treatment is a crucial element in improving survival for breast cancer 
patients. Recent guidelines from BASO and the COG stress the importance of 
multi-disciplinary care within specialist teams, with use of appropriate surgery and 
adjuvant therapy. Such guidelines were initiated in the King's Fund guidelines published 
in 1986. In the current study clear improvements in treatment in line with the guidelines 
were evident. However, variation in treatment across the region indicated possible 
inconsistency in clinical practice. This variation will now be examined in more recent 
years using standard population based cancer registration data. The lack of survival 
advantage for women treated by high caseload surgeons, or of a difference in the use 
adjuvant therapy according to caseload, is contrary to the recommendation made by the 
COG. Further work will be now be carried out in this area to assess whether caseload is 
a valid indicator of high quality care and improved patient outcome. 
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APPENDIX ONE 
THE TNM/PTNM TUMOUR CLASSIFICATION SYSTEM FOR BREAST CANCER 
Adapted from the TNM Atlas, Third edition, 2nd revision 1992 UICC 
The classification applies only to breast carcinomas. There should be histological confirmation 
of the disease. The anatomical subsite of origin is not considered in the classification. In the 
case of multiple simultaneous tumours in one breast, the tumour with the highest T category 
should be used for classification. Simultaneous bilateral breast cancers should be classified 
simultaneously. The separate T, N and M components are combined using the rules in Table 
A1. 1 to produce TNM stages. 
T - Primary Tumour 
- 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ; intraductal carcinoma, or lobular carcinoma in situ, or 
Paget's disease of the nipple with no underlying invasive tumour 
Note: Paget's disease associated with an underlying invasive tumour is classified 
according to the size of the invasive tumour 
T1 Tumour 2 cm or less in greatest dimension 
T1A 0.5 cm or less in greatest dimension 
T1B More than 0.5 cm but not more than 1 cm in greatest dimension 
T1C More than 1 cm but not more than 2 cm in greatest dimension 
Tumour more than 2 cm but not more than 5 cm in greatest dimension 
Tumour more than 5 cm in greatest dimension 
Tumour of any size with direct extension to chest wall or skin 
T2 
T3 
T4 
Note: The chest wall includes ribs, intercostal muscles and serratus anterior muscle 
but not pectoral muscle 
T4A 
T4B 
Extension to the chest wall 
Oedema (including peau d'orange) or ulceration of the skin or satellite 
skin nodules confined to the same breast 
T4C Both T4A and T4B 
T4D Inflammatory carcinoma 
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Inflammatory carcinoma is characterised by diffuse, brawny induration of the skin, usually with 
no underlying palpable mass. Pathological classification requires examination of the primary 
carcinoma with no gross tumour at the resection margins. A case can be classified pT if there 
is microscopic tumour in the margin. The pT categories correspond to T categories. When 
classifling pT the size is that of the invasive component. If there is a large in situ component 
(e.g. 4cm) and a small invasive component (e.g. 0.5 cm) the tumour is coded pT1A. 
The regional (local) lymph nodes 
1. AxiIlary (ipsilateral) nodes, interpectoral (Rotter's) nodes and lymph nodes along the 
axillary vein and its tributaries which may be divided into the following levels: 
i. Level I (low axilla): lymph nodes lateral to the lateral border of the 
pectoralis minor muscle 
Level II (mid axilla): lymph nodes between the medial and lateral borders of 
the pectoralis minor muscle and the interpectoral (Rotter's) nodes 
Level III (apical axilla): lymph nodes medial to the medial margin of the 
pectoralis minor muscle including those designated to subclavicular, 
infiaclavicular or apical 
ii 
iii. 
Note: intramammary nodes are coded as axillary nodes. 
Internal mammary (ipsilateral): lymph nodes in the intercostal spaces along the edge of 
the sternum in the endothoracic facia. 
2. 
Any other lymph node metastasis is coded as a distant metastasis (M1), including 
supraclavicular, cervical, or contralateral internal mammary lymph nodes. 
N - Clinical Regional Lymph Nodes 
NX 
N0 
N1 
N 2 
Regional lymph nodes cannot be assessed (eg.  previously removed) 
No regional lymph node metastases 
Metastasis to movable ipsilateral axillary node(s) 
Metastasis to ipsilateral axillary node(s) fixed to one another or to other 
structures 
Metastasis to ipsilateral internal mammary lymph nodes N3 
pN - Pathological Regional Lymph Nodes 
The pathological classification requires resection and examination of at least the low axillary 
lymph nodes. Such a resection should include six or more nodes. 
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M 
pNX Regional lymph nodes cannot be assessed (not removed or previously 
removed) 
pN0 No regional lymph node metastasis 
pN1 Metastasis to movable ipsilateral axillary node(s) 
pN1A 
pN1BI 
pN1BII 
pN1 BIII 
pN1BIV 
Only micro-metastasis (none larger than 0.2 cm) 
Metastasis to one to three lymph nodes, any more than 0.2 cm 
and all less than 2.0 cm in greatest dimension 
Metastasis to four or more lymph nodes, any more than 0.2 cm 
and all less than 2.0 cm in greatest dimension 
Extension of tumour beyond the capsule of a lymph node 
metastasis less than 2.0 cm in greatest dimension . 
Metastasis to lymph node 2.0 cm or more in greatest dimension 
pN2 
pN3 
Metastasis to ipsilateral nodes fixed to one another or other structures 
Metastasis to ipsilateral internal mammary lymph nodes 
Distant Metastases 
MX 
M0 
No information available about metastases 
No distant metastases present including metastasis to the supraclavicular, 
cervical or contralateral internal mammary nodes 
Distant metastasis to any site (including brain, bone, liver, lungs and skin), or 
to supraclavicular, cervical or contralateral internal mammary nodes 
M1 
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